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Ciliopathies: genetics in pediatric medicine
Adapted from Journal of Pediatric Genetics (2016) Feb
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Medical Centre, Nijmegen, The Netherlands; 2Department of biochemistry, University of Western 
Ontario, London, Ontario, Canada
Image: Ciliary localization of IFT88 in human-derived fibroblasts.
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1. Cilia
1.1. Structure of cilia 
Cilia are cellular organelles with an antenna-like structure that protrude from the cellular 
membrane of almost all cell types. Some cells have bundles with 200-300 cilia, while 
most cells only form a single cilium [1]. Cilia can be divided in two types, motile cilia, which 
often occur as groups of cilia on the cell surface and are capable of beating in a constant 
frequency whereby a fluid flow is generated, or primary cilia that occur one per cell and 
that are immotile and involved in the communication of the cell with its surroundings [2]. 
Besides their difference in capacity to actively move, motile and immotile cilia also differ 
structurally. Both cilia types erect from a basal body, a centriolar-based structure that 
is used as a foundation to build the ciliary microtubular skeleton; however, the number 
of microtubule pairs in motile and immotile cilia is unequal and components that drive 
active movement are only present on motile cilia (Figure 1) [1, 3, 4]. Formation of motile 
and immotile cilia also slightly differs as centriole replication precedes cilia formation 
in multiciliated cells, while this step is not required in monociliated cells [2]. Generally, 
when a cell starts to assemble a cilium, the centrosome that is normally involved in 
separating the chromosomes during mitosis, is relocated and anchors just below the 
surface of the apical membrane [5]. During the conversion of a centriole to a basal 
body, distal and subdistal centriolar appendages transform into transition fibers and 
basal feet, which act as physical attachments to the plasma membrane (Figure 1). These 
elements are also required to establish the orientation of the basal body in the plasma 
membrane [6]. Distal to the transition fibers resides the ciliary transition zone, which 
functions as a gate and regulates the entry and exit of proteins into and out of the 
cilium [7, 8]. Vesicles with membrane proteins are targeted here to be integrated into the 
ciliary membrane, a process that is coordinated by the BBSome, a complex of proteins 
that are mutated in Bardet-Biedl syndrome (BBS) [9, 10]. Vesicle delivery to the cilium 
contributes to the establishment of a highly specialized ciliary membrane that contains 
various receptors and signaling proteins [11]. Within the cilium proteins are transported 
from base to tip and back over the axonemal microtubules (Figure 1). This transport, first 
described in unicellular algae, is carried out by the intraflagellar transport (IFT) machinery 
[12, 13]. Two unique transport complexes are active in the cilium. Transport from the base 
of the cilium towards the tip, anterograde IFT, is regulated by the IFT-B complex and 
driven by a kinesin-2 motor complex. Retrograde IFT, from tip to base, is regulated by 
the IFT-A complex and an associated dynein motor complex [13]. IFT is essential for 
ciliary functionality as protein synthesis does not occur within the cilium [14]. In addition, 
transport of signaling molecules into and out of the cilium is key to proper functioning 
of signaling pathways, including but not limited to Wnt/β-catenin and Hedgehog 
signaling [15, 16].
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1.2. Function and occurrence of motile and immotile cilia 
Motile cilia are found in only a few tissues where they transport extracellular fluid over the 
epithelial surface. For example, they occur on respiratory epithelial cells in the trachea 
where they are essential for mucus clearance, and on the apical surface of epithelial 
cells that line the fallopian tubes where they facilitate transportation of the (fertilized) 
ovum [1]. Cells with a single motile cilium also exist; sperm cells have a specialized motile 
cilium (flagellum) that provides their motility, and single motile cilia are also found on the 
Figure 1: Schematic structure of motile and immotile cilia. Cilia are composed of a basal body and a ciliary 
axoneme that protrudes from the apical plasma membrane. These two structures are linked via the transition 
zone (TZ) that consists of three compartments, i.e. a base, and two compartments filling the space between 
the microtubules and the axonemal membrane, which are thought to act as a diffusion barrier for regulation of 
ciliogenesis and signaling. Cilia contain microtubule skeletons that are composed of nine microtubule doublets 
that organize in a ring. A central microtubule pair is usually also present in motile cilia but not in immotile cilia. 
Inner and outer dynein arms, radial spokes and nexin links are also solely present in motile cilia and actively 
regulate ciliary movement. During this process dynein heavy chains of one doublet slide against microtubules 
of a neighboring doublet thereby orchestrating the beating of the cilium in an ATP-dependent fashion. In both 
cilium types the ciliary microtubules also function as rails for IFT trains that control bidirectional ciliary transport. 
During this process IFT-B particles are associated with kinesin-2 motors and regulate transportation of cargo 
from the ciliary base to the tip, while IFT-A particles and ciliary dynein motors transport cargo in the opposite 
direction.
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apical surface of nodal cells that regulate left-right asymmetry during embryogenesis 
[17]. Non-motile cilia are found on almost all quiescent cells and function differently 
[1]. They generally act as a sensory signaling hub of the cell, and are key players in 
embryonic development and tissue morphogenesis and homeostasis by regulating 
Wnt-, Hedgehog-, and many other signaling pathways [2, 18, 19]. They initiate or regulate 
signaling by sensing their environment and by ensuring delivery and/or removal of 
signaling proteins to or from the cilium [18]. Taken together, over the last decades, cilia 
demonstrated to be essential organelles that regulate a wide array of developmental, 
cellular and physiological processes wherein their motile and/or sensory capacities play 
a major role. 
2. Ciliopathies 
Ciliopathies are disorders that are caused by defects in motile or immotile cilia. As cilia 
occur on virtually all cells of the human body, their dysfunction can lead to a broad 
spectrum of features [1]. Common features are renal cystic disease, blindness, neural 
tube defects, intellectual disability, skeletal abnormalities ranging from polydactyly to 
abnormally short ribs and limbs, ectodermal defects, obesity, situs inversus, infertility, and 
respiratory anomalies. These features can occur isolated or may be part of a recognizable 
syndrome. Here, we describe the different types of ciliopathies, their characteristics and 
to what extent they genetically and phenotypically overlap.
2.1. Renal ciliopathies 
Polycystic kidneys are commonly seen in ciliopathies. The best known renal ciliopathies 
are nephronophthisis (NPHP), and autosomal dominant and autosomal recessive 
polycystic kidney disease (ADPKD and ARPKD, respectively). ADPKD is most common 
with an incidence of ~1:1,000, and is characterized by enlarged polycystic kidneys [20]. 
Liver cysts and abnormalities of the vasculature and heart may also be present [20]. 
PKD1 and PKD2 mutations explain 85% and 15% of ADPKD patients, respectively. Most 
individuals with ADPKD have a normal renal function during childhood, however, renal 
insufficiency progresses during life and results in end-stage renal disease (ESRD) in 50% 
of affected individuals [20]. In contrast, ARPKD is usually diagnosed in late pregnancy 
or at birth by the detection of enlarged cystic kidneys by ultrasound. Grossly enlarged 
kidneys cause pulmonary hypoplasia and thoracic compression leading to respiratory 
distress and death in ~30-50% of affected neonates. In the majority of remaining patients 
ESRD evolves in adulthood. In addition, virtually all ARPKD patients show hepatic 
involvement, i.e. hepatomegaly and liver fibrosis [21]. To date, only mutations in PKHD1 
have been reported and these explain at least 80-87% of ARPKD patients [22]. PKHD1 
General introduction
11
1
encodes the fibrocystin protein that forms a ciliary protein complex together with PKD1 
and PKD2 [23]. Another monogenetic cause of ESRD in children is NPHP. Three types 
have been described based on age of onset of ESRD; infantile (<2 years), juvenile 
(~13 years), and adolescent (~19 years) NPHP [24]. Juvenile NPHP is most common and 
affects 5-10% of the children with ESRD [25]. It is estimated to occur in 1:50,000 births in 
Canada and 1:900,000 in the United States [25]. Typical histopathological characteristics 
are renal cysts, tubular basement membrane disruption, and tubulointerstitial fibrosis. 
Most features are shared between the different NPHP types; however, tubular basement 
membrane disruption is usually absent in infantile NPHP. Also, kidneys of patients with 
infantile NPHP are usually enlarged, while normal-sized or smaller kidneys are seen 
in patients with other forms of NPHP (Figure 2J) [25]. NPHP can both be isolated and 
syndromic. Twenty NPHP genes are known so far and explain roughly one-third of the 
patients. All NPHP proteins reside in the basal body, transition zone or axonemal base 
of primary cilia; however, they have also been found in other cellular sites such as cell 
junctions and nuclei [26, 27]. Mutations in NPHP genes perturb a variety of signaling 
cascades including Wnt-, Hedgehog-, Hippo-, and DNA damage response signaling, 
which in turn disrupt renal development and tissue homeostasis [27]. 
2.2. Ciliopathies with major skeletal involvement 
Many ciliopathies are characterized by skeletal abnormalities such as dwarfism, 
short limbs and ribs, and brachydactyly/polydactyly. Ciliopathies with major skeletal 
involvement can be divided into four groups: cranioectodermal dysplasia (CED), short-
rib thoracic dysplasia (SRTD), Ellis-van Creveld syndrome (EVC), and oral-facial-digital 
syndrome (OFDS). CED is rare and autosomal recessive. Typical features are sagittal 
craniosynostosis, narrow thorax with pectus excavatum, rhizomelia, brachydactyly, and 
ectodermal dysplasia (Figure 2F) [28]. Vital organ dysfunction often occurs and causes 
death in ~20% of CED patients before the age of seven [28]. SRTD is clinically and 
genetically related to CED. This family of disorders includes the following syndromes; 
short-rib polydactyly syndrome (SRPS), Jeune asphyxiating thoracic dysplasia (JATD), 
and Mainzer-Saldino syndrome (MZSDS). These disorders are autosomal recessive and 
frequencies range from 1:100,000 to 1:1,000,000 [29]. The most prominent SRTD features 
are limb shortening and a small rib cage. These features are most pronounced in perinatal 
lethal SRPS (Figure 2E). Additional SRPS features may include polydactyly, cleft lip/
palate, and anomalies of a variety of organs and tissues including the brain, heart, eyes, 
kidneys, liver, pancreas, intestines, and genitalia [30]. Patients with JATD present with 
similar, but milder skeletal anomalies compared to SRPS. The main complication in JATD 
patients is the narrow thorax phenotype that causes severe respiratory insufficiency; 
this phenotype causes lethality in 20-60% of JATD infants (Figure 2G). Besides skeletal 
abnormalities, JATD patients also occasionally present with nephronophthisis, blindness, 
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liver fibrosis, and intellectual disability [29]. Similar as in CED, MZSDS is also featured 
by a relatively mild narrow thorax phenotype. Other features of MZSDS are shortened 
limbs, blindness, nephronophthisis, liver fibrosis and pancreatic abnormalities [31]. EVC 
is another ciliopathy that is featured by major skeletal anomalies. Besides dwarfism, 
polydactyly, and ectodermal dysplasia, congenital heart malformations are commonly 
seen in EVC patients (Figure 2H,L). The latter have a major influence on the prognosis 
for individual patients [32]. Finally, a variety of oral-facial-digital syndromes have been 
reported; however, many are based on single or few cases that are not molecularly 
tested [33]. The best known OFD type is OFD1, which is X-linked and characterized 
by bifid tongue, oral frenula, cleft lip/palate, dental anomalies, syndactyly, polydactyly, 
polycystic kidney disease, and central nervous system abnormalities (Figure 2K). 
Ciliary chondrodysplasias are genetically heterogenous. EVC is caused by mutations 
in EVC and EVC2. EVC mutations have also been reported in patients with autosomal 
dominant Weyers acrodental dysostosis, which presents with a milder phenotype than 
EVC [29]. Genetic overlap is mostly seen between CED, JATD, SRPS, and MZSDS 
(Table 1), but also occurs between OFD and JBTS (Table 1) [33-36]. The majority of CED 
and SRTD mutations have been found in genes encoding IFT and associated motor 
proteins (Figure 1 and Table 1). OFDS is also genetically heterogeneous and recent data 
suggest that a proportion of OFDS proteins reside in centriolar appendages where 
they regulate ciliogenesis in an antagonistic manner; C2CD3 promotes ciliary growth, 
whereas OFD1 is a repressor [37, 38]. 
2.3. Neurodevelopmental ciliopathies 
Joubert syndrome (JBTS) and Meckel-Gruber syndrome (MKS) are rare 
neurodevelopmental disorders that genetically and phenotypically overlap. JBTS was 
first described by Marie Joubert in 1969 and is diagnosed when patients have hypotonia, 
ataxia, developmental delay and distinctive cerebellar and brain stem malformations that 
can be recognized as a “molar tooth sign” (MTS) on MRI (Figure 2A) [39-41]. JBTS patients 
also often present with kidney cysts, polydactyly, coloboma, retinal dystrophy, respiratory 
abnormalities (episodic tachypnea or apnea), oral frenulae, and hepatic fibrosis [42]. The 
health of JBTS patients largely depends on the occurrence and severity of liver and 
kidney disease that require appropriate management and treatment [40, 43]. MKS shows 
marked clinical overlap with Joubert syndrome, but is more severe and perinatal lethal. 
This disorder is characterized by occipital encephalocele, polycystic kidneys, polydactyly, 
and hepatic fibrosis (Figure 2B-D) [44]. MKS is diagnosed when two of these four features 
are present or when one is present in combination with two other anomalies including 
cleft lip/palate, cardiac septal defects, holoprosencephaly, agenesis of corpus callosum, 
Dandy-Walker malformation, microphthalmia, situs inversus, ambiguous genitalia, and 
shortening and bowing of long bones [45, 46]. The incidence of JBTS ranges from 
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Figure 2: Phenotypic features of ciliopathies. The following features are commonly seen in ciliopathies. (A) 
Distinctive cerebellar and brain stem malformation that is known as the “molar tooth sign” in a JBTS patient. 
Open and filled arrowheads point out a deepened interpeduncular fossa and elongated superior cerebellar 
peduncles, respectively. (B-D) MKS fetus at the 14th week of gestation showing swollen stomach due to 
enlarged kidneys (B), occipital encephalocele (C), and polydactyly of hands (B) and feet (D). (E) Radiograph 
of an SRTD fetus displaying a short and narrow thorax, horizontally oriented ribs, short tubular bones with 
smooth ends, short and ovoid tibiae, and postaxial polysyndactyly. (F) Patient with CED showing a narrow 
thorax, pectus excavatum, and rhizomelic shortening of limbs. (G) Narrow thorax in a JATD patient. (H, L) Images 
of an EVC patient with a long narrow chest and shortness of the limbs (H), and hypodontia, i.e. absence 
of upper and lower conical incisors (L). (I) BBS patient with truncal obesity, micropenis, and apathetic facial 
features. (J) Cystic kidneys of a patient with infantile NPHP. (K) Postaxial polydactyly of the right hand in a 
patient with OFDS. Reprinted from Brancati et al., Joubert Syndrome and related disorders, Orphanet J Rare 
Dis. Jul 8;5:20, Copyright (2010), with permission from BioMed Central Ltd (A); Tallila et al., Identification of 
CC2D2A as a Meckel syndrome gene adds an important piece to the ciliopathy puzzle, Am J Hum Genet. 
2008 Jun;82(6):1361-7, Copyright (2008) with permission from Elsevier (B-D); El Hokayem et al., NEK1 and 
DYNC2H1 are both involved in short rib polydactyly Majewski type but not in Beemer Langer cases, J Med 
Genet. Apr;49(4):227-33, Copyright (2012) with permission from BMJ Publishing Group Ltd (E); Gilissen et al., 
Exome sequencing identifies WDR35 variants involved in Sensenbrenner syndrome, Am J Hum Genet. Sep 
10;87(3):418-23, Copyright (2010) with permission from Elsevier (F); Schmidts, Clinical genetics and pathobiology 
of ciliary chondrodysplasias, J Pediatr Genet, November;3(2):46-94, Copyright (2014) Thieme Publishers (G); 
Baujat and Le Merrer, Ellis-van Creveld syndrome, Orphanet J Rare Dis, Jun 4;2:27, Copyright (2007) with 
permission from Central Ltd. (H, L); Sahin et al., Two brothers with Bardet-Biedl syndrome presenting with 
Chapter 1
14
1:80,000 to 1:100,000 live births [43], while the prevalence of MKS is less frequent at 
1:140,000 [47]. Exceptions exist as the occurrence of MKS in the Finnish population is 
as high as 1:9,000 births [48, 49]. Both JBTS and MKS syndromes are usually autosomal 
recessive, but a few JBTS cases with X-linked inheritance have been reported [34]. JBTS 
and MKS overlap genetically; 25% of the 25 known JBTS genes have also been found 
mutated in MKS (Table 1) [41, 50]. It remains elusive why certain mutations in a gene lead to 
JBTS, while other mutations in the same gene cause MKS. In some cases mutation type 
may determine the phenotypic outcome. For example, missense mutations in CC2D2A 
cause JBTS, whereas null alleles are associated with MKS [41]. Modifier genes have also 
been proposed to play a role in phenotypic outcome and could explain intrafamilial 
phenotypic differences [41, 50]. Genotype-phenotype correlations have been reported 
and can facilitate choices for specific genetic testing. For example, AHI1 mutations often 
occur in JBTS patients with retinal dystrophy, while NPHP1 and RPGRIP1L mutations are 
most frequent in JBTS with renal dysplasia. Moreover, in 50% of JBTS patients with both 
retinal and renal phenotypes CEP290 mutations are detected [40, 43]. When considering 
the protein localization it is evident that most JBTS and MKS proteins reside in the ciliary 
transition zone (Figure 1). When they are mutated the structure of the ciliary transition 
zone is perturbed causing disruption of its function as a ciliary gate thereby affecting a 
variety of signaling pathways, including Wnt/β-catenin and Hedgehog signaling [41, 50].
2.4. Isolated and syndromic obesity 
Nonsyndromic obesity is a growing problem in the general population and mainly caused 
by multifactorial factors. Yet, in some cases isolated obesity is a Mendelian disorder that 
results from ciliary anomalies [51]. Previously, ciliary defects had already been described 
in obesity syndromes such as in BBS and Alström Syndrome (ALMS). Both syndromes 
display an autosomal recessive inheritance; however, oligogenic inheritance has also 
been described in BBS [52, 53]. The prevalence of BBS varies markedly between 
populations; from 1:160,000 in northern Europe to 1:13,500 births in isolated communities 
in Kuwait [54]. Cardinal BBS features are rod-cone dystrophy, obesity, polydactyly, 
intellectual disability, hypogonadism, and renal dysfunction (Figure 2I). Secondary 
features include cardiovascular abnormalities, craniofacial anomalies, psychomotor 
delay, type 2 diabetes (T2DM), and hearing loss. The clinical diagnosis of BBS is based 
on the presence of at least four primary features or a combination of three primary plus 
two secondary features. In general the BBS phenotype evolves during the first decade 
chronic renal failure, Case Rep Nephrol. Apr 3;2015:764973, Copyright (2015) Sahin et al. (I); Oud et al., 
Early Presentation of Cystic Kidneys in a Family with a Homozygous INVS Mutation, Am J Med Genet A. 
Jul;164A(7):1627-34, Copyright (2014) with permission from John Wiley and Sons Inc (J); Poretti et al., Delineation 
and diagnostic criteria of Oral-Facial-Digital Syndrome type VI, Orphanet J Rare Dis. Jan 11;7:4, Copyright (2012) 
with permission from BioMed Central Ltd (K).
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of life, except for polydactyly which is present at birth; generating an accurate clinical 
diagnosis may therefore be challenging in infancy and early childhood [55]. BBS has an 
adverse prognosis, with renal impairment being a frequent and important cause of death 
[56]. The phenotypically related ALMS is characterized by cone-rod dystrophy, obesity, 
hearing impairment, cardiomyopathy, type 2 diabetes, hepatic and renal disease [57]. A 
clinical diagnosis is based on the above mentioned cardinal features, and differs from 
BBS by the presence of hearing impairment and absence of polydactyly and learning 
difficulties [54]. While it may be difficult to make a clinical diagnosis of BBS and ALMS in 
early childhood, molecular testing clearly distinguishes both disorders. To date, only one 
gene, ALMS1, is known to be mutated in ALMS (Table 1) [58]. In Bardet-Biedl syndrome 
mutations in 19 genes are reported to be causative (Table 1), explaining over 80% of 
the patients [54]. The protein encoded by ALMS1 and most of the proteins encoded by 
BBS-associated genes localize to the base of the primary cilium. ALMS1 is also found 
in endosomal structures and is suggested to play a role in the recycling endosome 
pathway [59]. The BBSome, composed of BBS1-2, 4-5, 7-9 and BBIP10, plays an important 
role in trafficking proteins into and out of the cilium, while the chaperonin complex that 
consists of BBS6 and BBS10-12 is required for assembly of the BBSome [54, 60, 61]. The 
remaining BBS proteins have variable functions. Some are thought to act as GTPases 
or E3 ubiquitin ligases, others have been shown to regulate centriole migration and IFT 
[54].  
2.5. Primary ciliary dyskinesia 
Most phenotypes associated by dysfunction of motile cilia result in primary ciliary 
dyskinesia (PCD). Cardinal symptoms are neonatal respiratory abnormalities and airway 
infections during childhood, which eventually develop into bronchiectasis. Patients also 
often present with situs inversus, dextrocardia, and infertility [62, 63]. Diagnosis of PCD 
is challenging due to the phenotypic overlap with other respiratory diseases such as 
asthma, immune deficiencies, and bronchomalacia, and the absence of clear diagnostic 
criteria further complicates making an accurate diagnosis [63]. The prevalence of PCD, 
being 1:10,000 – 1:20,000, may therefore be and underestimate [63]. Mutations in 30 
genes have been associated with PCD and explain 60-70% of the cases [3, 63]. The 
inheritance pattern associated with PCD is usually autosomal recessive; however, 
X-linked or autosomal dominant inheritance have also been reported in a few cases 
[63-65]. Roughly 60% of proteins that are encoded by PCD genes are found in protein 
complexes and axonemal structures that are typically found in motile cilia such as inner 
and outer dynein arms, radial spokes, the central microtubule pair and nexin links 
(Figure 1), while the remaining proteins are cytoplasmic with a role in (pre)assembly and 
transportation of dynein components [3]. 
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Gene OMIM Description
Neurodevelopmental ciliopathies
AHI1 608894 JBTS
ARL13B 608922 JBTS
ATXN10 611150 JBTS-like
B9D1 614144 MKS
B9D2 611951 MKS
C5orf42 614571 JBTS
CC2D2A 612013 JBTS, MKS
CEP104 616690 JBTS
CEP290 610142 JBTS, SLSN, LCA, MKS, BBS 
CEP41 610523 JBTS
CSPP1 611654 JBTS
EXOC4 608185 MKS
EXOC8 615283 JBTS
HYLS1 610693 MKS-like
ICK 612325 ECO
IFT81 605489 JBTS-like
INPP5E 613037 JBTS
KIAA0586 610178 JBTS, SRTD
KIAA0753 617127 JBTS, OFDS
KIF14 611279 MKS
KIF7 611254 JBTS, MKS-like, ACLS
MKS1 609883 MKS, BBS
NPHP1 607100 JBTS, NPHP, SLSN
NPHP3 608002 MKS, NPHP
PDE6D 602676 JBTS
PIBF1 607532 JBTS
RPGRIP1L 610937 JBTS, MKS
TCTN1 609863 JBTS
TCTN2 613846 JBTS
TCTN3 613847 JBTS, OFDS
TMEM107 616183 MKS, OFDS
TMEM138 614459 JBTS
TMEM216 613277 JBTS, MKS
TMEM231 614949 JBTS, MKS
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1Gene OMIM DescriptionTMEM237 614423 JBTS
TMEM67 609884 MKS, JBTS, NPHP, BBS
TTBK2 611695 JBTS-like
ZNF423 604557 JBTS, NPHP
Ciliopathies with major skeletal involvement
C2CD3 615944 OFDS
CEP120 613446 SRTD
C21ORF2 603191 JATD
DDX59 615464 OFDS
DYNC2LI1 617088 SRTD
DYNC2H1 603297 JATD, SRTD
EVC 604831 EVC, WAD
EVC2 607261 EVC, WAD
IFT122 606045 CED
IFT140 614620 SRTD
IFT172 607386 JATD, MZSDS, SRTD, RD
IFT43 614068 CED
IFT52 617102 CED, SRTD
IFT80 611177 SRTD
NEK1 604588 SRTD
OFD1 300170 OFDS, SGBS, JBTS 
SCLT1 611399 OFDS
TBC1D32 615867 OFDS
TCTEX1D2 617405 SRTD
TTC21B 612014 JATD, NPHP
WDR19 608151 JATD, CED, NPHP
WDR34 613363 SRTD
WDR35 613602 CED, SRTD
WDR60 615462 SRTD
Isolated and syndromic obesity
ALMS1 606844 ALMS
ARL6 608845 BBS, RP
BBIP1 613605 BBS
BBS1 209901 BBS
BBS10 610148 BBS
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Gene OMIM Description
BBS12 610683 BBS
BBS2 606151 BBS
BBS4 600374 BBS
BBS5 603650 BBS
BBS7 607590 BBS
BBS9 607968 BBS
CCDC28B 610162 BBS
CEP19 615586 MOSPGF
IFT27 615870 BBS
LZTFL1 606568 BBS
MKKS 604896 BBS, MKKS
TRIM32 602290 BBS
TTC8 608132 BBS, RP
WDPCP 613580 BBS
Renal ciliopathies
ANKS6 615370 NPHP
CEP164 614848 NPHP
CEP83 615847 NPHP
DCDC2 605755 NPHP
GLIS2 608539 NPHP
INVS 243305 NPHP
IQCB1 609237 SLSN
NEK8 609799 NPHP
NPHP4 607215 NPHP, SLSN
PKD1 601313 ADPKD
PKD2 173910 ADPKD
PKHD1 606702 ARPKD
SDCCAG8 613524 SLSN
VHL 608537 VHL
XPNPEP3 613553 NPHP-like
Primary ciliary dyskinesia 
ARMC4 615408 PCD
C21orf59 615494 PCD
CCDC103 614677 PCD
CCDC114 615038 PCD
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1Gene OMIM DescriptionCCDC151 615956 PCD
CCDC39 613798 PCD
CCDC40 613799 PCD
CCDC65 611088 PCD
CCNO 607752 PCD
CENPF 600236 PCD
DNAAF1 613190 PCD
DNAAF2 612517 PCD
DNAAF3 614566 PCD
DNAAF5 614864 PCD
DNAH11 603339 PCD
DNAH5 603335 PCD
DNAI1 604366 PCD
DNAI2 605483 PCD
DNAL1 610062 PCD
DRC1 615288 PCD
DYX1C1 608706 PCD
HYDIN 610812 PCD
LRRC6 614930 PCD
NME8 607421 PCD
PIH1D3 300991 PCD
RSPH1 609314 PCD
RSPH4A 612647 PCD
RSPH9 612648 PCD
SPAG1 603395 PCD
ZMYND10 607070 PCD
Table 1. Genes mutated in ciliopathies . This overview of genes mutated in ciliopathies shows the heterogeneity 
of certain ciliopathies. Corresponding OMIM identifiers are shown. Acrocallosal syndrome (ACLS), Alström 
syndrome (ALMS), autosomal dominant polycystic kidney disease (ADKPD), autosomal recessive polycystic 
kidney disease (ARKPD), Bardet-Biedl syndrome (BBS), cranioectodermal dysplasia syndrome (CED), 
endocrine-cerebro-osteodysplasia syndrome (ECO), Ellis-van Creveld syndrome (EVC), Jeune asphyxiating 
thoracic dysplasia (JATD), Joubert syndrome (JBTS), leber congenital amaurosis (LCA), McKusick-Kaufman 
syndrome (MKKS), Meckel-Gruber syndrome (MKS), morbid obesity and spermatogenic failure (MOSPGF), 
nephronophthisis (NPHP), oral-facial-digital syndrome (OFDS), primary ciliary dyskinesia (PCD), retinitis 
pigmentosa (RP), Senior-Løken syndrome (SLSN), short-rib thoracic dysplasia (SRTD), Simpson-Golabi-Behmel 
syndrome (SGBS), Von Hippel-Lindau syndrome (VHL), Weyers acrodental dysostosis (WAD).
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3. Classification of ciliopathies
The term “ciliopathies” was introduced in the previous decade to describe human 
disorders that are caused by ciliary dysfunction [66]. In general, ciliopathies are either 
classified based on the type of cilia involved (motile or non-motile), but a specific 
combination of clinical features may also indicate a particular syndrome or may be 
suggestive of a few disorders as there is significant overlap in clinical features that define 
each of the ciliopathies [66]. For example, the phenotypic features of JBTS and MKS or 
BBS and ALMS overlap significantly [41]. It is this overlap in clinical features between 
different ciliopathies that complicates generation of a correct diagnosis for clinicians 
and hampers accurate prognosis, counseling, prenatal screening, and management 
[67]. Therefore I suggest to classify ciliopathies according to clinical criteria, as well as, 
molecular, and functional information as this will enable us to truly distinguish between 
the different ciliopathies. 
4. Next-generation sequencing for ciliopathies
The introduction of next-generation sequencing (NGS) methods has made a significant 
impact on the diagnostics of hereditary disorders, including ciliopathies. Two methods 
that revolutionized screening of individual ciliopathy patients and cohorts for pathogenic 
mutations are targeted gene panels, in which multiple genes are analyzed in parallel, 
and whole-exome sequencing (WES). Targeted gene panels have been sequenced with 
NGS methods in dozens or even hundreds of subsets of patients for efficient and cheap 
mutation detection in known genes in a variety of ciliopathies, including but not limited 
to JBTS, BBS, ALMS, NPHP and PCD [68-71]. Some gene panels not only targeted known 
ciliary disease genes, but also included candidate genes, e.g. genes with a predicted 
ciliary function. These panels have proven to be successful tools to identify novel 
disease genes by various research groups [70, 72-74]. The advantage of targeted gene 
panel testing versus whole-exome sequencing (WES), whereby all exons of the genome 
are sequenced, is that panels usually result in higher coverage data at a relatively 
low cost and with high-throughput [75, 76]. In addition, the chance of identification of 
incidental findings, which are clinically relevant findings that are unrelated to the clinical 
problem for which screening was initially intended, is extremely low when only known 
ciliopathy-specific genes are being sequenced [77]; however, it is difficult to add new 
genes to existing gene panels [77]. The possibility of detection of incidental findings is 
an important concern when analyzing WES data, however, WES has proven to be highly 
successful for the identification of a mutation in a gene that has not previously been 
implicated in ciliary disease. Furthermore, retrospective analysis of the data is possible 
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[77]. In diagnostics, WES data are often analyzed as if data resulted from a gene panel. 
This approach only allows interpretation of variants that occur in a list of preselected 
genes, while variants in other genes remain hidden. This strategy minimizes incidental 
findings, maintains flexibility in gene panels, and retains the possibility to analyze the 
complete exome. It is only in the absence of candidate variants that the rest of the 
exome is opened for analysis if the patient consents for this. This approach reduces the 
patient’s medical costs, as pre-screening methods like (SNP) microarrays and targeted 
gene panels with only known mutations in ciliary genes become redundant, and is 
considered to be cost-effective when a clinician needs to investigate more than two 
genes to identify the genetic cause of disease, a scenario that often applies when a 
ciliopathy patient presents in the clinic considering the enormous genetic heterogeneity 
in these disorders [78, 79]. Finally, these NGS methods resulted in the detection of 
numerous pathogenic mutations and dozens of novel disease genes in a large group 
of patients in a nick of time. Thereby, NGS enormously facilitated our ability to make a 
fast and early diagnosis for individual patients and to recognize important genotype-
phenotype correlations in patient cohorts [68, 71]. This knowledge contributes to the 
clinician’s ability to correctly inform patients about expected clinical features and disease 
progression, and, allows clinicians to form appropriate interdisciplinary teams leading to 
optimal clinical care and disease management. For example, the knowledge that within 
a certain genetic spectrum renal disease might develop, enables a clinician to monitor 
renal function in patients before severe renal failure occurs, and, allows a timely start of 
a general conservative treatment to slow the process of organ deterioration. Similarly, 
early diagnosis is highly beneficial to PCD patients as preventive measurements, such 
as regular airway clearance therapy and aggressive management of infections, delay 
progression to irreversible lung disease [80].    
4.1 NGS-based screening of ciliary disease genes
With the current knowledge of disease genes (Table 1) and mutations, we can genetically 
explain 45-90% of JBTS and MKS patients [71, 81, 82], 55-70% of CED and SRTD patients 
[29, 83], 84% of EVC patients [84], 80% of BBS and ALMS patients [54], 21% of NPHP 
patients [85], and 65% of PCD patients with panels [86]. A recent research study reported 
that WES provides a molecular diagnosis in 44% of ciliopathy patients [78]. Thus, a large 
percentage of ciliopathies can be genetically explained upon NGS-based screening. 
The chances of finding novel ciliary disease genes are decreasing, but at the same 
time the number of detected variants are increasing as more and more screens are 
performed and as genetic tests become more comprehensive. To illustrate the latter, 
the current development of whole-genome sequencing (WGS), where the complete 
human genome is sequenced in a single effort, is exponentially increasing the number 
of detected variants as not only the coding DNA is analyzed, but also intragenic and 
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intronic DNA.  
4.2 Technical challenges
Although NGS sequencing has tremendously improved mutation detection for numerous 
disorders, ciliopathies included, there are still a number of hurdles to take with respect 
to accurate variant detection and prioritization. Technical challenges may impact the 
coverage of genes, referring to the number of times a genomic region is read, and 
lower the yield of variant detection. For example, it remains difficult to sufficiently cover 
genes that have multiple pseudogenes (e.g. PKD1), or genomic regions with high CG 
contents and repetitive sequences [87, 88]. Another NGS challenge is represented 
by the occurrence of pathogenic mosaicisms [89]. Such variation is difficult to detect 
because of the sporadic occurrence of these variants in sequence reads. Stringent 
filtering criteria may thus prevent us from identifying these mutations in WES data. These 
technical challenges need to be resolved to improve accurate molecular diagnosing of 
patients and will likely at least in part be resolved in time as NGS machines, bioinformatics 
platforms and kits continue to advance. 
4.3 Variant interpretation and classification
To improve and standardize reporting of variants, the Association for Clinical Genetic 
Science (ACGS) has developed guidelines for variant classification. There are five classes 
starting from clearly not pathogenic (1) to clearly pathogenic (5) based on published and 
bioinformatic information [90]. In between are classes that require further investigation; 
class 2 Unlikely to be pathogenic, class 3 Unknown significance (VUS), and class 4 
Likely to be pathogenic. To classify a variant according to this system, scientific reports, 
bioinformatic tools (e.g. SIFT, CADD, PolyPhen, PhyloP), and public variant databases 
(e.g. ClinVar and ExAC) are used to estimate the characteristics of a variant. These tools 
and databases provide information about changing amino acid properties, conservation 
of the amino acid, and the minor allele frequency in specific populations. However, this 
information can be conflicting and is not sufficient to interpret the functional effect as 
(likely) benign or (likely) pathogenic. Additional functional studies are required to shed 
more light on variants that have not been associated with a clinical phenotype before, 
and lack any compelling information about variant incidence and functional impact [90, 
91]. 
Besides bioinformatic and functional investigations to interpret variants one can 
choose to make use of public databases to register and share identified variants and 
associated phenotypes [78]. An initiative that promotes data sharing for rare disorders 
is the “MatchmakerExchange” database (http://www.matchmakerexchange.org/). When 
genotypic and phenotypic data is entered on this website, it is registered in various 
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connected databases that in turn allows bonding between scientists and clinical staff 
with matching interests [78]. 
5. Functional testing
Functional studies have been used for many years already to advance research and 
increase knowledge about the function of proteins and variants [92, 93]. These studies 
can be performed in model organisms, cell-lines, or patient-derived material. The 
implementation of NGS-based techniques in diagnostics has revolutionized molecular 
testing, but also introduced the need for functional testing to characterize the various 
detected variants. Whether a variant is pathogenic or not cannot always solely be based 
on genomic testing results but may require protein studies. This section discusses 
various different platforms for functional testing and emphasizes how patient-derived 
cells can be obtained and used to determine the pathogenicity of variants. 
5.1. Models: organisms and cell lines
Model organisms such as D. rerio (zebrafish), C. elegans (worm) and D. melanogaster 
(fruit fly) are used in ciliopathy research to both model mutational effects and derive 
information on the normal function of disease associated genes that encode ciliary 
proteins [92, 94, 95]. Even though these organisms seem evolutionary distant from 
humans, they show a 43-70% genetic similarity to humans, and are well-suited for studying 
orthologous genes [96]. The short and simple reproductive cycle, cheap housing costs, 
and relative straightforwardness to mutate genes, makes these organisms ideal for 
(large) genetic studies. Importantly, they all express ciliary genes and comprise ciliated 
cells; the worm and fruit fly have ciliated sensory neurons, and the zebrafish has ciliated 
organs, including the Kupffer’s vesicle, kidney, eye, sensory systems, and the neural 
tube. Over the years the zebrafish has become a strong model for the investigation of 
human genetic disease, showing a 70% genomic similarity and physiological proximity 
to humans [96]. For example, the zebrafish pronephros constitutes a simplified version 
of the human kidney, meaning that the two bilaterally paired nephrons in zebrafish are 
structurally similar to the human nephron, which constitutes the basic structural and 
functional unit of the kidney [97-99]. Because of this physiological similarity, zebrafish 
embryos were used to study the functional role of NPHP3 (involved in NPHP and MKS) 
in normal embryonic development and in the pathogenesis of cystic kidney disease. 
Results showed that nphp3 interacts with nphp2, and that this interaction plays an 
essential role in ciliary function [100]. This is just one example of how a model organism 
can contribute to the molecular understanding of the function of a protein in health and 
disease. Besides employing model organisms to evaluate ciliary function, several assays 
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based on cultured ciliated mammalian cells can also be used. These cells can be derived 
from patient material such as skin biopsies (see: section 5.2), but several immortalized 
cell lines available at central repositories can also be used to interrogate the effect 
of mutations in ciliary proteins. Examples of cell lines that are often used in ciliopathy 
research are human embryonic kidney 293T (HEK293T) cells, human retinal pigmented 
epithelium (hTERT-RPE1) cells, H69 cholangiocytes, and mouse inner medullary collecting 
duct (mIMCD3) cells. The choice of the cell line depends on the phenotype of the patient, 
the expression pattern of the gene, and the type of experiments that will be performed. 
For example, HEK293T or mIMCD3 cell lines can be quite suitable for studies of gene 
mutations associated with a renal cystic phenotype, while H69 cholangiocytes could be 
more appropriate for studying genes associated with polycystic liver disease. The ability 
of cells to form a flat monolayer is preferred for microscopic techniques, which means 
that use of hTERT-RPE1 cells is optimal for imaging, whereas HEK293T cells are preferred 
in protein interaction studies as they grow fast and are easy to transfect.
5.2. Patient-derived cells
Cellular-based phenotyping to assess the effects of VUS in vitro can be performed in 
ciliated cells derived from patient’s shed deciduous teeth, skin biopsy or urine samples 
[101, 102]. Ciliated fibroblast cells can be cultured from both skin biopsies and deciduous 
teeth. These cultures can be easily expanded and allow for multiple tests over several 
weeks.  The growth of renal cells derived from urine samples is more restrictive in 
comparison. An urine sample contains cells from different tissues of the urinary tract 
such as kidneys, ureters, bladder, and urethra. Under specific culturing conditions the 
renal cells, urine-derived renal epithelial cells (URECs), can be expanded and used 
for numerous experiments, however, these ciliated cells undergo a limited number of 
cell divisions and are thus restricted to approximately four to seven passages [101]. All 
three sources of patient-derived cells have certain benefits and drawbacks (Table 2). 
For instance, an invasive procedure is required to obtain a skin biopsy, while collecting 
urine and shed teeth are non-invasive. As ciliopathy patients are often children when 
the need for functional studies arises, an invasive procedure is not desired and the 
attainment of ethical approval is not trivial. Collection of urine samples could provide 
a solution in these cases as these samples are easy to collect, even at multiple time 
points. A clear drawback of urine-derived cells is that once a patient has received a 
kidney transplant this source of patient-derived cells is gone. The limiting factor for the 
collection of shed deciduous teeth is time as the period that children shed teeth is 
brief and age-dependant. Children usually change to their permanent teeth around the 
age of seven. In addition, the initial culture of fibroblasts from teeth is not trivial, and a 
resulting cell line is not guaranteed. 
Another important aspect to consider is the origin of the patient-derived material, 
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since expression levels of genes may differ between tissues, and different tissues 
may express different isoforms of the same gene. Isoforms are different transcripts of a 
gene produced through alternative splicing, posttranslational modifications, proteolytic 
cleavage, somatic recombination, or genetic variations in protein-coding regions [103]. 
Thus, the origin of the patient-derived cells can influence the results of functional studies 
for certain genes. For many ciliopathies there is renal involvement suggesting that urine 
may be a suitable source for patient-derived cells in many patients. 
URECs Skin-fibroblasts
Be
ne
fit
s
Co
lle
ct
io
n • Non-invasive
• Serial collection possible
• Collection in home-environment
   possible
Cu
ltu
re
• 3D spheroid studies possible • 99% success in obtaining 
   cell-line
• Passage number >20
• Easy to store in liquid N₂
Ex
pe
rim
en
ts • Cells originate from tissue often
   affected in ciliopathies
• Excellent for microscopic
   purposes
• Excellent for signaling studies
• Homogeneous cell population
• Excellent for microscopic
   purposes
Dr
aw
ba
ck
s
Co
lle
ct
io
n • Processing required within 4   hours after collection
• Not useful after kidney tran
   plant or severe renal
   insufficiency 
• Invasive 
• Single collection
• Strenuous for children
• Collected in clinic
Cu
ltu
re
• 1 in 3 samples result in URECs
• Passage number <10
• Poor response to liquid N₂
   storage
• Laborious 
Ex
pe
rim
en
ts • Heterogeneous cell population • Cells originate from unaffected
   tissue
• Challenging to reproduce
   signaling experiments
Table 2. Benefits and drawbacks of URECs and skin-fibroblasts
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5.3. Functional assays in cells 
URECs, or fibroblasts derived from skin or teeth, can be used to study the ciliary phenotype 
of a patient. When patient-derived cells are unavailable, commercially available ciliated 
model cell lines can be used for functional studies. Depending on the candidate gene 
associated with the VUS, different techniques can be explored to determine the impact 
of this variant. 
Assays for cell lines are based on methods to silence genes (small interfering RNA), 
insert or delete coding DNA (CRISPR/Cas9), or over express fusion proteins. Although 
these methods introduce harsh alterations to the cells that can have a negative effect 
on the physiological properties of the studied protein, these methods are widely and 
successfully used to study the localization and function of a specific protein. One 
elegant assay to study differences in localization of wild type and mutant proteins is 
immunocytochemistry (ICC). This technology is based on the use of antibodies that label 
specific proteins or compartments of the cell. ICC can be used for cilium phenotyping, 
which means that cilium presence, length, morphology, and IFT are visualized and 
analyzed (Figure 3, chapter 2). Moreover, patient-specific ciliary phenotypes can be 
analyzed, which further allows interrogation of the targeted variant (chapter 2,3,6). For 
example, retrograde IFT defects can easily be studied in ciliated cells, by analyzing the 
localization of anterograde proteins that will accumulate at the ciliary tip when retrograde 
transport is defective. This assay is especially relevant for skeletal ciliopathies that are 
often caused by mutations in IFT genes. 
An advantage of URECs is that they can be cultured on glass coverslips in 2D, as well 
as, in matrigel to form 3D spheroids [101]. These 3D spheroids form a lumen resembling a 
more physiological relevant model of the renal tubule, which can be necessary to detect 
the mutational effect of certain variant [104]. Furthermore, URECs can be used to study 
signaling cascades that require the cilium, like Wnt-, Hedgehog-, and Hippo signaling. 
Transcriptomics and other RNA-based studies are well-suited for detecting signaling 
defects. 
Besides the above-explained cellular-based functional studies the effects of VUS 
can be studied by analyzing protein interactions and complex formations (chapter 5). 
Comparison of interaction networks of wild type and mutant proteins provides important 
information about the loss or gain of protein function due to a mutation, which may in turn 
facilitate variant interpretation.
To conclude, functional studies come in a variety of flavors and can be performed in 
multiple sources of cells. For each variant there is an optimal set of experiments that can 
be performed to study if protein function is significantly impacted by the variant or not. 
Such knowledge strongly facilitates variant interpretation and accurate diagnosis.
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Figure 3. Ciliary phenotypes. (A-B) Visualization of cilia in fibroblasts with the ciliary axoneme in red and the 
basal body in green. The nucleus is shown in blue. One can assess the presence or absence of cilia (A), and 
the same images can be used for measurements of the axonemal length. The three classes of length are 
depicted here represent short (2.03 µm), normal (3.44 µm), and long (6.17 µm) cilia (B). The analysis should 
include measurements of >50 cilia, and, must be repeated in at least 3 independent experiments, because 
culture conditions may influence ciliogenesis resulting in false positive or negative results. (C) Analysis of 
IFT in fibroblasts. The ciliary axoneme is shown in red, the basal body in pink, and the anterograde IFT-B 
protein IFT88 in green. The presence of IFT88 in the cilium indicates (at least partially) functional anterograde 
IFT, while abnormal localization of IFT88 may be an indicator of disrupted IFT-A retrograde transport, as 
disrupted retrograde transport can lead to accumulation of different amounts of IFT88 in the ciliary tip. (D) 
Cilium morphology of URECs. The ciliary axoneme is shown in red and the basal body in green. The nucleus is 
shown in blue. Variants in ciliary genes may cause length abnormalities and bulging of cilia. The images show 
(1) multiple bulges in axoneme and extreme ciliary length (24 µm), (2) long cilium (11 µm) with bulged tip, (3) cilium 
with bulged tip (3.6 µm in length).
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6. Aim of this thesis
In the previous sections I explained that ciliopathies are rare hereditary disorders caused 
by dysfunction of the cilium, and that the cilium is an intriguing organelle that is present 
on nearly every cell of the human body with essential roles in embryonic development 
and beyond. As the phenotypic spectrum of ciliopathies is broad and overlapping, 
molecular knowledge greatly enhances the ability of clinicians to provide their patients 
with an accurate diagnosis. In this thesis I show how a variety of genetic and functional 
experiments facilitate diagnosis of patients with disorders that affect the kidney and 
other organs. 
In chapter 2, I imaged cilia in fibroblasts derived from a patient with endocrine-cerebro-
osteodysplasia (ECO) syndrome, and showed that mutations in intestinal cell kinase (ICK) 
result in ciliary defects that contribute to this disorder. 
In chapter 3, I detected a novel inversin (INVS) mutation and used patient-derived 
fibroblasts to prove its pathogenicity. In addition, I reported on the phenotypic expansion 
associated with INVS-related infantile NPHP. 
In chapter 4, I identified a de novo 4.5-Mb microdeletion, containing IFT43, on 
chromosome 14q24.2q24.3 in a ciliopathy patient. Defective retrograde transport was 
detected in patient-derived fibroblasts, suggesting a ciliary defect in the pathogenesis 
of this disorder.
In chapter 5, I report on how several genetic and functional technologies and approaches 
revealed that mutations in exostosin-like glycosyltransferase 3 (EXTL3) cause a novel 
neuro-immuno-skeletal dysplasia phenotype.
In chapter 6, I demonstrate a novel proteomics-based method that allows assessment 
of the effects of mutations in protein complexes. Fibroblasts derived from CED patients 
were used to determine the mutational effect on the stoichiometry of the IFT-A complex 
in this study.
In chapter 7, I used patient-derived URECs to investigate the effect of two novel IFT140 
variants on the ciliary phenotype in order to determine the pathogenicity of the variants, 
and, to confirm the clinical diagnosis of SRTD9.
Chapter 8 provides a general discussion of the studies presented in this thesis and my 
vision on how combining clinical, molecular, and functional data can improve patient 
diagnosis. 
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Image: Overexpression of wildtype mRFP-ICK in mIMCD3 cells.
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Abstract 
Background
Endocrine-cerebro-osteodysplasia (ECO) syndrome [MIM:612651] caused by a recessive 
mutation (p.R272Q) in intestinal cell kinase (ICK) shows significant clinical overlap with 
ciliary disorders. Similarities are strongest between ECO syndrome, the Majewski and 
Mohr-Majewski short-rib thoracic dysplasia (SRTD) with polydactyly syndromes and 
hydrolethalus syndrome. In this study, we present a novel homozygous ICK mutation in 
a fetus with ECO syndrome, and compare the effect of this mutation with the previously 
reported ICK variant on ciliogenesis and cilium morphology. 
Results
Through homozygosity mapping and whole-exome sequencing we identified a second 
variant (c.358G>T; p.G120C) in ICK in a Turkish fetus presenting with ECO syndrome. In 
vitro studies of wild type and mutant mRFP-ICK (p.G120C and p.R272Q) revealed that, 
in contrast to the wild type protein that localizes along the ciliary axoneme and/or is 
present in the ciliary base, mutant proteins rather enrich in the ciliary tip. In addition, 
immunocytochemistry revealed a decreased number of cilia in ICK p.R272Q-affected 
cells. 
Conclusions
Through identification of a novel ICK mutation we confirm that disruption of ICK causes 
ECO syndrome, which clinically overlaps with the spectrum of ciliopathies. Expression 
of ICK-mutated proteins result in an abnormal ciliary localization compared to wild type 
protein. Primary fibroblasts derived from an individual with ECO syndrome display 
ciliogenesis defects. In aggregate, our findings are consistent with recent reports that 
show that ICK regulates ciliary biology in vitro and in mice, confirming that ECO syndrome 
is a severe ciliopathy. 
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Background 
We have previously described an extended consanguineous family from an Old Order 
Amish community affected with neonatal lethal endocrine-cerebro-osteodysplasia (ECO) 
syndrome, characterized primarily by endocrine, cerebral and skeletal abnormalities 
[1]. This is the only family with ECO syndrome known to date. Through homozygosity 
mapping and candidate gene sequencing, we identified a homozygous missense 
mutation (c.815G>A [UCSC HG19: NM_014920] and p.R272Q [UCSC: NP_055735]) in ICK, 
which encodes the intestinal cell kinase [1]. The ICK protein belongs to the ros-cross 
hybridizing kinase (RCK) family, which consists of two other proteins, i.e. male germ-cell-
associated kinase (MAK) and MAPK/MAK/MRK-overlapping kinase (MOK) [2-4]. Recent 
studies suggest that ICK is a ciliary protein, involved in ciliogenesis and regulation of 
intraflagellar transport (IFT) [5-8]. Here, we describe a new family with one affected 
fetus who was initially diagnosed with short-rib thoracic dysplasia (SRTD), a clinically 
and genetically heterogeneous group of disorders that are characterized by skeletal 
abnormalities, including a narrow thorax, short ribs, short and bowed tubular bones, 
and a number of extraskeletal features [MIM:PS208500]. Homozygosity mapping and 
whole-exome sequencing in the affected fetus revealed a novel homozygous missense 
mutation in ICK (c.358G>T; p.G120C), confirming that disruptions in this gene cause ECO 
syndrome, a disorder that shows marked clinical overlap with the short-rib thoracic 
dysplasia syndromes (SRTD), Majewski and Mohr-Majewski in particular [1]. Based on 
the clinical overlap between ECO syndrome and these other ciliopathies, and recent in 
vitro and mouse studies [5, 6] that showed that ICK is a ciliary protein, we tested whether 
either mutation (p.G120C or p.R272Q) affect cilium presence, morphology and function in 
ciliated mouse Inner Medullary Collecting Duct 3 (mIMCD3) cells and in skin fibroblasts 
derived from a p.R272Q patient with ECO syndrome.
Methods
Collection of human blood samples and ethics consent and permissions 
Blood samples were collected from twenty-two family members (I:1 to I:4, II:1 to II:15 and 
III:3 to III:5) from family 1. Genomic DNAs (gDNA) were extracted from blood using a 
Qiagen kit (Cat# 74106) and from a fetal skin sample (III:6) by standard procedure. Parents 
gave their informed consent for study participation and the study was approved by 
the Clinical Research Ethics Committees of Singapore (IRB #2013/1029/E) and Istanbul 
Medical Faculty with protocol number 2012.743-IRB2.1061.
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Collection of human fibroblasts lines and ethics statement
A fibroblast cell line from an Old Order Amish patient (family 2 in this paper) with ECO 
syndrome and two healthy controls from non-Amish (control I) and Amish (control II) 
communities were collected previously [1]. Tissues were obtained with informed consent, 
whereby it should be noted that parents provided informed consent for the patient with 
ECO syndrome. Material was collected with approval by the Office of Research Ethics of 
the University of Western Ontario with the following reference number: 07920E. 
Genotyping and homozygosity mapping  
The 14 individuals, including I:2, I:4, II:1, II:4, II:8, II:9, II:10, II:11, II:12, II:13, III:3, III:4, III:5 and 
III:6, were genotyped using Illumina HumanCoreExome-12v1 BeadChips following 
manufacturer’s instructions. Call rates were above 99%, gender and relationship were 
verified using Illumina GenomeStudio software. Identical-By-Descent (IBD) mapping was 
performed by searching for homozygous regions in the unique affected individual using 
custom programs written in Mathematica (Wolfram Research, Inc.). Allowing 1% error rate, 
all homozygous regions that were >2cM were examined. Candidate regions were further 
refined by exclusion of common homozygous segments with any of the 13 unaffected 
family members. 
Whole-exome sequencing   
One microgram of high-molecular weight gDNA extracted from fetus III:6 was used 
for exome capture with ION TargetSeq Exome Kit. DNA was sheared using Covaris 
M220 Focused-ultrasonicator (Covaris Inc., Woburn, MA, USA) to target an average 
fragment size of 200 bp. Shearing was followed by end repair, ligation of adapters, 
nick repair, purification, size selection and final amplification prior to exome capture 
as per TargetSeq protocol. The amplified DNA was cleaned with Ampure XP reagent 
(Agencourt, Boston, USA) and the DNA was eluted in 30 µl low TE buffer. The libraries 
were quantified using a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA). 
The exome library was used for emulsion PCR on an Ion OneTouch System or Ion Chef 
System (Life Technologies, Carlsbad, CA, USA) following the manufacturer’s protocol. 
Each library was sequenced on an Ion Proton instrument (Life Technologies, Carlsbad, 
CA, USA) using one ION PI chip.
Sequence reads were aligned to the human reference genome (Human GRCh37 (HG19) 
build) using Torrent Mapping Alignment Program (TMAP) from the Torrent Suite (v4.2.1). 
PCR duplicates in the BAM file were identified by the Filter Duplicates plugin (v4.2) 
and removed. The variants were called using the Torrent Variant Caller (TVC) plugin 
(v4.2.1) and imported into Ion Reporter (v4.2), where each variant was annotated using 
the “annotate single sample variants” workflow. Information including the associated 
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gene, variant location, quality-score, coverage, amino acid change, predicted functional 
consequences using SIFT [9], PolyPhen2 [10] and Grantham [11], phyloP conservation 
scores [12] and 5000 genomes Minor Allele Frequencies were provided for each variant. 
Common SNPs using the NCBI’s “common and no known medical impacts” database 
(ftp://ftp.ncbi.nih.gov/pub/clinvar/vcf_GRCh37) and the Exome Sequencing Project (http://
evs.gs.washington.edu/EVS/) common SNP database were filtered out. Variants that 
were predicted to be synonymous or not having a location on either a coding exon, UTR, 
splice site junction or flanking intron were also removed. Variants were next compared 
to an in-house database of 138 previously sequenced samples. Those variants that were 
present in greater than 3% of the previously sequenced samples were removed. 
Cloning 
The ultimate ORF clone of human ICK cDNA (IOH38087) in pENTR221 [1] was used to 
transfer ICK into p733 (Life Technologies) through Gateway cloning (Life Technologies) 
according to the manufacturer’s instructions. The p733 vector encodes a monomeric 
Red Fluorescent Protein (mRFP). The p.G120C and p.R272Q mutations were introduced 
through site-directed mutagenesis, and constructs were validated with restriction digests 
and Sanger sequencing. 
Cell culture
Localization studies of mutant and wild type mRFP-ICK were performed in two different 
cell lines, i.e. Human Embryonic Kidney Cells 293 with Tantigen of SV40 (HEK293T) and 
mouse Inner Medullary Collecting Duct 3 (mIMCD3) cells. HEK293T cells were cultured 
in Dulbecco’s Modified Eagle’s medium (DMEM) with 10% Fetal Calf Serum (FCS) and 
mIMCD3 cells in DMEM/F12 (1:1) supplemented with 10% FCS. Fibroblasts from an Old 
Order Amish patient with ECO syndrome and two healthy controls from non-Amish 
(control I) and Amish (control II) were cultured for immunocytochemistry experimentation. 
Fibroblasts were cultured in DMEM supplemented with 20% FCS. All cell lines were 
cultured at standard cell culture conditions.  
Transfections in HEK293T and mIMCD3 cells 
To analyze the cellular localization of mRFP-ICK in HEK293T cells, these cells were cultured 
on sterile coverslips for 24 hours. Cells were then transfected with p733 vector DNA 
encoding either wild type or mutant (p.R272Q or p.G120C) mRFP-ICK using Lipofectamine 
(Life Technologies, Bleiswijk, The Netherlands) according to manufacturer’s instructions. 
48 hours post transfection cells were fixed in ice-cold methanol for 10 minutes. After a 
quick wash with PBS cells were permeabilized with 0.5% Triton X-100 in PBS. A drop of 
DAPI containing Fluoromount-G (Southern Biotech, Birmingham, AL, USA) was added 
to the cells, and cover glasses were then placed on microscopic glass slides. The 
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experiment was performed twice and >35 cells were counted per condition. Microscopic 
analysis was conducted with a Zeiss Axio Imager Z2 fluorescence microscope (Zeiss, 
Sliedrecht, The Netherlands) equipped with an ApoTome slider. Images were obtained 
with ZEN 2012 software (Zeiss) and processed with Photoshop CS4 (Adobe Systems, 
San Jose, CA, USA) and FIJI software. The protocol to determine the ciliary localization of 
mRFP-ICK in mIMCD3 cells was largely similar compared to HEK293T studies; however, 
after culturing mIMCD3 cells for 24 hours on sterile coverslips followed by 24 hours 
of transfection, culture medium was replaced by serum-low medium containing 0.2% 
FCS. mIMCD3 cells were grown in this medium for 24 hours to induce ciliogenesis. 
Subsequently, immunocytochemistry and microscopy were performed. The experiment 
was performed in quadruplicate and >50 cilia were analyzed per condition.
Immunocytochemistry
The mutational effects of p.R272Q were analyzed in patient-derived fibroblasts from 
an affected individual from family 2 compared to fibroblasts from healthy non-Amish 
(control I) and Amish (control II) controls. The fibroblast cell lines were cultured on sterile 
coverslips for 24 hours. Subsequently, ciliogenesis was induced by replacing the culture 
medium for DMEM with 0.2% FCS for 48 hours, followed by immunostaining. For this 
purpose, cells were washed in PBS, fixed in 2% paraformaldehyde in PBS for 20 minutes 
permeabilized in 1% triton X-100 in PBS for 5 min. Prior to antibody binding the cells were 
blocked for 30 minutes in 2% bovine serum albumin (BSA) in PBS. The following primary 
antibodies were used: ARL13B (rabbit polyclonal, Proteintech Group, Manchester, United 
Kingdom, 1:500), and RPGRIP1L (custom-made guinea pig polyclonal; SNC039, 1:500). 
Primary antibodies were diluted in 2% BSA/PBS and incubated for 1 hour at room 
temperature. After washing with PBS, cells were incubated with fluorescently-labeled 
secondary antibodies for 30 minutes. These include anti-guinea pig IgG Alexa Fluor 
568 and 647 (1:400), and anti-rabbit IgG Alexa Fluor 488 (1:400). These antibodies were 
all obtained from Life Technologies (Bleiswijk, The Netherlands). After washing cover 
glasses in PBS, a drop of DAPI containing Fluoromount-G (Southern Biotech, Birmingham, 
AL, USA) was added to the cells. Cover glasses were placed on microscopic glass slides 
and microscopic analysis was performed as previously described. 
Results
Clinical description of patient I 
The affected fetus from family 1 (III:6, patient I) was born to a consanguineous Turkish 
couple with three unaffected children (III:3, III:4, and III:5), a newborn who died 12 hours 
after birth (III:1) due to an unknown etiology, and a still birth (SB) baby (III:2) (Figure 1A). 
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Antenatal ultrasound at 16 weeks of gestation showed cystic hygroma, scalp edema 
ascites, bilateral ventriculomegaly,  very short tubular bones and polydactyly of hands 
and feet, and short ribs. A differential diagnosis of SRTD was made. Follow up scan at 
19 weeks of gestation revealed large and hyperechogenic kidneys, and a ventricular 
septal defect. Fetal karyotype was 46, XY. The pregnancy was terminated at 33 weeks 
of gestation. In addition to hydropic appearance, short thorax and very short limbs, 
postmortem examination revealed oro-facial-digital defects with syndromic craniofacial 
features such as high and broad forehead, deep set eyes, hypertelorism, very small 
nose, anteverted nares, midline pseudocleft of the upper lip, clefting of the soft palate, 
natal teeth, labiogingival fusion, irregular alveolar crest, tongue fused to the lower palate, 
multiple frenula, micrognathia, low-set and posteriorly rotated ears, ostaxial heptadactyly 
of the hands, and preaxial heptadactyly of the feet. Sex reversal with hypoplastic labial 
folds and anterior ectopic anus were also noted. Radiographs showed resemblance 
to SRTD type II, with very short tubular bones, torpedo-like femura, ovoid hypoplastic 
tibiae, premature epiphyseal ossifications in the lower limbs, short ribs, mildly defective 
ossification of the vertebrae, and small ilia with normal shape. Figure 1B shows various 
phenotypic characteristics of patient I. The clinical features observed in patient 1 
significantly overlap with the features described of the affected infants in family 2, 
described by Lahiry et al. [1]. Table 1 shows a phenotypic comparison of the patients from 
both families. 
Genotyping and homozygosity mapping 
Homozygosity mapping identified IBD regions in the unique affected individual that were 
refined by exclusion of common homozygous segments with any of the 13 unaffected 
members of family 1. Four homozygous loci (> 2 CM), totaling 50 Mb, were delineated 
on chromosomes chr6:33,784,864-55,502,257, chr8:119,886,091-129,606,949, 
chr11:120,548,318-131,461,292 and chr20:29,834,107-37,252,342 (HG19) (Figure 1C). 
Whole exome sequencing
Whole-exome sequencing of the fetus III:6 gDNA generated 15.6 Gb of data with an 
average read length of 169 bp. An average coverage of 194X was achieved over the 
exome, with 96% of bases covered at least 20X. A total of 34,881 variants were identified 
across protein-coding exons, UTRs, splice sites and flanking introns. After applying all 
filters, a final set of 548 variants (49 homozygous and 499 heterozygous) were identified 
(Additional file 1: Table S1). Only 5 homozygous variants were found in the IBD blocks, of 
which 4 have been seen in population or affect a non-conserved amino acid, leaving 
only one new protein-changing variant (c.358G>T) in ICK (NM_014920.3) (Figure 1C). 
Genotypes of the 376 flanking SNPs (Chr6:50,746,213-54,121,367 – HG19) were found 
homozygous only in the fetus compared to the 13 unaffected relatives (Additional file 
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Clinical features Present fetus
Pt I
Affected Individuals 
combined/updated   
from Lahiry P. et al, 2009
IV-1,2,3,4,7,8, new
Age at delivery (weeks) 33 Range 24-34
Karyotype 46, XY 46 (6/6), XY (4/6), XX (2/6)
Height (centile) 41 cm (10th-25th) 3rd-10th (3/5), 90th-97th (2/5)
Weight (centile) 2450 g (90th-97th) 90th-98th (5/7), 10th-25th (2/7)
Head circumference (centile) 34 cm (>97th) 90->98th 4/6),3rd-20th (2/6)
Autopsy - + (3/6)
Oral
Cleft palate Cleft soft palate Midline (5/6), notch in alveolar (1/6)
Cleft lip Midline notching Midline (5/7), bilateral (2/7)
Presence of premaxilla + + (2/6)
Prominent upper lip region - + (2/6)
Hypoplastic/absent epiglottis Unknown + (2/3)
Hypoplastic/absent larynx Unknown + (2/3)
Craniofacial
Dolicocephaly - + (3/6)
Midface hypoplasia + + (6/6)
Microphthalmia + + (4/6), cystic (2/6)
Retinal dysplasia Unknown + (1/3)
Deep-set eyes + + (5/5)
Fused eyelids - + (1/6)
Hypotelorism - + (1/1)
Flat and wide nasal bridge + + (6/6)
Dysplastic and low-set ears + + (5/5)
Micrognathia + + (6/6)
Excess skin below chin - + (4/6)
Single nostril - + (1/1)
Natal teeth + + (1/6)
Limbs - thorax
Micromelia +, severe + (7/7)
Polydactyly (postaxial) Upper limbs, heptadactyly + (6/6)
Polydactyly (preaxial) Lower limbs, heptadactyly -
Brachydactyly +, severe + (6/6)
Syndactyly 4 Limbs, total syndactyly + (7/7)
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Clinical features Present fetus
Pt I
Affected Individuals 
combined/updated   
from Lahiry P. et al, 2009
IV-1,2,3,4,7,8, new
Hitch-hikers' thumbs - + (1/6)
Palmar creases abnormalities Irregular, vertical creases + (3/3)
Ulnar deviation of hands - + (6/6)
Bowing of forearms + + (6/6)
Bowing of lower legs - + (2/6)
Abducted hips + + (6/6)
Sandal gap - + (6/6)
Talipes equinovaris + -
Chest width Narrow Broad (1/6), narrow (1/6)
Prominent xyphoid - + (1/6)
Radiography
Abnormal long bones 
(radius, ulna, tibia, fibula)
Very short with bowed 
radii and more severe 
involvement of the lower limb
Short diaphysis (1/1)
Short and incurved ulnae + + (1/1)
Short and ovoid tibiae Very short, with very short fibula + (1/1)
Abnormal humerus Very short Short diaphysis (1/1)
Abnormal femur Very short, torpedo-like Short and ovoid (1/1)
Spondylar involvement +, Mildly defective ossification Unknown
Premature epiphyseal 
ossification +, Knees Unknown
Abnormal ilium Small ilia with normal contour + (1/1)
Abnormal/hypoplastic 
acetabular roof - + (1/1)
Central nervous system
Evidence of holoprosencephaly - + (4/4)
Corpus callosum + + (3/3)
Absence of septum pellucidum + + (2/2)
Hydrocephalus 
(ventriculomegaly) + + (2/2)
Dysmorphic cerebral aqueduct Unknown + (2/2)
Olfactory bulbs Unknown + (2/2)
Cerebral cortex malformation Unknown + (3/3)
Brainstem malformation Unknown + (3/3)
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2: Table S2). We also confirmed by Sanger sequencing that this ICK mutation was 
homozygous in the fetus, heterozygous in both parents and either heterozygous or wild 
type in 20 other relatives (Additional file 3: Figure S1). To date (October 2015), this variant 
has not been reported in any public databases such as the online Exome Aggregation 
Consortium (ExAC)  (http://exac.broadinstitute.org). Neither has the variant been reported 
in 1020 individuals who were whole exome sequenced by the Turkish National 
Clinical features Present fetus
Pt I
Affected Individuals 
combined/updated   
from Lahiry P. et al, 2009
IV-1,2,3,4,7,8, new
Cerebellar abnormalities - + (2/2)
Hippocampus agenesis Unknown + (2/2)
Leptomeningeal glioneuronal 
heterotopia Unknown + (1/1)
Spinal cord malformation Unknown + (1/2)
Endocrine system
Pituitary gland Unknown + Absent (2/2)
Adrenal glands Unknown + Absent (1/3), hypoplastic (2/3)
Other
Polyhydramnios - + (1/6)
Fetal hydrops + -
Pulmonary hypoplasia Unknown + (1/1)
Congenital heart defect +, VSD -
Gastrointestinal anomalies Unknown + (2/3)
External genitalia abnormalities Sex reversal with hypoplastic labial folds + (4/7)
Cryptorchidism n/a + (1/6)
(Hyper)echogenic kidneys + + (3/6)
Large kidneys + + (1/6)
Squamous metaplasia of 
bladder Unknown + (1/3)
Table 1. Clinical description and comparison of affected individuals carrying a homozygous mutation in ICK
Note: Blank cells indicate that information was unavailable. 
ªInformation gathered from attending-physician reports. 
Report from International Skeletal Dysplasia Registry (Cedars-Sinai Medical Center) for patient 1.
Feature is reported as patient had ambiguous external genitalia.
Large kidneys displayed cystic tubules.
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Fig. 1 Phenotypic characteristics of a proband with endocrine-cerebro-osteodysplasia (ECO) syndrome 
caused by a new missense mutation in ICK. A Pedigree of Family 1. B Photographs and radiographs of the 
affected fetus. Note hydrops, tetramicromelia, narrow thorax, polydactyly with hypoplastic fingers and toes, and 
craniofacial anomalies including high forehead, deep set eyes, cleft lip and palate, natal teeth, multiple frenula 
of the upper lip, and low-set ears. C Homozygosity mapping delineated four candidate regions including 
one of 21 Mb on chromosome 6. Whole-exome sequencing of the fetus revealed a homozygous mismatch 
at position UCSC HG19 chr6: 52,895,863, causing one residue change p.G120C in ICK protein (NP_055735). 
D The mutated residue p.G120C is localized in the catalytic domain of the serine-threonine kinase ICK. The 
previously indentified variant p.R272Q that was found in ECO fetuses of an Old Order Amish family also resides 
in this domain. The glycine residue at p.120 is conserved in all vertebrate ICK homologs. CL: Catalytic Loop; AL: 
Activation Loop; NLS: Nuclear Localization Signal
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Genomics Research groups under TUBITAK. In addition, the p.G120C variant was not 
found in our in-house database containing exomes of 72 other Turkish individuals, which 
further underlines the rare character of this mutation. This missense mutation (p.G120C) 
leads to the alteration of a conserved glycine (Additional file 4: Figure S2) and is distinct 
from the ICK mutation p.R272Q previously reported in fetuses and newborns with ECO 
syndrome [1] (Figure 1D). Both mutations are located in the serine-threonine protein 
kinase catalytic domain of ICK, while p.R272Q also affects a nuclear localization signal 
(Figure 1D). To conclude, through identification of a second ICK mutation in a fetus who 
displays ciliopathy related features, we confirm that genetic changes in ICK gene cause 
ECO syndrome.
Ciliary localization of ICK is altered in ICK mutants
We studied the cellular and ciliary localisation of the two homozygous missense 
mutations in ICK, c.815G>A, p.R272Q known to cause ECO syndrome, and c.358G>T, 
p.G120C from the family reported here. The cellular localization of ICK was analyzed 
using HEK293T cells that were transiently transfected with mRFP-ICK constructs. As 
previously shown by Lahiry et al. wild type ICK localized to the nucleus of these cells, 
whereas the ICK p.R272Q mutant remained in the cytoplasm. On the contrary, the novel 
ICK mutant p.G120C behaved as wild type ICK protein and localized in the HEK293T 
cell nucleus (Figures 2A and 2B). Since the mutation p.R272Q resides in the nuclear 
localization signal domain of ICK, it may affect the nuclear import of ICK protein. To 
examine the effect of p.R272Q and p.G120C mutations on ciliogenesis, we transiently 
transfected mIMCD3 cells with mRFP-ICK constructs and stimulated the cells to form cilia 
by serum starvation. While wild type mRFP-ICK was often present in the ciliary axoneme 
with or without enrichment at the ciliary base (92%), both ICK mutants were enriched 
at the ciliary tip in ~75% of the cells (Figures 2C and 2D). Figure S3 in Additional file 5 
visualizes each of the ciliary phenotypes shown in Figure 2D. Cilia of cells expressing 
mutant mRFP-ICK display an aberrant bulged tip in ~70% of ciliated cells as visualized 
with ARL13B (Figure 2C), while ciliary length is not essentially altered (Additional file 6: 
Figure S4). In summary, while the nuclear localization of ICK is only compromised by the 
p.R272Q mutation, we found that the ciliary localization is affected by both p.R272Q and 
p.G120C mutants. 
Ciliogenesis is reduced in ECO patient-derived fibroblasts
To study the endogenous effect of the homozygous missense mutation p.R272Q on 
cilia, we monitored ciliogenesis and ciliary length in primary fibroblasts derived from an 
ECO patient (Patient II) and compared them to cells derived from two healthy controls, 
one non-Amish (Control I) and one from the Amish community (Control II). While 92% 
and 85% of the control cells were ciliated, only 24% of patient-derived cells formed 
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Figure 2 Mutations found in ICK affect ciliogenesis and ciliary localization (A, B) The cellular localization of 
ICK was analyzed in HEK293T cells overexpressing wild type or two mutated forms of mRFP-ICK: p.R272Q 
(positive control, mutation previously studied in ECO infants) and p.G120C (new mutation detected in the 
current study). Nuclei were stained with DAPI (blue) and mRFP-ICK proteins are shown in red. mRFP-ICK with 
the p.G120C mutation showed the same nuclear localization as wild type mRFP-ICK transfected cells, while 
nuclear import was completely lost when mRFP-ICK with the p.R272Q mutation was expressed (Fisher’s exact 
test two-tailed p<0.0001, >35 cells counted per condition). (C, D) The ciliary localization of ICK was studied in 
mIMCD3 cells transiently transfected with wild type or two mutant forms of mRFP-ICK: p.R272Q or p.G120C. 
Wild type mRFP-ICK mostly localized to the ciliary axoneme and was often enriched at the ciliary base, while 
both mRFP-ICK mutants enriched at ciliary tips. Ciliary axonemes were visualized with anti-ARL13B (green), 
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cilia (Figures 2E and 2F). This was determined with a Fisher’s exact two-tailed test that 
showed p<0.0001 when comparing the patient sample to each of the controls. We 
did not observe any major differences in ciliary length (Additional file 7: Figure S5). In 
summary, we found that ECO patient-derived fibroblasts display reduced ciliogenesis, 
while the cilia that form are of normal length.
Discussion
In this study we identified a novel homozygous missense mutation (c.358G>T [UCSC HG19: 
NM_014920] and p.G120C [UCSC: NP_055735]) in the ICK gene in a consanguineous 
Turkish family with one affected fetus who was initially clinically diagnosed as SRTD type 
II. After mutation identification, the clinical features of the proband were compared to 
those of the affected progeny of a previously published Amish family with ECO syndrome 
who had a different homozygous missense mutation in ICK (p.R272Q) [1]. Although it 
remains unclear if the Turkish proband had typical endocrine abnormalities seen in ECO 
syndrome, there was significant clinical overlap with Amish fetuses, which leads us to 
conclude that we identified the second family with ECO syndrome world-wide. This 
study thus confirms that aberrations of ICK can indeed cause severe phenotypes that 
resemble the short-rib thoracic dysplasia spectrum. Our in vitro studies performed in 
mIMCD3 cells show that mutant mRFP-ICK with either p.R272Q or p.G120C accumulates 
in the ciliary tip, while the wild type protein localizes along the ciliary axoneme with 
enrichment in the ciliary base. Our findings are in line with the data published by Moon 
et al. [6] who reported similar localization patterns for both wild type and mutant ICK 
(p.R272Q). In contrast, Chaya et al. [5] showed that wild type ICK localizes to the ciliary 
tip and that this localization is lost in the p.R272Q mutant. These different observations 
in ICK localization may be due to variation in the expression level of ICK as well as the 
type and the position of tags in the protein. Typical accumulations of protein at ciliary 
tips were also observed in fibroblasts derived from patients with ciliopathies such as 
asphyxiating thoracic dystrophy [MIM:208500] [13] and cranioectodermal dysplasia 
ciliary transition zones that are present at the ciliary base were marked with anti-RPGRIP1L (pink), mRFP-ICK 
constructs were shown in red, and nuclei were stained with DAPI (blue). Per construct >50 transfected, ciliated 
cells were counted. (E,F) Cilium presence was studied in serum-starved fibroblasts derived from an ECO 
patient with a homozygous missense mutation in ICK (c.815G>A; p.R272Q) and compared to fibroblasts derived 
from two healthy unrelated controls. Control I represents a non-Amish individual, while control II is from the 
Amish community. Ciliogenesis was significantly reduced in fibroblasts from the ECO patient compared to the 
controls (Fisher’s exact test two-tailed p<0.0001 for both). At least 80 cells were counted per condition. Ciliary 
axonemes were visualized with anti-ARL13B (green), ciliary transition zones were marked with anti-RPGRIP1L 
(red), while nuclei were stained with DAPI (blue).
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[MIM:218330] [14]; cilia of these patients often display abnormal ciliary tip accumulation 
of intraflagellar transport complex B (IFT-B) proteins. The protein accumulations at ciliary 
tips may be due to defective IFT and disruption in retrograde intraflagellar transport, i.e. 
transport occurring from the ciliary tip to its base [14]. Thus, the protein accumulations at 
the ciliary tip that we observe may also be caused by defective IFT, and suggest a role 
for ICK in the regulation of this process. Recent papers by Broekhuis et al. and Chaya et 
al. [8, 5] indeed indicate that ICK coordinates IFT probably through phosphorylation of 
KIF3A, a motor protein that drives IFT from the ciliary base towards the tip. Considering 
the presence of p.G120C and p.R272Q mutations in the serine-threonine protein kinase 
domain, it is tempting to speculate that both mutations affect phosphorylation of KIF3A, 
thereby dysregulating IFT. While various reports suggest that ICK is a regulator of cilia 
length [8, 5, 6], we did not observe dramatic differences in the length of cilia expressing 
mutant ICK, nor in those cilia occurring on the apical surface of cells derived from an 
ECO patient (Additional file 6: Figure S4 and Additional file 7: Figure S5). This may be 
in part be explained by the likely hypomorph effects of the ECO syndrome-associated 
missense mutations. We did, however, observe a significantly reduced number of cilia 
in ECO patient-derived fibroblasts compared to two healthy controls. This may explain 
the previously described hyperproliferative behavior of these cells [15]. Our reasoning is 
that cilium formation depends on docking of the mother centriole of the centrosome to 
the plasma membrane from which the cilium can then emerge. When cilia are unstable 
or do not form, such as in ECO patient-derived cells, centrioles become available for 
assembly of the mitotic spindle promoting cell division. The ciliogenesis defect seen in 
ECO patient-derived fibroblasts is comparable to the defects observed in Ick-deficient 
mouse embryonic fibroblasts (MEFs), recently described by Chaya et al. [5].
 Loss of Ick results in aberrant ciliary Hedgehog signaling in multiple murine 
organs and fibroblasts [5, 6], and this pathway is also dysregulated in other ciliary 
chondrodysplasias that share clinical features with ECO syndrome and SRTD [16-19]. 
It is currently unclear how the Hedgehog pathway is affected upon Ick depletion. One 
hypothesis is that loss of Ick directly affects IFT thereby altering Hedgehog signaling 
[5]. Another hypothesis is that Ick depletion impacts mTORC1 signaling thereby causing 
an imbalance in ciliary tubulin synthesis resulting in structural ciliary defects that in turn 
impact ciliary signaling [8]. In any case many ECO and SRTD syndrome-associated 
anomalies are probably due to disturbances of ciliary signaling cascades regulating 
human development, including but probably not limited to the Hedgehog pathway. 
Conclusions
In conclusion, we here report a novel ICK mutation in a family with ECO syndrome. This 
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is the first replicative allele, which confirms that ICK mutations are indeed associated 
with severe SRTD resembling phenotypes. We found ciliogenesis defects in fibroblasts 
derived from a previously reported individual affected by ECO syndrome, and noted 
that expression of mutant ICK (p.R272Q and p.G120C) results in aberrant localization of 
ICK in ciliary tips. Although ciliary phenotypes vary slightly between cells and species, 
our findings are in agreement with recent reports on Ick knockout mice and murine Ick 
depleted cells that reveal a role for Ick in ciliogenesis, ciliary transport and regulation of 
cell signaling. Our study is the first to show that ciliary defects occur in cells derived from 
a patient with ECO syndrome with mutated ICK, and thereby provides additional support 
for inclusion of ECO syndrome in the severe ciliary disease spectrum. 
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Additional file 1. Table S1. Filtering of WES data. Available upon request.
Additional file 2. Table S2. SNP genotypes flanking the p.G120C mutation present in the fetus and 13 
unaffected relatives. Available upon request.
Additional file 3. 
Figure S1. The ICK missense mutation (c.358G>T; p.G120C) segregates with disease. Sanger sequencing 
was performed on the proband and 22 healthy relatives.
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Additional file 4. 
Figure S2. Alignment of the protein kinase domain in ICK, MAK and MOK in different species. 
The protein kinase domain in ICK, MAK and MOK is a conserved region, and it includes both 
described mutations in ICK, i.e. p.G120C and p.R272Q. The alignment is based on sequences from 
proteins with the following UniProt identifiers; Q9UPZ9 (H. sapiens ICK), Q9JKV2 (M. musculus ICK), 
B3WFY8 (C. elegans DYF-5b), P20794 (H.sapiens MAK), Q04859 (M. musculus MAK), Q7ZTX0 
(D. rerio MAK), Q9UQ07 (H. sapiens MOK), Q9WVS4 (M. musculus MOK), Q9VL64 (D. melanogaster CG42366). 
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The alignment was made using the online tool Clustal omega 1.2.1: http://www.ebi.ac.uk/Tools/msa/clustalo/.
The annotations made by this tool visualize the conservation of each residue; an asterisk indicates “positions 
which have a single, fully conserved residue”, a colon and a period indicate “conservation between groups 
of strongly similar properties” and “weakly similar properties”, respectively. The colors assigned by Clustal 
omega inform about the properties of individual amino acids; red indicates small residues, blue indicates acidic 
residues, magenta shows basic residues, and green refers to amino acids with hydroxyl, sulfydryl and amine 
groups or to glycine residues. The protein sequences for each of the presented species was obtained from 
UniProt (www.uniprot.org). TreeFam (www.treefam.org), and ZFIN (http://zfin.org) websites were used to identify 
proteins that are homologues to ICK.
Additional file 5. 
Figure S3. Different classes of ciliary phenotypes. The ciliary localization of mRFP-ICK was studied in 
transiently transfected mIMCD3 cells. Five distinct expression patterns were classified; these are indicated 
above the upper images. Ciliary axonemes were visualized with anti-ARL13B (green), and ciliary transition 
zones that are present at the ciliary base were marked with anti-RPGRIP1L (pink). mRFP-ICK is shown in red.
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Additional file 6. 
Figure S4. Ciliary length is not essentially altered in cilia of cells expressing mutant mRFP-ICK. IMCD3 cells 
were transiently transfected with wildtype or mutant (p.R272Q or p.G120C) mRFP-ICK and ciliary length was 
measured after 24 hours serum starvation to induce ciliogenesis. The cilia of cells expressing R272Q mutant 
mRFP-ICK tend to be slightly longer than wildtype mRFPICK cilia, however, the ciliary length is not majorly 
altered. The ciliary axoneme, visualized with ARL13B, of at least 28 cilia were measured per construct.
Additional file 7. 
Figure S5. Ciliary length is not markedly altered in ECO patient-derived fibroblasts. The ciliary length of ECO 
patient-derived fibroblasts harboring a mutation in ICK at position c.815G>A; p.R272Q was compared to those 
of two healthy unrelated controls. Control I represents a non-Amish individual, while control II is from the Amish 
community. Natural variability in ciliary length is seen in control cell lines from different individuals as displayed 
in this graph; we can therefore only conclude that there are no major differences in the ciliary length of ECO 
patientderived cells compared to control lines. Cells were serum starved for 48 hours to induce ciliogenesis 
and subsequently stained with ARL13B to visualize the ciliary axoneme. The ciliary axoneme of at least 125 cilia 
per cell line was measured.
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Abstract
Nephronophthisis (NPHP) is an autosomal recessive cystic kidney disease that is the 
most frequent monogenetic cause of end-stage renal disease in children. Infantile 
NPHP, often in combination with other features like situs inversus, are commonly caused 
by mutations in the INVS gene. INVS encodes the ciliary protein inversin, and mutations 
induce dysfunction of the primary cilia. In this paper we present a family with two 
severely affected fetuses that were aborted after discovery of grossly enlarged cystic 
kidneys by ultrasonography before 22 weeks gestation. Exome sequencing showed 
that the fetuses were heterozygous for a previously unreported homozygous nonsense 
mutation, resulting in a truncation in the IQ1 domain of inversin. This mutation induces 
nonsense-mediated RNA decay, as suggested by a reduced RNA level in fibroblasts 
derived from the fetus. However, a significant amount of mutant INVS RNA was present 
in these fibroblasts, yielding mutant inversin protein that was mislocalized. In control 
fibroblasts, inversin was present in the ciliary axoneme as well as at the basal body, 
whereas in the fibroblasts from the fetus, inversin could only be detected at the basal 
body. The phenotype of both fetuses is partly characteristic of infantile NPHP and Potter 
sequence. We also identified that the fetuses had mild skeletal abnormalities, including 
shortening and bowing of long bones, which may expand the phenotypic spectrum 
associated with INVS mutations.
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Introduction
Nephronophthisis (NPHP) is an autosomal recessively inherited cystic kidney disease, 
and one of the most frequent genetic disorders that causes end-stage renal disease 
(ESRD) in children and adolescents [Hildebrandt and Otto 2005]. Three phenotypic 
variants of NPHP have been described, taking into account the age of onset for ESRD; the 
infantile, the juvenile, and the adolescent variant [Saunier et al. 2005]. To date, mutations 
in at least 14 genes are associated with any of the three variants, explaining 40% of the 
cases, rendering NPHP as a genetically heterogeneous disorder [Arts and Knoers 2012; 
Halbritter et al. 2013; Hurd and Hildebrandt 2011]. Infantile NPHP is the most progressive 
variant and has an early onset of ESRD before the age of two years. In infantile NPHP 
the kidneys are often significantly enlarged due to cortical cysts, and patients often 
show hepatic fibrosis. Two other features commonly found in patients with infantile NPHP 
are situs inversus and cardiac ventricular septal defects. Histological findings in infantile 
NPHP differ from juvenile and adolescent NPHP, in the fact that thickening of the tubular 
basement membrane is rarely found [Gagnadoux et al. 1989; Tory et al. 2009]. Thus far, 
only two genes, INVS and NPHP3, have been associated with infantile NPHP. Patients 
with mutations in INVS have a more severe kidney phenotype, and the progression 
towards ESRD in these patients is faster than in patients carrying a mutation in NPHP3 
[Otto et al. 2003; Tory et al. 2009]. The phenotypic spectrum associated with INVS 
mutations ranges from ESRD in combination with hepatic fibrosis and situs inversus to a 
syndrome with respiratory failure and oligohydramnios that resembles Potter sequence 
[Haider et al. 1998]. Potter sequence or Potter syndrome, first described by Edith L. Potter 
in 1946, is characterized by severe oligohydramnios causing pulmonary hypoplasia, 
and facial dysmorphism also known as a Potter facies [Thomas and Smith 1974]. In this 
paper we present a family with two severely affected fetuses. Pathological examination 
showed enlarged cystic kidneys, liver fibrosis, oligohydramnios, and suspected skeletal 
abnormalities. Exome sequencing demonstrated that both fetuses had a previously 
unreported homozygous nonsense mutation in INVS that predicted a truncation of the 
IQ1 domain of inversin. 
Clinical report
In this family there were four pregnancies of which two were terminated before gestational 
week 22 (Figure 1A). The pregnancies of individuals II:1 and II:4 were complicated by 
oligohydramnios, with small lungs and a flattened nose. Both individuals, II:1 and II:4, had 
grossly enlarged cystic kidneys that were detected by ultrasonography (Figure 1D-F). 
Pathologic examination of individual II:1 showed situs inversus of the lungs, dextroversion, 
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a cystic liver with fibrosis, and possible shortening and mild bowing of the femora 
(Figure 1). An overview of all clinical features of both fetuses is given in Table I, while 
Table II shows the body parameters and organ weights of both fetuses. Histological 
features of the renal cortex of individual II:1 included multiple dilated cystic ductal 
structures and dilated glomerular cysts (Figure 2A-B). Thickening of the tubular basement 
membrane was absent in the renal cortex of individual II:1 (Figure 2C). Sections of the 
liver of individual II:1 showed congenital hepatic fibrosis, dilated cystic biliary structures, 
and ductal plate malformation (Figure 2D). DNA and histological- or radiographic records 
were unavailable for individual II:4, although these were requested at the time of autopsy.
Table I. Clinical Features of the Present Family and Three Individuals from the Bedouin Family Described 
by Haider et al. [1998].
Present family Haider et al., 1998
Features II:1 II:4 VII:1 VII:3 VII:18
Gestational age (wk) 22 16 term term term
Gender F F M F M
Age at onset NPHP (yrs) NA NA 2,5 2,5 0
Enlarged cystic kidneys +++ + + + ++
End-stage renal disease NA NA + + +
Oligohydramnios ++ + - - +
Flattened nose + NS NS NS NS
Narrow thorax + NS NS NS NS
Respiratory failure NA NA - - +
Pulmonary hypoplasia ++ + NS NS NS
Anemia NA NA + + NA
Situs inversus of the lungs + NS NS NS NS
Dextroversion + NS NS NS NS
Enlarged cystic liver + - - - -
Congenital liver fibrosis + + NS NS NS
Bowed femora + NS NS NS NS
Lobulated spleen + - NS NS NS
Enlarged adrenal glands + - NS NS NS
Hyperkalemic metabolic acidosis NA NA NA + +
Increased serum creatine NA NA NA + +
NS means not stated in clinical report, NA means not applicable, number of plus signs indicates the severity of 
the feature, negative signs mean the feature is not present.
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Figure 1. A. Pedigree of present family. B. Radiographs of fetus II:1 showing a narrow thorax and possible short-
ening and mild bowing of the femora (indicated by arrowheads). C-H. Pathological images of fetus II:1. C-D. The 
enlargement of the belly is due to the grossly enlarged kidneys. All organs are present. E-F. Enlarged cystic 
kidneys. G. Dextroversion (indicated by arrowhead). H. Cystic and fibrotic liver.
Present family
Body parameters II:1 (22 weeks) II:4 (16 weeks)
Body weight (g) 658 (461) 68.1 (108)
Crown-rump length (cm) 17.5 (19.3 ) 11 (12.4 )
Crown-heel length (cm) 28  (28 ) 15 (17.5 )
Head circumference (cm) 19.5 (19.4 ) 10.3  (12..4 )
Organs (all in grams)  
Kidneys (left + right) 100 (4.6) 13.2 (0.9)
Lungs (left + right) 5.7 (13.1) 1.5 (3.9)
Liver 36.8 (25.5) 3.9 (5.9)
Heart 3.7 (3.1) 0.7 (0.8)
Adrenals 1.2 (1.9) 0.2 (0.6)
Table II. Clinical Measurements
The normal weight or length at the indicated gestational week is given in parentheses.
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Materials and methods
Single nucleotide polymorphism (SNP) array analysis
Genomic DNA of both affected fetuses and their parents was genotyped with Affymetrix 
250K arrays according to the manufacturer’s protocols (Affymetrix, Santa Clara, California, 
USA). The 250K SNP genotypes were analyzed as described [de Leeuw et al. 2011]. 
Exome sequencing
Exome sequencing was performed essentially as described [Becker et al. 2011; Gilissen 
et al. 2010; Hoischen et al. 2010; Hoischen et al. 2011]. In brief, the exome enrichment 
was performed using a SureSelect v2 50Mb kit (Agilent, Santa Clara, USA), followed 
by sequencing on a SOLiD 5500xl System (Life Technologies, Foster City, USA). 
Figure 2. Histological features of individual II:1. A-B. Renal cortex with cystic ductal structures indicated by the 
asterisk and dilated glomerular cysts indicated by the arrow (A-B. Hematoxylin and eosin (H&E) staining; A. 25x 
magnification; B. 100x magnification). C. Liver section showing fibrosis indicated by the arrowhead, ductal plate 
malformation indicated by the arrow, and dilated cystic bile structures indicated by the asterisk (H&E staining; 
50x magnification). D. Periodic acid Schiff staining of the renal cortex showing the absence of significant 
tubular basement membrane thickening, indicated by the arrows (100x magnification).
Early Presentation of Cystic Kidneys in a Family with a Homozygous INVS Mutation
67
3
Read mapping and variant calling were performed using the LifeScope Software v2.1 
(Life Technologies, Foster City, USA). Variant annotation was done using an in-house 
annotation pipeline. To prioritize variants in our sequencing data a quality filter was 
applied (>5 variant reads and >15% variant reads). Variants that were excluded were 
nongenic, intronic (except for canonical splice sites) or synonymous. Other variants 
that were excluded were present in dbSNPv130 or our in-house variants database that 
contains data from the 1000 Genomes Project as well as published variants and 133 
in-house analyzed exomes. Candidate variants were validated by Sanger sequencing 
and segregation analysis. Ethics approval was provided by the ethics review board of 
the University of Nijmegen.
Histology
Renal and liver specimens from individual II:1 were stained with hematoxylin and eosin 
(H&E) in a semi-automatic manner using a Tissue-Tek Prisma from Sakura (Sakura Finetek, 
Torrance, CA, USA). A renal specimen from individual II:1 was stained with periodic acid-
Schiff (PAS) using the Special Stains Module from Roche (Roche Diagnostics International 
Ltd, Rotkreuz, Switserland).
Immunocytochemistry
Fibroblasts from individual II:1 and control individuals were cultured on glass slides 
under standard cell culture conditions in Dulbecco’s Modified Eagle’s Medium (DMEM) 
with 20% Fetal Calf Serum (FCS). Cilia formation was stimulated using serum-starved 
medium (DMEM with 0.2% FCS) for 48 hours prior to staining. Cells were then fixated in 
2% paraformaldehyde in Phosphate Buffered Saline (PBS) and permeabilized with 1% 
Trition-X-100 in PBS. Subsequently, the cells were blocked with freshly made 2% bovine 
serum albumin in PBS, followed by a one-hour incubation with the primary antibody at 
room temperature. Cells were washed with PBS before incubation with the secondary 
antibody at room temperature for 45 min. The following primary antibodies were used: 
anti-inversin (rabbit polyclonal directed against amino acids 1-100; Protein tech, 1:100), 
anti-RPGRIP1L (guinea pig polyclonal; SN040, 1:500 [Arts et al. 2007]), and anti-acetylated 
α-tubulin (mouse monoclonal, Life Technologies, Foster City, USA, 1:1000). Secondary 
antibodies (all from Life Technologies) that were used: anti-guinea pig IgG Alexa Fluor 
405 (1:300), anti-rabbit IgG Alexa Fluor 488 (1:300) and anti-mouse IgG Alexa Fluor 568 
(1:300). Glass slides containing stained cells were embedded in Vectashield (Vector 
Laboratories, Burlingame, CA, USA) on a microscopic glass slide. Microscopic analysis 
was performed on a Axio Imager ZI fluorescence microscope (Zeiss, Sliedrecht, The 
Netherlands) with an ApoTome slider. Images were processed using AxioVision (Zeiss) 
and Photoshop CS4 (Adobe Systems, San Jose, CA, USA) software.
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Reverse Transcriptase PCR and Quantitative PCR
cDNA was synthesized from fibroblast RNA using the iScript cDNA synthesis kit 
(Bio-Rad Laboratories, Hercules, CA, USA) according to manufacturer’s instructions. 
Reverse transcriptase PCR was conducted using primers for inversin cDNA spanning 
exons 11-13. PCR fragments were sequenced by Sanger sequencing. Quantitative PCR 
(qPCR) was conducted to quantitatively compare inversin mRNA expression in Individual 
II:1 versus control individuals. qPCR analysis was performed on a 7900 Fast Real-Time 
PCR System (Applied Biosystems, Foster City, USA) with GoTaq PCR Master Mix (Promega, 
Madison, WI, USA) according to the manufacturer’s instructions. Primers were developed 
using the Primer 3 program (freely available online) and validated as described [de 
Brouwer et al. 2006]. GUSB was used as reference gene. qPCR quantifications were 
performed as described [Coene et al. 2011]. 
Results
Homozygosity mapping
Genome-wide homozygosity mapping using Affymetrix 250K arrays was conducted for 
individual II:1. Homozygosity analysis was performed as described by de Leeuw et al. 
[2011] using the loss of heterozygosity (LOH) algorithm at a threshold of 15. Only a single 
homozygous region of 2.36 Mb was detected. This regions contained 16 annotated 
RefSeq genes with dbSNP rs16918660 (HG19 chr9:102,353,541) and rs10123826 (HG19 
chr9:104,709,913) as bordering SNPs (see supplemental table SI for the genes in this 
region). The most likely candidate in this region was the INVS gene, which is associated 
with cystic kidney disease. To date, the other 15 genes have not been reported to be 
associated with a renal disorder. 
Exome sequencing
We applied exome sequencing (ES) to individual II:1 and targeted ~20,000 genes 
[Becker et al. 2011; Gilissen et al. 2010; Hoischen et al. 2010; Hoischen et al. 2011]. In 
total, 161,679,674 reads were obtained and 113,300,711 of them could be mapped to 
the human genome (HG19). In total, 41,811 variants were called in genes. Subsequently, 
these data were filtered for an autosomal recessive disease model, which yielded 
three homozygous variants and 11 compound heterozygous variants (see supplemental 
table SII for the variants). The variants were validated by Sanger sequencing and were 
checked for segregation of a recessive disease. All compound heterozygous variants 
were excluded as pathogenic because the unaffected mother I:2 carried the same 
combination of variants. Two of the variants that were initially marked as homozygous by 
ES were actually found by Sanger sequencing to be heterozygous in individual II:1. The 
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Figure 3. Confirmation and evaluation of a novel nonsense mutation in INVS. A. Sequence of the homozygous 
nonsense mutation in INVS (NM_014425) at position c.1726C>T in fetus II:1, and the heterozygous state of the 
parents (I:1 and I:2), which fits the segregation of the disease. The bottom sequence shows the confirmation of 
the mutation in the RNA of fetus II:1. B. Immunofluorescent stainings of fibroblasts from a control individual and 
fetus II:1. Cilia were stained with a polyclonal antibody against inversin (shown in green), the ciliary axoneme 
is visualized by a monoclonal antibody against acetylated-α-tubulin (shown in red), and the ciliary transition 
zone is marked by a polyclonal antibody against RPGRIP1L (shown in purple). The fibroblasts of fetus II:1 show 
a mislocalization of inversin: in control fibroblasts, inversin is present in the previously described ‘inversin 
compartment’ of the ciliary axoneme [Shiba et al. 2009] as well as at the basal body, whereas in the fibroblasts 
from the fetus, inversin can only be detected at the basal body. C. A reduction, but not absence, of inversin 
RNA in cDNA of fetus II:1 is detected by qPCR. D. A schematic representation of inversin (NP_055240) with 
its predicted motifs: 16 ankyrin repeats, two IQ domains, transcriptional regulator ICP4, a bipartite nuclear 
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last remaining homozygous variant, however, was confirmed. This indeed concerned 
the strong candidate gene INVS from our homozygosity mapping study (Figure 3A), in 
which a previously unreported homozygous nonsense mutation in INVS was found at 
position c.1726C>T of NM_014425 (p.Arg576* of NP_055240). This mutation predicts the 
truncation of the IQ1 domain of the protein (Figure 3D). However, nonsense-mediated 
decay is another potential consequence of this type of mutation. Inversin contains 16 
ankyrin repeats, two IQ domains (IQ1 and IQ2, respectively), transcriptional regulator ICP4, 
a bipartite nuclear localization sequence, two D-box motifs, and a ninein homologous 
region. All homozygous nonsense mutations described in the literature thus far are 
located after the IQ1 domain (Figure 3D).
RT-PCR and qPCR
We studied the cDNA of individual II:1 by reverse transcription PCR (RT-PCR) followed by 
sequencing, and by quantitative PCR (qPCR). Analysis of the cDNA sequence showed 
the nonsense mutation c.1726C>T to be present in the RNA of individual II:1 (Figure 3A). 
qPCR analysis showed a reduced level of INVS in fibroblasts of individual II:1 compared 
to two healthy control individuals (Figure 3C). 
Evaluation of the ciliary defect by immunocytochemistry
In order to identify a potential ciliary defect in individual II:1, we evaluated cilia length, 
morphology, and localization of inversin by immunofluorescent staining of cilia in skin 
fibroblasts from the fetus, and from healthy control individuals. We were not able to 
detect a statistically significant difference in length nor morphology of the cilia in cells 
from individual II:1 compared to two control individuals (data not shown); however, the 
inversin localization appeared to be dramatically altered in cilia of individual II:1. In control 
fibroblasts, inversin localized to the ciliary axoneme in more than 50% of the cells, and 
in 25% of the cells we also detected inversin at the basal body. For individual II:1 inversin 
localized to the basal body in 30% of the cells, but inversin was completely absent from 
the ciliary axoneme (Figure 3B).
localization sequence, two D-box motifs, and one ninein homologous region [Lienkamp et al. 2012]. Mutations 
visualized in red were identified homozygously in patients, and mutations visualized in black were only found 
in a heterozygous state in combination with other heterozygous mutations [Chaki et al. 2011; Otto et al. 2003; 
Tory et al. 2009].
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Discussion
Nephronophthisis (NPHP) is an autosomal recessive cystic kidney disease that is the 
most frequent monogenic cause of end-stage renal disease in children [Hildebrandt 
and Otto 2005]. Two genes associated with infantile NPHP are NPHP3 and INVS [Otto 
et al. 2003; Tory et al. 2009]. We found that mutations in the latter gene, INVS, caused 
the severe prenatal phenotype in the present family. This mutation was found through 
exome sequencing. The ES data were filtered for an autosomal recessive disease model 
and the candidate genes were, subsequently, checked for segregation within the family. 
The homozygous nonsense mutation in INVS at position c.1726C>T of NM_014425 was 
the only candidate left after segregation analysis within the family.
The phenotype of these fetuses is much more severe than in previously published 
reports of infantile NPHP and, because of the poor prognosis, led to termination of the 
pregnancies. Detailed phenotypic analysis showed a combination of grossly enlarged 
cystic kidneys, congenital liver fibrosis, and hypoplasia of the lungs associated with 
oligohydramnios. This is rarely seen in infantile NPHP, although Haider et al. [1998] 
previously described a large consanguineous family with NPHP including one individual 
who died shortly after birth due to respiratory failure. The causative mutation in this 
family was a homozygous nonsense mutation found in INVS at position c.2719C>T 
(found by Otto et al.  [2003]), and the pregnancy of this individual was also complicated 
by oligohydramnios. A more detailed phenotypic characterization was, however, not 
included. Our combined data suggest that the co-occurrence of cystic kidneys and 
oligohydramnios is not compatible with life. The suspected skeletal abnormalities, these 
being shortening and mild bowing of the femora, have not been described in infantile 
NPHP before, but are a prominent feature of ciliopathy syndromes. These syndromes 
include asphyxiating thoracic dystrophy (OMIM 208500), cranioectodermal dysplasia 
(OMIM 218330), and short-rib polydactyly (OMIM 263530), and are caused by mutations in 
ciliary genes, such as genes encoding intraflagellar transport particle subunits (involved 
in retrograde axonemal transport in the cilium) [Huber and Cormier-Daire 2012]. To date, 
causative mutations for these syndromes have never been found in INVS.
From a molecular point of view, it is known that inversin is important in left-right 
asymmetry during early embryonic development [Otto et al. 2003]. Inversin acts as a 
molecular switch between the canonical and non-canonical Wnt signaling pathways 
by its interaction with dishevelled. A loss of function or absence of inversin will cause 
renal cyst formation by disruption of the balance between these two signaling pathways. 
Although the C-terminus of the protein is known to interact with dishevelled, the exact 
epitope remains to be identified [Simons et al. 2005]. The nonsense mutation in the 
family reported here is localized in the IQ1 domain of inversin at position p.Arg576* 
(NP_055240). It is the most amino-terminal homozygous nonsense mutation in INVS 
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reported in the literature for infantile NPHP. We show that although INVS RNA levels 
are significantly diminished in the patient-derived fibroblasts, likely due to nonsense-
mediated decay, some mutated RNA remains present. Protein translated from this RNA 
is predicted to lack most of the protein including important motifs: IQ1 and IQ2, bipartite 
nuclear localization signals (NLS), destruction-box (D-box) 2, and the ninein homologous 
region. Shiba et al. [2009] found that a 60 amino acid region at the C-terminus, including 
the ninein homologous region, is required for the localization of inversin to the ciliary 
axoneme. This finding supports our ciliary mislocalization results, i.e., that mutant inversin 
solely localizes to the basal body and has lost its axonemal function. The exact roles 
of the other domains are still unknown, however, we do show that a truncation of the 
protein at the predicted IQ1 domain restricts the ciliary localization to the basal body.
In summary, we showed that the severe phenotypes of two fetuses with characteristics 
of infantile NPHP and Potter sequence were caused by a homozygous mutation in 
INVS at c.1726C>T of NM_014425 (p.Arg576*), which causes nonsense-mediated decay. 
Nonetheless, a small amount of mutant protein forms and mislocalizes to the basal body. 
The suspected skeletal abnormalities in the presented family may indicate that the 
phenotypic spectrum associated with INVS mutations is broader than presently thought, 
however, further investigation is required to gather complementary evidence to support 
this rationale. 
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Supplemental data
Table SI. Overview of Genes Within Homozygous Region
Gene name
NR4A3 MSANTD3 ZNF189
LOC441461 TMEFF1 ALDOB
STX17 MURC RNF20
ERP44 LPPR1 GRIN3A
INVS BAAT
TEX10 MRPL50
Overview of annotated RefSeq genes within 2.36Mb homozygous region between dbSNP rs16918660 (HG19 
chr9:102,353,541) and rs10123826 (HG19 chr9:104,709,913).
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Table S2. Overview of whole-exome sequencing variants for proband II:1.
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Columns from left to right: chromosome (Chr), variant (obtained by WES), percentage of reads with the variant 
allele (% Var), where a percentage of variation above 80% is called homozygous and a percentage variation 
between 20% and 80% is called heterozygous, gene name in which the variant is located (Gene), RefSeq gene 
id (Gene Id), log odds ratio for evolutionary conservation based on USCC genome browser HG19 (PhyloP), 
variation in amino acid (Variation aa), where “SS” indicates a canonical splice site, sequence results obtained 
by Sanger sequencing (DNA), where “-“ means not sequenced.
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Image: Ciliary localization of IFT88 in patient-derived fibroblast. 
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Abstract
We report an eleven-year-old girl with mild intellectual disability, skeletal anomalies, 
congenital heart defect, myopia and facial dysmorphisms including an extra incisor, 
cup-shaped ears and a preauricular skin tag. Array comparative genomic hybridization 
analysis identified a de novo 4.5-Mb microdeletion on chromosome 14q24.2q24.3. The 
deleted region and phenotype partially overlap with previously reported patients. Here, 
we provide an overview of the literature on 14q24 microdeletions and further delineate 
the associated phenotype. We performed exome sequencing to examine other causes 
for the phenotype and queried genes present in the 14q24.2q24.3 microdeletion that 
are associated with recessive disease for variants in the non-deleted allele. The deleted 
region contains 65 protein-coding genes, including the ciliary gene IFT43. Although 
Sanger and exome sequencing did not identify variants in the second IFT43 allele or in 
other IFT complex A-protein-encoding genes, immunocytochemistry showed increased 
accumulation of IFT-B proteins at the ciliary tip in patient-derived fibroblasts compared 
to control cells, demonstrating defective retrograde ciliary transport. This could suggest 
a ciliary defect in the pathogenesis of this disorder.
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Introduction
Interstitial deletions encompassing the 14q24.2q24.3 region are rare and associated with 
intellectual deficit in the majority of patients. Defining a consistent clinical phenotype 
and determining the causal genes within the deletion remains a challenge. Recently, 
two patients with overlapping 14q24 deletion were reported: one with a 5.4-Mb deletion 
and mild intellectual disability (ID), atrial septal defect (ASD), small thumbs and facial 
dysmorphisms [Oehl-Jaschkowitz et al., 2014] and one with a 5.3-Mb deletion and mild 
psychomotor delay, ASD, short digits, facial dysmorphisms and focal epilepsy [Tassano 
et al., 2014]. The DECIPHER database reports thirteen patients with overlapping copy 
number loss in the 14q24 region, and clinical features that include ID in seven patients, 
heart defect in one patient and preauricular skin tag in one patient [Firth et al., 2009] 
(Supplemental Table I). Here, we report a patient with a de novo 4.5-Mb 14q24.2q24.3 
microdeletion with clinical features as previously reported in patients with overlapping 
14q24 deletions: mild ID, skeletal anomalies including small thumb, ASD and facial 
dysmorphisms including cup-shaped ears and preauricular skin tag. We explored genetic 
and environmental factors that could have contributed to the phenotype and further 
characterized the phenotypic spectrum associated with 14q24 microdeletions. Finally, 
we investigated whether the distinctive skeletal, ocular and ectodermal abnormalities 
in the index patient could reflect a ciliary defect associated with deletion of the gene 
encoding intraflagellar transport protein 43 (IFT43) (MIM# 614099), one of the 65 protein-
coding genes located within the 14q24.2q24.3 microdeletion.
Clinical report
The index patient is the second child of non-consanguineous caucasian parents; she 
has a healthy older brother. Mother of the patient has a history of insulin-dependent 
diabetes type I. The patient was born after a full-term pregnancy, with birth length: 
51 cm (0 SD), weight: 3505 grams (0 SD) and OFC: 32.5 cm (-1.2 SD). At 11 years of 
age, she presented at the genetics clinic with mild ID (TIQ 66 measured with WISC-III, 
VIQ 71, PIQ 66) and multiple congenital malformations. Her height was 141.5 cm (-0.4 
SD), weight: 35.6 kg (+0.5 SD) and OFC: 52 cm (-0.4 SD). She had a wide nasal bridge, 
cup-shaped ears, long limbs (sitting-height/length ratio 0.49 (-1.8 SD), arm span 157.2 cm 
(+2 SD)) and digits, and a short, broad thorax (Fig. 1). Previous medical history mentioned 
hip dysplasia, deviation of the sacrum with dysplastic corpora and lipomas around the 
conus and proximal filum terminale. On the right hand she had a small thumb for which she 
underwent pollicization of the index finger, contracture of the proximal interphalangeal 
joint of the third finger and flexion contracture of the wrist. Her preauricular skin tag and 
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extra central incisor had been surgically removed. In addition, she had a ventricular 
septal defect that had closed without intervention and a large ASD that required surgical 
closure. Ultrasound of the abdomen showed normal kidneys. She had astigmatism and 
myopia (-5 and -8 ODS). Retinal examination was normal.
Materials and methods
Genome-wide array comparative genomic hybridization analysis
Array-CGH microarray analysis was performed using 180K (Amadid 023363, hg19) 
microarray slides from Agilent Technologies (Santa Clara, CA, USA) following 
manufacturer’s protocols and a mixed pool of 50 healthy controls as reference. Scanned 
images were analyzed by Feature Extraction software (Agilent Technologies). CNV 
analysis was performed with Nexus software (version 7). Parentage was confirmed by 
DNA fingerprinting. The deletion has been submitted to ClinVar database, accession 
number SCV000245406 (www.ncbi.nlm.nih.gov/clinvar). 
Exome sequencing
Exome sequencing was performed on the patient to exclude other causes, to query 
genes present in the 14q24 microdeletion that are associated with recessive diseases for 
variants on the non-deleted allele and to query ciliopathy-associated genes for variants 
that could complement the IFT43 deletion resulting in possible oligogenic inheritance. 
Fragment library preparation and exome target enrichment using the SureSelect 50 Mb 
(V4) All Exon Kit (Agilent Technologies, CA, USA) was performed as described previously 
[Harakalova et al., 2011] (Supplemental Methods 1) and sequencing of barcoded samples 
was performed on the SOLiD 5500XL platform (Life technologies, Carlsbad, CA, USA). 
Sanger sequencing (ABI 3730 DNA Analyzer, Life Technologies, Forster City, CA, USA) 
of the coding regions and intron-exon boundaries of IFT43 was performed. Primer 
sequences are available upon request.
Immunocytochemistry of IFT43 and IFT88
As chromosome 14 contains numerous imprinted regions, we assessed expression of 
IFT43 using immunofluorescence in patient-derived fibroblasts to exclude imprinting 
of the non-deleted allele (Supplemental Methods 2). In addition, we assessed primary 
cilia length and morphology in control- and patient-derived fibroblasts as previously 
described [Arts et al 2011]. For a list of antibodies used, see Supplemental Methods 3.
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Results
Genetic analysis identifies a de novo 4.5-Mb microdeletion on chromosome 
14q24 
Array-CGH analysis identified a de novo 4.5-Mb microdeletion on chromosome 
14q24.2q24.3 (73,152,115 – 77,698,582; GRCh 37/hg 19) in the patient. No CNVs were 
detected in the parents. The deleted region contained 65 protein-coding genes listed in 
Online Mendelian Inheritance in Man (OMIM). Supplemental Fig. 1 shows an overview of 
the genes and overlapping deletions in DECIPHER. Exome sequencing did not identify 
variants in genes present in the 14q24 microdeletion that are associated with recessive 
diseases and there were no other variants that could likely explain the phenotype 
(Supplemental Table II). We did not detect mutations in the non-deleted IFT43 allele or in 
other ciliopathy-associated genes. 
Figure. 1. Phenotype index patient. A. Physical characteristics of index patient during infancy: preauricular 
skin tag (i) and small right thumb (ii). B. Patient at age ten. Cup-shaped ears with preauricular scar from surgical 
removal of skin tag (iii). Long upper and lower limbs and short, broad thorax (iv). Long, slender digits on feet (v) 
and hands (vi) with right hand showing pollicization of index finger.
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IFT43 is expressed along the ciliary axoneme in patient-derived fibroblasts
IFT43 expression was detected in the cytoskeleton and along the primary cilium axoneme 
in control- and patient-derived fibroblasts (Supplemental Fig. 2), excluding methylation of 
the non-deleted IFT43 allele.
Accumulation of IFT88 at the ciliary tip in patient-derived fibroblasts
Primary cilia morphology was evaluated in skin fibroblasts derived from the index patient. 
Supplemental Fig. 3 illustrates the cilia phenotype in detail and Supplemental Fig. 4 
shows a whole-field image of the cells. Patient-derived fibroblasts showed a statistically 
significant increase in cells with substantial accumulation of IFT88 in the ciliary tip 
compared to control fibroblasts (P equals 0.0002). There was no statistically significant 
difference in primary cilia length or number between patient- and control cells (data not 
shown). 
Discussion
We describe a patient with mild ID, ASD, skeletal anomalies and facial dysmorphisms 
who carries a de novo 14q24.2q24.3 microdeletion encompassing 65 protein-coding 
genes. Mild ID and congenital heart defect have been reported in all four previously 
reported patients with a 14q24 deletion [Oehl-Jaschkowitz et al., 2014; Tassano et al., 
2014] and small or proximally-set thumb in two. However, the deletion in the index patient 
does not overlap with the smallest region of overlap of the previously reported patients 
(Supplemental Fig. 5), suggesting the effect of multiple loci on 14q24 or elsewhere in 
the genome associated with these features. Haploinsufficiency of genes located within 
the deletion could contribute to the phenotype. Heterozygous mutation in TGFB3 
(MIM# 190230) has been reported in patient with arachnodactyly and marked 
contractures of the proximal interphalangeal joints that were also observed in the index 
patient [Rienhoff et al., 2013] and in four other patients with Marfan and Loeys-Dietz-
like phenotypes [Matyas et al., 2014; Keuchler et al., 2015], suggesting that this gene 
could be involved in skeletal features. The mouse homologue of VSX2 (MIM# 142993) 
was demonstrated to be a regulator of formation of the lumbosacral region, possibly 
accounting for sacral hypoplasia [Wellik and Capecchi, 2003]. Previously, C14of169 
(MIM# 611919), NUMB (MIM# 603728) and PSEN1 (MIM# 104311) have been proposed to 
contribute to skeletal, cardiac and neurological anomalies [Tassano et al., 2014]. Maternal 
diabetes mellitus, a risk factor for sacral hypoplasia and congenital heart defect, could 
also have contributed to the phenotype [Al Kaissi et al., 2008; Liu et al., 2013]. Because 
of the combination of skeletal, ectodermal and ocular features in the index patient, we 
investigated a ciliary defect on the cellular level and found excess accumulation of 
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IFT88 in ciliary tips of patient-derived fibroblasts. Accumulation of IFT-B proteins (marked 
by IFT88) in ciliary tips indicates impaired retrograde ciliary transport [Arts et al., 2011; 
Cole et al., 2003], characteristic of cranioectodermal dysplasia (CED) (MIM# 614099) 
[Arts et al., 2011;Lin et al., 2013]. Biallelic mutations in IFT43 have been identified in a 
family with CED [Arts et al., 2011]. Deletion of IFT43 could therefore be a modifier of the 
14q24 microdeletion syndrome phenotype. However, there are differences between the 
phenotype of the index patient and CED (long fingers and limbs instead of short fingers 
and limbs, a short, broad thorax instead of a narrow thorax and an extra central incisor 
instead of hypodontia) and we did not detect mutations in or imprinting of the non-
deleted IFT43 allele. Exome sequencing was used to examine oligogenic inheritance 
and modifier genes, which have been reported in ciliopathies [Katsanis et al, 2001]. 
Although we did not identify variants in other ciliopathy-associated genes, we cannot 
exclude variants in genes encoding unknown regulators of IFT-A or regulatory elements 
of ciliopathy-associated genes. In conclusion, we report a patient with mild ID, skeletal 
anomalies, congenital heart defect, myopia and facial dysmorphisms caused by a 
de novo 14q24.2q24.3 microdeletion. The deletion encompasses 65 genes and shows 
partial overlap with previously reported 14q24 microdeletions. Patient cells showed 
defective retrograde ciliary transport. This could be associated with haploinsufficiency 
of IFT43, however additional variants in ciliary genes or gene regulatory elements are 
required to support the role of a ciliary defect in the pathogenesis of skeletal, ocular and 
ectodermal features.  Further patients with overlapping deletions are needed to confirm 
the pathophysiological mechanisms underlying this phenotype.
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Supplemental data
Supplemental Fig. 1. Schematic overview gene content of the 14q24.2q24.3 region according to UCSC 
Genome Browser (GRCh37/hg 19 assembly; http://genome.ucsc.edu) and of previously reported patients with 
overlapping deletions.
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Supplemental Fig. 2. IFT43 is expressed along the ciliary axoneme in control- and patient-derived 
fibroblasts. Patient-derived skin fibroblasts were used to qualitatively assess IFT43 protein expression in the 
primary cilium compared to control fibroblasts. IFT43 expression was observed in the cytoskeleton and along 
the ciliary axoneme (indicated by arrows) in both control- and patient-derived fibroblasts. The ciliary axoneme 
is shown in green (acetylated-α-tubulin) and IFT43 is shown in white. The scale bar represents 5 μm.
Supplemental Fig. 3. IFT88 accumulates in ciliary tips in patient-derived cells. Patient-derived skin fibroblasts 
were used to evaluate the localization of IFT88 in the primary cilium in comparison to fibroblasts from a healthy 
control. A. Cilium from a control individual with modest IFT88 levels (red) in the ciliary tip and a cilium in a cell 
from the index patient with substantial IFT88 accumulation in the ciliary tip (arrows). The ciliary axoneme is 
shown in green (acetylated-α-tubulin), the transition zone that marks the proximal cilium is indicated in pink 
(RPGRIP1L), and IFT88 is shown in red. The scale bar represents 1 μm. B. An accumulation of IFT88 at the tip 
of the ciliary axoneme was seen in 51% of cilia in patient-derived fibroblasts, whereas such accumulations 
were only seen in 25% of cilia in control fibroblasts (>50 cells analyzed). The asterisks indicate that this is a 
statistically significant difference (two-tailed P value equals 0.0002, calculated using the Fisher’s exact test).
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Supplemental Fig. 4. IFT88 protein localization in cilia from patient- and control cells. The ciliary axoneme 
is marked by acetylated-α-tubulin (green), the transition zone that marks the proximal cilium is marked by 
RPGRIP1L (pink), and IFT88 is shown in red. The arrow points at an accumulation of IFT88 in the ciliary tip in one 
of the patient-derived cells (lower panel).
Supplemental Fig. 5. Schematic overview of 14q24 deletions in index patient and patients reported in 
literature with similar phenotype. Phenotype of Patients 1 to 3 reported by Oehl-Jaschkowitz et al. and 
patient reported by Tassano et al. (Patient 4) overlaps with phenotype observed in index patient. Dashed lines 
represent smallest region of overlap between these patients. Deletion found in index patient does not overlap 
with this region.  
Supplemental Table I. Patients with overlapping 14q24 deletions and associated clinical findings.
+, present; -, absent; NA, not reported/not applicable.
For patients with DECIPHER ID 253894, 265207, 277160, 282030, 289298, 290148 and 292650 and 
overlapping 14q24 microdeletions, phenotypic information was limited. Note that IFT43 is deleted in patient 
with DECIPHER ID 261280. 
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Oehl-Jaschkowitz B, Vanakker OM, De Paepe A, Menten B, Martin T, Weber G, Christmann A, Krier 
R, Scheid S, McNerlan SE, McKee S, Tzschach A. 2014. Deletions in 14q24.1q24.3 are associated 
with congenital heart defects, brachydactyly, and mild intellectual disability. Am J Med Genet A 
164A:620-626.
Tassano E, Accogli A, Panigada S, Ronchetto P, Cuoco C, Gimelli G. 2014. Phenotypic and genetic 
characterization of a patient with a de novo interstitial 14q24.1q24.3 deletion. Mol Cytogenet 7:49-
56.
Presence of variants in ciliopathy-associated genes including IFT-complex genes and their synonyms, and 
all genes contained within the deletion, was investigated in whole-exome sequencing data. All variants in 
ciliopathy-associated genes were present in heterozygous form. Variants in TMEM216 and CEP120 were 
filtered out because of population frequency >1%. Because there is no direct interaction between NPHP3 and 
IFT-A complex proteins, digenic inheritance involving heterozygous variants in these genes is unlikely.  The 
variant in OFD1 is a ‘variant of unknown significance’ (VUS) and was discarded because the phenotype in the 
index patient does not match criteria for Oral-facial-digital syndrome type I. IRF2BPL is not associated with 
recessive disease.
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Abstract 
EXTL3 regulates the biosynthesis of heparan sulfate (HS), important for both skeletal 
development and hematopoiesis by the formation of HS proteoglycans (HSPGs). By 
whole-exome sequencing, we identified here homozygous missense mutations in EXTL3, 
c.1382C>T, c.1537C>T, c.1970A>G, and c.2008T>G, in nine affected individuals from five 
unrelated families. Notably, we found the identical homozygous missense mutation 
c.1382C>T (p.Pro461Leu) in four affected individuals from two unrelated families. Affected 
individuals presented with variable skeletal abnormalities and neurodevelopmental 
defects. Severe Combined Immunodeficiency (SCID) with a complete absence of T cells 
was observed in three families. EXTL3 was most abundant in hematopoietic stem cells 
and early progenitor T cells, which is in line with a SCID phenotype at the level of early 
T cell development in the thymus. To provide further support for the hypothesis that 
mutations in EXTL3 cause a neuro-immuno-skeletal dysplasia syndrome, and to gain 
insight into the pathogenesis of the disorder, we analyzed the localization of EXTL3 
in fibroblasts derived from affected individuals and determined glycosaminoglycan 
concentrations in these cells as well as in urine and blood. We observed abnormal 
glycosaminoglycan concentrations and increased concentrations of the non-sulfated 
chondroitin disaccharide D0a0 and the disaccharide D0a4 in serum and urine of all 
analyzed affected individuals. In summary, we show that biallelic mutations in EXTL3 
disturb glycosaminoglycan synthesis and thus lead to a recognizable syndrome 
characterized by a variable expression of skeletal, neurological and immunological 
abnormalities.
Image on page 94: Cellular localization of EXTL3 in a human-derived fibroblast.
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Introduction
A number of complex immunodeficiency syndromes additionally include skeletal 
dysplasia as part of their variable phenotype. For example, Schimke immuno-osseous 
dysplasia (SIOD [MIM: 242900]) and cartilage-hair hypoplasia (CHH [MIM: 250250]) are 
(spondylo-epiphyseal-)metaphyseal dysplasias that can also result in disproportionate 
short stature.1;2;3 Besides featuring skeletal dysplasia, CHH is further characterized 
by T cell immunodeficiency, brittle hair, ligamentous laxity, hypoplastic anemia, and 
sometimes neuronal dysplasia of the intestine, leading to Hirschsprung disease.4 SIOD is 
commonly associated with skeletal dysplasia, nephropathy, and T cell immunodeficiency 
(GeneReviews, see Web Resources). Notably, both CHH and SIOD are recessive 
disorders caused by mutations in RMRP (MIM: 157660) and SMARCAL1 (MIM: 606622), 
respectively,4;5 and affected individuals display both broad interfamilial and intrafamilial 
variability of the immunological abnormalities (GeneReviews and Ridanpää et al.4). 
Here, we report on a neuro-immuno-skeletal disorder caused by pathogenic mutations 
in EXTL3 (exostosin-like glycosyltransferase 3 [MIM: 605744]), a gene not previously 
associated with human disease. EXTL3 is a member of the exostosin (EXT) family of 
glycosyltransferases, comprising EXT1, EXT2, EXTL1, and EXTL2. These enzymes 
regulate glycosylation, a process by which glycans are attached to both proteins and 
lipids in the endoplasmic reticulum or Golgi complex. EXTL3 and its family members 
are known to be involved in the biosynthesis of the glycosaminoglycan (GAG) heparan 
sulfate (HS) in a variety of species.6;7;8;9;10;11 EXT family members exert an effect on many 
physiological activities by the covalent binding of HS chains to proteoglycans, forming HS 
proteoglycans (HSPGs). HSPGs are a major component of the extracellular matrix (ECM) 
in all organs in the human body and are involved in numerous physiological processes.12 
Notably, there are three subfamilies of HSPGs: membrane-spanning proteoglycans, 
glycophosphatidylinositol-anchored proteoglycans, and secreted ECM proteoglycans,12 
all of which have been implicated in skeletogenesis and hematopoiesis.13;14 EXTL3 is a 
N-acetylglucosaminyltransferase (GlcNac transferase) that exhibits GlcNac-TI activity by 
catalyzing GlcNac binding to a GAG linkage region, thereby initiating the biosynthesis 
of HS chains. EXTL2 shares GlcNac-TI activity with EXTL3 but initiates HS chains on 
different core proteins than EXTL3 by discriminating the amino acid sequences.9 EXTL1 
is involved in the elongation of HS chains by exhibiting GlcNAcT-II activity,9 whereas the 
EXT family members EXT1 and EXT2 form a heterooligomeric complex with GlcNAc and 
GlcA transferase activity essential for the polymerization of HS. The crucial role of EXTL3 
in general organogenesis is exemplified by embryonic lethality of mice homozygous for 
a null mutation.11 Regarding human disorders, EXT1 (MIM: 608177) and EXT2 (MIM: 608210) 
are associated with autosomal-dominant hereditary multiple exostoses (MIM: 133700 
and 133701, respectively).15 In addition, autosomal-recessive mutations in EXT2 lead to 
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seizures, scoliosis, and macrocephaly syndrome (MIM: 616682).16 EXTL3 mutations have 
not yet been connected to any disease. In this report, we describe nine individuals 
from five unrelated families affected by an autosomal-recessive neuro-immuno-skeletal 
dysplasia syndrome caused by biallelic missense mutations in EXTL3.
Material and methods
Collection of samples and informed consent
For all five families, DNA samples were extracted from blood according to standard 
laboratory practice and used for whole-exome sequencing (WES). Fibroblast lines 
obtained from skin biopsy material of the affected individuals (A:II-1, B:II-1, B:II-2, C:II-1, D:III-1, 
D:IV-1, and E:II-1) and three in-house control fibroblast lines were used for GAG analysis 
and immunocytochemistry. Heparinized peripheral-blood samples and urine were 
collected from healthy age-matched control individuals and from affected individuals 
during routine diagnostic procedures. Urine collected from affected individuals A:II-1, B:II-
1, and B:II-2 and serum collected from the blood of these individuals and parents B:I-1 and 
B:I-2 were used for GAG analysis. After identification of the EXTL3 mutations in family A, 
other genetic laboratories were contacted via GeneMatcher and Matchmaker Exchange; 
this linked our EXTL3 submission to PhenomeCentral, resulting in the ascertainment of 
families B–E.17;18;19 All participants in this study gave written informed consent, and all human 
material was collected after approval by the local ethic committees (NL40332.078.12 
for family A, PV3802 for family B, 1000029424 for family C, 09CM32 for family D, and 
06/Q0508/16 for family E).
Whole-exome sequencing 
Genomic DNA from the unaffected parents and affected individuals II-1 (family A), II-1 and 
II-2 (family B), II-1 and her unaffected parents (family C), III-1, III-2, and IV-1 (family D), and II-1, 
II-2, and their unaffected parents (family E) were used for WES. WES experiments were 
performed in different centers with slightly different procedures that have essentially 
been described before (family A,20;21;22;23 family B,24 family C,25;26 and families D and E27). 
In brief, exome enrichment was performed with an Agilent SureSelect Human All Exon 
50 Mb Kit (V4 for families A, D, and E; V5 for families B and C), and then sequencing was 
performed on a SOLiD 5500xl System (Thermo Fisher Scientific; family A), Illumina HiSeq 
2500 (family B), or HiSeq 2000 (families C–E). Read mapping and single-base-pair variant 
and indel calling were performed with LifeScope Software v.2.1 (Life Technologies) for 
family A. For families B–E, reads were aligned to the human genome assembly (UCSC 
Genome Browser hg19) with the Burrows-Wheeler Aligner (v.0.5.87.5 for family B and 
v.0.7.7 for family C), and detection of genetic variation was performed with SAMtools 
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(v.0.1.18), PINDEL (v.0.2.4t), and ExomeDepth (v.1.0.0). For family C, indel realignment and 
base recalibration were performed with Genome Analysis Toolkit (GATK) v.3.1.1. Duplicated 
reads were removed by Picard v.1.108, and genetic variation was detected with SAMtools 
(v.1.2) and BCFtools (v.1.2).28 Variant calling for families D and E included GATK base quality 
score recalibration, indel realignment, and duplicate removal. SNP and indel discovery 
and genotyping were performed with standard hard filtering parameters or variant quality 
score. The variant annotation and interpretation analyses were generated by Ingenuity 
Variant Analysis software (v.3.1.20140902, QIAGEN).
Copy-number variation (CNV) detection was performed on WES data of each affected 
individual. For family A, the CoNIFER computational pipeline29 was used as described 
previously.30 For family C, FishingCNV software31 was used to call CNVs and compare 
the read depth of these CNVs against the distribution of reads in more than 50 control 
samples without related genetic disorders (all samples were sequenced and aligned 
according to the same protocol). In addition, the eXome-Hidden Markov Model (XHMM) 
algorithm was applied for the detection of rare CNVs.32;33;34 A SNP array was then 
performed in affected individuals from family B as previously described.35
Bioinformatic filtering
Variant annotation was performed with four independent in-house annotation pipelines. 
To prioritize variants in the sequencing data, we excluded variants that were non-
genic, intronic (except for canonical splice sites), or synonymous. Further, we excluded 
variants that were present in dbSNP 135 at a frequency > 1% or > 1% in the in-house 
variant database (2,096 in-house-analyzed exomes for family A and ~3,000 exomes for 
family C). For family C, variants with a minor allele frequency (MAF) > 5% in 1000 Genomes36 
(October 2014), the NHLBI Grand Opportunity (GO) Exome Sequencing Project (ESP) 
(v.0.0.30, November 3, 2014), or Exome Aggregation Consortium (ExAC) Browser 
(v.0.2, October 29, 2014) were excluded. Variants excluded in families D and E had a 
MAF > 1% in the NHLBI GO ESP and ExAC Browser. The NHLBI GO ESP contains data 
from more than 200,000 individuals. At the time of this study, the ExAC Browser included 
sequences of 60,706 unrelated individuals from different ethnic backgrounds. We used 
a quality filter to exclude variants with <5 reads or <20% variant reads. Candidate variants 
were validated by Sanger sequencing, and segregation analysis was conducted in all 
five families.
Immunophenotyping
Peripheral-blood mononuclear cells (PBMCs) were isolated by standard density gradient 
centrifugation techniques with Lymphoprep (Nycomed). For immunophenotyping, 
PBMCs were resuspended in phosphate buffered saline (PBS) containing 
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0.5% (w/v) bovine serum albumin (BSA) and 0.01% sodium azide and incubated with 
saturating concentrations of fluorescently labeled conjugated monoclonal antibodies. 
Cells were analyzed with a FACSCanto-II flow cytometer and FlowJo software. Samples 
from the affected individuals were analyzed simultaneously with PBMCs from healthy 
control individuals. The following conjugated monoclonal antibodies were used: 
CD4 PE-Cy7, CD8 PerCP-Cy5.5, CD20 PerCP-Cy5.5, CD27 APC, CD38 PE-Cy7, CD45 
APC-H7, and IgD PE from BD Biosciences; CD3 Alexa 700 and CD19 Alexa 700 from 
eBioscience; CD27 FITC from Sanquin; CD45RA (2H4-RD1) PE from Beckman Coulter; IgM 
FITC and IgG FITC from Dako; and IgA FITC from Miltenyi Biotec. In order to analyze the 
in vitro activation of T and B cells, we resuspended the PBMCs in PBS at a concentration 
of 5×106 to 10×106 cells/mL and labeled them with 0.5 μM carboxyfluorescein succinimidyl 
ester (CFSE) (Molecular Probes, Thermo Fisher Scientific) in PBS for 10 min at 37°C under 
constant agitation. Cells were washed and subsequently resuspended in Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 10% fetal calf serum (FCS, 
BioWhittaker), antibiotics, and 3.57×10-4% (v/v) β-mercaptoethanol (Merck). Labeled 
PBMCs containing a fixed number of B cells (2×104 per well) were cultured in 96-well 
flat-bottomed plates for 6 days at 37°C and stimulated with saturating amounts of 
anti-IgM mAb (clone MH15, Sanquin), anti-CD40 mAb (clone 14G7, Sanquin), and 20 ng/ml 
IL-21 (Invitrogen); 1 μg/mL CpG oligodeoxynucleotide 2006 (Invivogen) and 100 U/mL IL-2 
(R&D Systems); or anti-CD3 (clone 1xE, Sanquin) and anti-CD28 (clone 15E8, Sanquin). We 
assessed the proliferation of B and T cells by measuring CFSE dilution by flow cytometry.
We assessed the secretion of IgG and IgM by mature B cells by analyzing supernatants 
for secreted IgM and IgG with an in-house ELISA assay using polyclonal rabbit anti-
human IgM, IgG reagents, and a serum protein calibrator. All reagents were from Dako, 
as described previously.37;38 
Validation of EXTL3 antibody
We used a commercial antibody targeting EXTL3 (goat, AF2635, R&D Systems) to 
detect the level of EXTL3 in different cell lines and human tissue. In order to ensure the 
specificity of the antibody, we knocked out EXTL3 in human embryonic kidney 293T 
(HEK293T) cells by using the CRISPR/Cas9 technique. Three different single guide 
RNAs (sgRNAs)—5’-CTTCTCTATAACGTCAGTAC-3’, 5’-GGGACTGGCTTTCGGCCTAT-3’, 
and 5’-AGAAGCTCGGGACCGCATCG-3’—were each inserted into a pLentiCRISPR v.2 
vector (52961, Addgene) as described by Sanjana et al.39 The pLentiCRISP v.2 construct 
containing the EXTL3 sgRNA or the empty vector was transfected into HEK293T cells 
with a Genius DNA Transfection Reagent (Westburg) according to the manufacturer’s 
instructions. After transfection, we cultured the cells in standard cell-culture medium 
containing 2.5 μg/mL puromycin for 3 days to select only the transfected cells. 
Subsequently, we prepared and analyzed the cell lysates by western blotting to test the 
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specificity of the EXTL3 antibody.
Analysis of EXTL3 in lymphocytes and thymus tissue
We used western blotting to assess the level of EXTL3 in different lymphocyte cell lines. 
Protein lysates were made from diffuse large B cell lymphoma cell lines OCI-Ly1, OCI-
Ly7, and U2932; myeloma cell lines ANBL6 and RPMI-8226; leukemia-derived T cell 
lines Jurkat, CCRF-CEM, and Molt4; T cell lymphoma cell line SupT1; Burkitt lymphoma 
cell line Namalwa; lymphoblast cell line Ramos; mobilized peripheral-blood CD34+ 
progenitor cells; and CD4-CD8-, CD4+CD8+, CD4-CD8+, and CD4+CD8- cells sorted from 
thymocytes. All cell lines were cultured in IMDM containing 10% fetal bovine serum and 
100 units/mL penicillin. Protein lysates were separated by 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and subsequently immunoblotted according to a 
standard procedure. The immunoblots were incubated in PBS containing 5% milk and 
0.2% tween with antibodies targeting human EXTL3 (goat, AF2635, R&D Systems) and 
β-actin (clone AC-15, mouse, A5441, Sigma Aldrich). Primary antibodies were detected 
by horseradish peroxidase (HRP)-conjugated secondary antibodies donkey-anti-goat 
(605-703-125, Rockland Immunochemicals) and rabbit-anti-mouse (P0161; Dako) and 
then detected by Amersham ECL Western Blotting Detection Reagent (GE Healthcare).
Paraffin-embedded thymus tissue for immunohistochemical investigations was obtained 
from a neonate who had died from asphyxia at birth and had a post-mortem examination 
unrelated to this study. To ensure optimal staining of EXTL3, we treated thymus tissue 
sections of 4 μm thickness with Tris ethylenediaminetetraacetic acid (EDTA, pH 9) for 
20 min at 121°C for antigen retrieval. Sections were incubated overnight at 4°C with 
an antibody targeting human EXTL3 (goat, AF2635, R&D Systems). Subsequently, the 
tissues were washed with PBS and incubated with rabbit-anti-goat antibody (6160-01, 
Southern Biotech) for 30 min at room temperature. EXTL3 was detected by poly-HRP-
anti-rabbit IgG (DPVR110HRP, Immunologic) and then by Ultra DAB (Immunologic).
Immunocytochemistry in human fibroblasts
The localization of EXTL3 was assessed in primary fibroblasts derived from A:II-1, B:II-1, 
and B:II-2 and compared with that in fibroblasts from two healthy control individuals. 
The fibroblasts were cultured in Dulbecco’s modified Eagle’s medium with 20% FCS 
on sterile coverslips for 72 hr and subsequently immunostained. For this purpose, cells 
were washed in PBS and fixed in 2% paraformaldehyde in PBS for 20 min. In order 
to enable antibody binding, we incubated cells in 10 mM sodium citrate buffer for 30 
min at 60°C. Cells were then permeabilized in 1% Triton X-100 in PBS for 5 min and 
blocked for 30 min in 2% BSA in PBS. We used primary antibodies targeting EXTL3 at 
1:100 dilution (goat, AF2635, R&D Systems) and the Golgi marker GM130 at 1:250 dilution 
(mouse, 610822, BD Biosciences). Primary antibodies were diluted in 2% BSA in PBS 
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and incubated for 1 hr at room temperature. After being washed with PBS, cells were 
incubated with fluor-labeled secondary antibodies for 30 min. These included donkey-
anti-goat IgG Alexa Fluor 488 (1:400) and donkey-anti-mouse IgG Alexa Fluor 568 
(1:400) from Life Technologies. After cover glasses were washed in PBS, a drop of DAPI 
containing Fluoromount-G (Southern Biotech) was added to the cells. Cover glasses 
were placed on glass microscope slides. Microscopy was conducted with a Zeiss Axio 
Imager Z2 fluorescence microscope equipped with an ApoTome slider. Images were 
obtained with ZEN 2012 software (Zeiss) and processed with Photoshop CS4 (Adobe 
Systems) and freely available Fiji software.
Heparan sulfate, dermatan sulfate, and chondroitin sulfate analysis
GAG concentrations were determined in serum, urine, and fibroblasts as described 
previously.40;41 In brief, we made homogenates from fibroblasts by disrupting the cells in 
PBS with a Vibra-Cell sonicator (Sonics & Materials). Protein concentrations were measured 
in whole-cell lysates as described by Lowry et al.42 To obtain GAG disaccharides, we 
enzymatically digested 50 μL serum, 50 μL urine, or 25 μg fibroblast protein in a mixture 
containing 100 mM NH4Ac (pH 7.0), 10 mM Ca(Ac)2, 2 mM DTT, 5 mIU each of heparinase 
I, II, and III, and 50 mIU chondroitinase B or 50 mIU chondroitinase ABC in a final volume 
of 150 μL. After 2 hr of incubation at 30°C, 15 μL of 150 mM EDTA (pH 7.0) was added 
along with 125 ng of the internal standard, 4UA-2S-GlcNCOEt-6S (HD009, Iduron), and 
the reaction was stopped and boiled for 5 min for protein denaturing. The reaction 
mixture was centrifuged at 20,000 × g for 5 min at room temperature. Subsequently, 
the supernatant was applied to an Amicon Ultra 30K centrifugal filter (Millipore) and 
centrifuged at 14,000 × g for 15 min at 25°C. The filtrate was stored at 20°C until analysis. 
HS, dermatan sulfate (DS), and chondroitin sulfate (CS) levels were quantified on a 
Waters Quattro Premier XE (tandem) mass spectrometer (Waters Corporation) coupled 
to an Acquity UPLC system (UPLC-MS/MS) with a Thermo Hypercarb HPLC column (100 
× 2.1 mm, 5 μm) and a mobile phase consisting of 10 mM NH4HCO3 (pH 10). Disaccharides 
were eluted with an acetonitrile gradient of 0%–20% for 2.5 min, held at 20% for the 
next 2.5 min, and equilibrated for 2 min at 0% before the next injection; the flow rate 
was 0.2 mL/min, and the total run time was 7.1 min. All disaccharides were detected 
and quantified in multiple-reaction-monitoring acquisition mode with the transitions m/z 
378.1 > 175.1 for D0A0, 458.0 > 299.9 for D0a4, 378.0 > 175.0 for D0a0, and 458.0 > 
97.0 for D0a6 (according to the nomenclature of Lawrence et al.43) and 472.0 > 97.0 for 
the 4UA-2S-GlcNCOEt-6S internal standard. The concentration of each disaccharide 
was calculated with a calibration curve for each of the disaccharides. All samples were 
digested and analyzed in duplicate. For each subject, all serum and urine GAG levels 
were compared with those of age-matched control individuals (n = 4). The normal range 
for each GAG was defined as the mean ± 2 SDs of the control samples.
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Results 
Clinical report
We report on nine affected individuals from five unrelated families affected by neuro-
immuno-skeletal dysplasia syndrome. Families A and B were consanguineous, suggesting 
autosomal-recessive inheritance of the disorder (Figure 2A, Table 1, and Tables S1 and 
S2). Family C was from a geographically isolated district in Colombia (South America) and 
possibly had a distant degree of consanguinity. Family D was the offspring of families who 
had lived for several generations in two small neighboring Portuguese villages. Family E 
was of Indian descent and had no history of consanguinity.All nine affected individuals 
presented with various skeletal dysplasias. In four families (A and C–E), X-rays revealed 
severe platyspondyly leading to disproportionate stature (Figure 1). Lumbar gibbus 
and kyphoscoliosis were observed in families C and D, respectively. Three individuals 
(from families D and E) had cervical malformations and a hypoplastic odontoid peg with 
cervical instability. Short stature was also present in families A and B but appeared to 
be the result of limb shortening. Metaphyseal abnormalities of the long bones were 
found in families A and E, whereas families B–D showed epiphyseal abnormalities 
(Figure 1). Brachydactyly was observed in affected individuals from families A, B, and D. In 
addition to showing skeletal abnormalities, all affected individuals in families B and C had 
intellectual disability (ID). This could not be assessed for individuals A:II-1, E:II-1, and E:II-2 
because of their early death at 7 weeks, 6 months, and 10 months of age, respectively. 
Both siblings of family B were severely disabled and unable to speak and are currently 
wheelchair bound. Dysmorphic facial features were non-discriminatingly mild but 
included coarse facial features, a prominent nose, and full cheeks in almost all affected 
individuals (Figure S1). A single palmar crease was also observed in six of nine affected 
individuals. A striking phenotype present in three of the five families was T-cell-negative 
A:II-1 B:II-1 B:II-2 C:II-1 D:III-1 D:III-2 D:IV-1 E:II-1 E:II-2
Neurological 
abnormalities n.a. +++ +++ + +ª - - n.a. n.a.
Immunological 
abnormalities +++ +++ +++ - - - - ++ ++
Skeletal 
abnormalities +++ + + +++ +++ +++ +++ +++ +++
ªNormal/borderline cognition
Number of plus signs indicates the severity of the abnormality 
n.a. means not assessed due to early death of the affected individuals (A:II-1 at 6 weeks, E:II-1 at 6 months, 
E:II-2 at 10 months of age)
Table 1. Overview of the most affected organ systems in all affected individuals.
Chapter 5
104
SCID. Affected individuals from families A and B showed a lack of T cells, whereas B cell 
numbers were normal (Figure 4). Family E showed idiopathic CD4+ lymphopenia and 
an absolute lack of naive T cells (both CD4+CD45RA+ and CD8+CD45RA+ T cells were 
missing). In families B and E, a typical skin rash prompted further evaluation of the blood 
cells. Maternal T cells were excluded, and the oligoclonal T cell reaction found in the 
presence of eosinophilia was compatible with an Omenn-like presentation of SCID.1;2 
Worth mentioning are also the liver cysts seen in affected individuals from families A and 
E. Although the phenotypes were widely variable and partly contrasting (e.g., severe 
versus no ID, severe versus mild platyspondyly, and epiphyseal versus metaphyseal 
changes), all major malformations and features occurred in three organ systems only: 
the immune system, the skeleton, and the neurological system. All together, we classify 
these five families as having phenotypic variability of an EXTL3-related neuro-immuno-
skeletal dysplasia phenotype. The affected individuals from families A and E died in early 
infancy, whereas the others are currently between 2 and 38 years of age. Individual III-1 
from family D died at 30 years of age from a unknown cause. Table 1 gives an overview 
of the most affected organ systems in all affected individuals. Detailed case reports and 
clinical data for each affected individual can be found in the Supplemental Note.
Whole-exome sequencing
Massive parallel sequencing of genomic DNA of nine affected individuals from five 
unrelated families was performed in four different centers (Figure 2A). WES data were 
filtered according to a recessive disease model given that families A and B showed 
consanguineous bonds and families B, D, and E each had more than one affected 
individual. The severity of the phenotype, especially in families A and E, suggests that the 
disease is caused by a rare genetic mutation. We therefore prioritized homozygous and 
compound-heterozygous variants, nonsense variants, and variants with a phyloP score 
> 2.7 given that the majority of annotated variants in the Human Gene Mutation Database 
have such scores.45 After application of these rules in family A, only 2 of 37 candidate 
variants segregated with the disease in the family (Table 2 and Table S3). These two 
mutations were homozygous missense mutations in EXTL3 (c.1537C>T [p.Arg513Cys] 
[GenBank: NM_001440.3]) and CHST9 (MIM: 610191; c.1133A>G [p.Asn378Ser] [GenBank: 
NM_031422]) (Figure 2B). Left with two candidate genes, we made use of GeneMatcher, 
a web-based tool for researchers and clinicians working on identical genes.17 A match 
was found in four independent families from different centers. WES data from these 
families revealed likely pathogenic homozygous missense mutations in EXTL3. Data 
from these families also revealed one or more genes carrying biallelic variants that 
segregated with the disease; however, in each family the variant in EXTL3 was the most 
likely candidate given the position and predicted impact of the variant together with the 
segregation analysis ( Table 2 and Tables S3–S7). In total, we found four homozygous 
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Figure 1. Clinical features of the skeleton of all five families A-E. (A) Lateral spine radiographs arranged 
chronologically. The affected individuals show severe platyspondyly (red boxes) with progressively severe 
kyphosis with increasing age (visualized for C:II-1, D:III-1, and D:IV-1), except for the affected siblings of family B 
who do not show severe platyspondyly (green boxes). Affected individual C:II-1 shows an additional abnormality 
of absent ossification of the anterior parts of the vertebral bodies in the upper lumbar region. Furthermore, 
wide intervertebral spaces are visible and the vertebral bodies show some posterior constriction giving a 
‘pear-shape’. (B) Hand radiographs arranged chronologically. Up to the age of about 6 years there is delay 
in carpal bone ossification. The 1st metacarpals (arrowhead) and the II middle phalanges (broad arrow) are 
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missense mutations: c.1382C>T (p.Pro461Leu), c.1537C>T (p.Arg513Cys), c.1970A>G 
(p.Asn657Ser), and c.2008T>G (p.Tyr670Asp). Variant analysis in the ExAC Browser 
showed that homozygous non-synonymous alterations in coding regions of EXTL3 are 
not tolerated. Only one such alteration was present (c.1324G>C [p.Val442Leu]), and it is 
predicted to be tolerated by SIFT prediction software (analysis performed in October 
2016). Furthermore, variants p.Arg513Cys and p.Tyr670Asp were both absent from the 
ExAC Browser. The other two variants, p.Pro461Leu and p.Asn657Ser, were present 
only in a heterozygous state with detected MAFs of 1.6×10-5 and 5.8×10-5, respectively. 
CNV analysis, including the SNP array in family B, did not reveal any likely pathogenic 
alterations (data not shown). All together, we found homozygosity for four missense 
mutations in EXTL3 in five unrelated families as a cause of a recessive form of neuro-
immuno-skeletal dysplasia. 
Validation of EXTL3 antibody
In order to validate the specificity of the antibody targeting EXTL3, we made use of 
CRISPR/Cas9 techniques to knock out EXTL3 in HEK293T cells and study the protein 
lysate on western blotting. A band of approximately 130 kDa was clearly visible in lanes 
1, 2, and 4, corresponding to cell lysates from HEK293T cells transfected with sgRNA 1, 
sgRNA 2, and the empty vector pLentiCRISP v.2, respectively. The absence of a band 
in lane 3 corresponding to cell lysates from HEK293T cells transfected with sgRNA 3 
validates the specificity of the antibody targeting EXTL3 (goat, AF2635, R&D Systems) 
(Figure 3D).
short. The V middle phalanges are short or absent in A:II-1, E:II-1, and E:II-2 (newborns). Affected individual B:II-2 
has soft tissue preaxial polydactyly. (C) The pelvic radiographs show a variable degree of sloping acetabula 
with shallow lateral notches, coxa valga, and small capital femoral epiphyses. Elbow radiographs showing 
dislocated radial heads with dysplastic radial heads.
Table 2. Causative EXTL3 (NM_001440.3) mutations detected by WES in the five families.
Family Chr HG19 
position
Variant Amino acid ExAC 
frequency
PhyloP SIFT 
score
PolyPhen-2 
score
A Chr8 g.28575113 c.1537C>T p.Arg513Cys n.p. 6.238 0 1
B Chr8 g.28575584 c.2008T>G p.Tyr670Asp n.p. 7.984 0 1
C,D Chr8 g.28574958 c.1382C>T p.Pro461Leu 1.65x10-05 7.727 0 1
E Chr8 g.28575546 c.1970A>G p.Asn657Ser 5.80x10-05 9.206 0 1
n.p. means not present in database
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Figure 2. Four homozygous missense mutations in EXTL3 in five unrelated families (A) Pedigrees of five 
affected families. All affected individuals carry homozygous missense mutations in EXTL3 (NM_001440.3). In 
family A II-1 is homozygous for c.1537C>T (M1). In family B, II-1 and II-2 are homozygous for c.2008T>G (M2). 
Families C and D segregate c.1382C>T. Family E segregates c.1970A>G (M4). (B) Schematic overview of EXTL3 
and corresponding protein (NP_001431) showing the position of the missense mutations and changes at the 
protein level. All four mutations are in exon 3. EXTL3 consists of two annotated domains, a transmembrane 
domain (amino acids 29-51) and a coiled coil domain (amino acids 86-148). In addition, there are two predicted 
Pfam domains; a conserved Exostosin domain (amino acids 190-500), and glycosyl transferase family 64 
domain (amino acids 663-904) that is conserved between enzymes that catalyse the transfer reaction of 
N-acetylglucosamine and N-acetylgalactosamine.44
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EXTL3 is present during early T cell development
Investigation of immune cells detected a complete or nearly complete absence of T 
cells but normal counts of B and natural killer (NK) cells in affected individuals from three 
families (A, B, and E; Table 3). Only a limited number of gene defects are known to result 
in T-negative SCID.1;2 The disease is most often caused by a lack of signaling of the 
T cell receptor to propagate the development of thymocytes toward the single CD4+ 
and CD8+ T cell stage.46 There is no published information about the actual level of 
EXTL3 in T cells. To elucidate the disease mechanism underlying the T cell deficiency 
seen in three of these five families, we studied the levels of EXTL3 in both T and B 
lymphocytes of normal control samples. EXTL3 was not observed by western blotting 
in circulating T or B lymphocyte cell types (Figure 3A). After strong activation by a 
combination of CD3 and CD28 during culture for 6 days into T cell blasts (CD4+CD27- or 
CD8+CD27-), low levels of EXTL3 were detected (Figure 3A). It was far less, if any at all, 
for activated B cells differentiating for 6 days into plasmablasts (CD38+CD138+) (Figure 
3A).These findings suggest that the effect of the selective T cell defect that we observed 
in EXTL3 deficiency could depend on the early protein levels during hemato- and/or 
lymphopoietic development before the circulating stage in peripheral blood. Indeed, 
EXTL3 was demonstrated at the protein level in purified CD34+ hematopoietic stem 
cells (HSCs) (Figure 3B), as well as in the immature (leukemic) T cell lines (Figure 3A). 
As was expected from the analysis of T and B cell subsets from blood or upon in vitro 
activation, none of the more mature T or B cell lines or any additional hematopoietic 
cell lines tested (including Jurkat cells, Ramos cells, Epstein-Barr virus B cell blasts, KG1a 
cells, HL-60 cells, and U937 cells) demonstrated any EXTL3 at the protein level (Figure 
3A). To assess thymic tissue from neonates for the level of EXTL3, we fractionated 
the thymocytes into early double-negative, double-positive, and late single-positive 
thymocytes. EXTL3 was observed in all fractions, including the single-positive CD4+ or 
CD8+ thymocytes (Figure 3B). Upon immunohistochemistry staining of thymus tissue 
from a normal neonate obtained at post-mortem examination (cause of death: asphyxia), 
EXTL3 showed moderate localization throughout the thymus in both the cortical and 
extramedullary niches (Figure 3C). These findings suggest that the level of EXTL3 is 
downregulated when T cells enter the circulation.
By determining the immunophenotype of circulating B and T cells in families A and B, 
we confirmed the T cell selective effect in the EXTL3-mutated individuals with a so-
called T-negative SCID phenotype. Skewing of the distribution of the T cell memory 
subset toward a highly differentiated phenotype was observed in individual B:II-1, but not 
in the transplanted sibling, B:II-2 ( Figure 4A). Upon stimulation with anti-CD3 and anti-
CD28, the proliferative response of both CD4+ and CD8+ T cells in individual B:II-1 was 
impaired in comparison with that of the transplanted sibling (B:II-2) and healthy control 
Mutations in EXTL3 cause neuro-immuno-skeletal dysplasia syndrome
109
5
individuals (Figure 4C). Furthermore, the T cells in individual B:II-1 were unable to induce 
B cell proliferation (Figure 4C). To exclude a functional B cell defect due to the early lack 
of EXTL3 at the HSC and common lymphoid progenitor (CLP) stages within the bone 
marrow, we generated plasmablasts and tested antibody release into the supernatant 
upon stimulation with CpG and IL-2 in families A and B. The distributions of memory B cell 
subsets were normal for their age (Figure 4A). Functionally, these data showed normal B 
cell activation and plasmablast formation (low-normal for age) with IgM and IgG release 
Table 3. Lymphocyte counts in EXTL3-mutated individuals compared to controls (< 2 years).
Case CD3+
T cell
(per µl) ª
CD3+CD4+
T cells
(per µl)
CD3+CD8+
T cells
(per µl)
CD19+
B cells
(per µl)
CD56+
NK cells
(per µl)
IgG
(g/L)
IgA
(g/L)
IgM
(g/L)
A:II-1 0 0 0 1436 279 1.0 <0.1 0.3
B:II-1
(7 yrs)
(8 yrs)
367
(25%)
488
(25%)
157
(8%)
176
(9%)
210
(11%)
293
(15%)
656
(34%)
819
(42%)
262
(13%)
585
(30%)
5.65
4.52
0.39
0.29
0.24
<0.2
B:II-2
(3 mo)
2442
(51%)
2442
(51%)
0 1436
(30%)
575
(12%)
12.9 0.2 2.5
C:II-1
(12 yrs)
819
(44%)
348
(19%)
221
(12%)
557
(30%)
453
(25%)
n.a. n.a. n.a.
D:III-1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
D:III-2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
D:IV-1
(12 yrs)
600
(36%)
382
(23%)
206
(12%)
538
(32%)
513
(31%)
n.a. n.a. n.a.
E:II-1
(2.5 mo)
1800
(40%)
500
(11%)
1310
(25%)
2030
(45%)
360
(8%)
<1.6 <0.4 0.5
E:II-2
(8 mo)
10
(0.2%)
0 0 1950
(69%)
760
(27%)
4.7 <0.06 0.11
Pediatric
controls
700-1500 400-900 400-1100 300-1500 50-400 5-10 0.7-1.5 0.3-1.2
ªAll values were obtained pre-HSCT
B:II-2: IgG before administration of IVIG and before HSCT. Ig subclasses (g/l): IgG1 11.9, IgG2 1.69, IgG3 0.57, 
IgG4 0.19).
Already developed Omenn syndrome
In brackets the percentage of the lymphocyte subtype within the total lymphocyte count. n.a. means no data 
available 
Chapter 5
110
Figure 3. EXTL3 levels in lymphocytes EXTL3 levels in T and B lymphocyte cell lines. (A) EXTL3 is absent 
in any B-cell lymphoma cells, myeloid cells, or circulating B and T lymphocyte cell lines. However, strong T 
cell stimulation seemed to induce low levels of EXTL3. (B) Purified CD34+ hematopoietic stem cells as well as 
thymocyte cells are positive for EXTL3. This is true for early double-negative, double positive and late single-
positive thymocyte cells. (C) Immunohistochemistry staining of normal neonate tissue for localization of EXTL3 
shows a moderate localization throughout the thymus. (D) EXTL3 antibody validation. The EXTL3 antibody 
shows a band for cells transfected with sgRNA 1 and 2, and the empty vector indicating the presence of EXTL3 
in the cell lysate. Upon transfection with sgRNA 3 an EXTL3 knock out cell line is obtained and there is no band 
visible, indicating the specificity of the antibody.
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in individual A:II-1 (Figures 4B and 4D–4F). The low in vitro IgG production in individual 
B:II-2 can be ascribed to the fact that she had been transplanted only 1 year earlier with 
a few circulating donor memory B cells at this stage, whereas the older sibling (B:II-1) 
showed 5% CD27+ memory B cells, plasmablast formation, and production of IgG and 
IgM (Figures 4B and 4D–4F). On the other hand, in one of the two families affected by 
the p.Pro461Leu variant and not prone to infections (family C), normal lymphocyte counts 
were found in initial white blood cell differentials. We confirmed that the lymphocyte 
numbers, maturation, subset distribution (naive, central-memory, and effector-memory T 
cells; naive, non-switched, and switched memory B cells; and NK cells), and proliferative 
capacity were completely normal (Figure S2). Together, these immunological data 
indicate that a severe T cell defect is most apparent, although variable, whereas the 
other hematopoietic cell lineages seem to develop normally.
EXTL3 mislocalizes in fibroblasts derived from affected individuals
In order to determine the effects of the missense variants identified herein, we compared 
EXTL3 localization in fibroblasts derived from A:II-1, B:II-1, and B:II-2 with that in cells from 
two unaffected control individuals by immunofluorescence microscopy. Overlap between 
the EXTL3 signal and that of GM130, a Golgi marker, indicates that EXTL3 localized to 
the Golgi complex in control fibroblasts. In contrast to the control cell lines, fibroblasts 
derived from individual A:II-1 did not show any EXTL3 in the Golgi complex (Figure 5), 
further supporting the causality of EXTL3 mutations in this individual. However, we could 
detect EXTL3 in the Golgi complex in fibroblasts from affected individuals in family B. 
We suspect that the p.Arg513Cys variant, which is located near the EXT domain ( Figure 
2B), causes degradation of EXTL3 and leads to its absence from the Golgi complex in 
cells from individual A:II-1. On the other hand, we speculate that the p.Tyr670Asp variant 
detected in family B does not affect EXTL3 localization but rather disrupts its GlcNAc 
transferase activity, given that this variant lies in the glycosyl transferase family 64 region 
of the protein (Figure 2B).
Figure 4. Immunophenotype and in vitro proliferation, plasmablast formation and immunoglobulin 
production Data are shown for individuals A:II-1, B:II-1, B:II-2 and a healthy adult control. (A) T cell subsets gated 
on CD3+CD4+ or CD3+CD8+ lymphocytes and B cell subsets gated on CD19+CD20+ lymphocytes. Numbers 
indicate percentages in corresponding gates. (B) CFSE-labeled PBMCs were cultured with either medium or 
CpG/IL-2 and gated on CD19+CD20+/- lymphocytes. Gates were set for either CD27bright (left) or CFSE+/- and 
CD38+/- (right) B cells to analyze cell division and plasmablast formation. (C) CFSE-labeled PBMCs were cultured 
with either medium or anti-CD3/anti-CD28 and were gated on CD3+CD4+ or CD3+CD8+ T lymphocytes and 
CD19+CD20+/- B lymphocytes to analyze direct (T cell) or indirect (B cell) proliferation upon TCR stimulation, ND 
not determined. (D, E) Levels of IgG and IgM were determined by ELISA in the supernatants after 6 days of 
culture with either medium, CpG/IL-2 or anti-IgM/anti-CD40/IL-21.
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HS levels are altered in material derived from affected individuals
We then determined whether the identified mutations in affected individuals A:II-1, B:II-
1, B:II-2, C:II-1, D:IV-1, and E:II-1 alter GAG synthesis, given that EXTL3 is known to be 
essential for HS biosynthesis.9 GAG concentrations were measured in serum and urine 
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of A:II-1, B:II-1, and B:II-2 and compared with those in age-matched control individuals 
(Figures 6B and 6C). In addition, the GAG concentrations were measured in fibroblasts 
from all families. Because the levels of most disaccharides were below the limit of 
quantification in several samples, we present only the results for the most abundant 
disaccharides for each GAG: D0A0 for HS, D0a4 for DS, and D0a6 and D0a0 for CS. The 
Figure 5. Localization of EXTL3 to the Golgi complex is lost in p.Arg513Cys mutated cells The localization 
of EXTL3 in fibroblasts derived from affected individuals is compared to two healthy controls. The cells are 
stained for EXTL3 (green), Golgi marker GM130 (red), and DAPI for the cell nucleus (blue). The localization of 
EXTL3 to the Golgi complex seen in control fibroblasts is lost in cells derived from affected individual A:II-1, but 
not in both fibroblast cell lines from affected siblings B:II-1 and B:II-2.
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Figure 6. Mutations in EXTL3 affect glycosaminoglycan concentrations GAG concentrations in urine, 
serum, and fibroblasts from affected individuals and aged-matched control samples. D0A0 concentrations 
for heparan sulfate (HS), D0a4 for dermatan sulfate (DS), and D0a6 (sulfated) and D0a0 (non-sulfated) for 
chondroitin sulfate (CS). Error bars indicate standard deviation (SD). (A) GAG concentrations in fibroblasts. 
Reduced HS concentrations in fibroblasts from all affected individuals except for C:II-1. The DS concentrations 
were within normal range for the affected family members of family B and of D:IV-1, increased in C:II-1, and 
reduced in A:II-1 and E:II-1. (B) GAG concentration in serum from affected individuals and both parents of family 
B. HS concentrations were normal in affected individual A:II-1 and in both parents of family B (B:I-1 and B:I-2), but, 
decreased in the siblings of family B (B:II-1 and B:II-2). DS concentrations were elevated in all affected family 
members of A and B, as well as in parent B:I-1. Non-sulfated CS concentration was elevated in individuals B:II-1 
and B:II-2 and the sulfated CS concentration was markedly increased in B:II-2. (C) GAG concentrations in urine. 
HS concentrations for A:II-1 were normal, whilst decreased for both B:II-1 and B:II-2. DS was elevated in all three 
affected individuals. The non-sulfated CS concentration was elevated in all affected individuals, whereas, 
D0a6 was only elevated in B:II-2.
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concentrations of these disaccharides strongly correlate with total GAG concentrations.40 
HS concentrations in fibroblasts of all affected individuals except C:II-1 were markedly 
lower than those in control fibroblasts. For the affected individuals in family B, the HS 
concentrations were also reduced in serum and urine, whereas both parents in family B 
had serum HS concentrations within the normal range. Surprisingly, for individual A:II-1, 
HS concentrations were normal in serum and urine. DS concentrations, measured by the 
disaccharide D0a4, showed more variable results. They were within the normal range 
in fibroblasts from families B and D, reduced in families A and E, and increased in family 
C. In serum and urine, they were elevated in all three affected individuals studied (A:II-
1, B:II-1, and B:II-2). The DS concentration was also elevated in the serum of the father 
in family B (B:I-1) and was below the limit of detection in the serum of the mother (B:I-2). 
The CS concentrations in urine and serum showed an increase in the non-sulfated CS 
disaccharide D0a0. The other CS disaccharide, D0a6, was elevated only in the urine 
and serum of individual B:II-2, whereas this disaccharide was in the normal range in 
the samples from both A:II-1 and B:II-1. In summary, although the findings differ among 
affected individuals and among the biological materials investigated, the results show 
abnormal glycosylation patterns in the affected individuals with generally lower HS and 
elevated DS and CS concentrations.
Discussion
In this study, we identified homozygous missense mutations in EXTL3 in nine neuro-
immuno-skeletal dysplasia individuals with a variable phenotype from five unrelated 
families. EXTL3 and the other four EXT family members are involved in the biosynthesis of 
HS.9;47 Specifically, EXTL3 regulates the initiation of HS chain formation by enzymatically 
catalyzing GlcNac binding to the GAG linkage region of a specific protein.9 This process 
is crucial in early development, given that complete Extl3 knockdown in mice is lethal 
around 9 days postcoitum.11 Zebrafish with the mutant tm70g allele in extl3 (previously 
boxer) have been reported to have penetrant pectoral fin and jaw phenotypes and lack 
swim bladders, which can be completely rescued with wild-type extl3.48 This phenotype 
could turn out to be comparable to the human one. Because the affected individuals 
reported in the current study survived past the neonatal period, we expect that 
homozygosity for the variants (p.Pro461Leu, p.Arg513Cys, p.Asn657Ser, and p.Tyr670Asp) 
leads to diminished EXTL3 activity. The mutations probably have different effects on 
EXTL3 function. This is supported by the immunofluorescence data (Figure 5), which 
showed that EXTL3 was absent from the Golgi complex only in fibroblasts derived from 
individual A:II-1, whereas it was still detectable in fibroblasts derived from siblings B:II-1 
and B:II-2. The localization defect in A:II-1 could be explained by EXTL3 degradation 
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due to the p.Arg513Cys variant in this family, whereas the variant in family B presumably 
affects the enzymatic function of EXTL3 without disrupting its localization to the Golgi 
complex. The latter speculation is based on the presence of the p.Tyr670Asp variant in 
the glycosyl transferase family 64 domain of EXTL3 (Figure 2B). The pathophysiological 
effects of the EXTL3 variants identified in families C and D are clearly different from 
those in families A, B, and E; further functional reconstitution assays should formally 
prove the effects on functional activity. The p.Pro461Leu variant detected in families C 
and D is located within the EXT domain. This domain is shared among the EXT family 
members and appears to be associated with skeletal phenotypes,49 whereas the severe 
immunological phenotype seems to be associated with improper GAG modifications 
that rely on intact function of EXTL3. It remains unclear which proteins, either cellular or 
extracellular,50 will be most affected by the perturbed GAG production in individuals with 
EXTL3 variants.
All four described EXTL3 variants show an effect on GAG concentrations, whereas all HS 
concentrations are generally lower and both DS and CS concentrations are elevated. 
This supports the hypothesis that improper function of EXTL3 leads to unbalanced GAG 
synthesis and results in less HS and more DS and CS. The only unexpected findings 
were normal HS concentrations in the urine and serum of individual A:II-1, who did have 
markedly reduced HS concentrations in fibroblasts, and normal HS concentrations in 
the urine and serum of affected individual C:II-1. At the moment, we cannot explain these 
results, and they require further investigation.
Despite the common neuro-immuno-skeletal dysplasia phenotype of the affected 
individuals, the presence or absence of the concomitant SCID phenotype clearly 
suggests phenotypic variability (with an immense impact on survival) between the 
reported families. The skeletal phenotype is mainly spondyloepy(meta)physeal dysplasia, 
overlapping the growing clinical spectrum of other linkeropathies (e.g., associated 
malformations, dislocations, etc.). Linkeropathies are associated with a short trunk or 
short stature resulting from spinal malformations and platyspondyly, as well as joint laxity, 
dislocations, and osteoporosis. Furthermore, extra-skeletal features such as ID, facial 
dysmorphisms, and congenital anomalies are common in linkeropathies and are also 
present in the affected individuals described here. Motor development appears to be 
seriously affected by the EXTL3-related neuro-skeletal features in most of the reported 
affected individuals (Table 1 and Table S1). ID appears not to be a constant feature. 
Whether these phenotypic differences are due to the different positions of the mutations 
in the gene or caused by other unknown modifiers remains unclear. That said, it is worth 
noting that variable penetrance of a T cell immunodeficiency, as observed in the five 
presented families, has previously been reported in SIOD and CHH (GeneReviews and 
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Ridanpää et al.4).
With respect to the SCID phenotype in three families, we have demonstrated that the 
EXTL3 defect is at the level of early T cell development in the thymus. According to 
current models of hematopoiesis, lymphoid-primed multi-potent progenitors (Lin-Sca-1+ 
c-Kit+CD34+Flt3hi) and common myeloid progenitors (Lin-Sca-1+c-Kit+CD34+CD41hi) establish 
an early branch point for separate lineage commitment from hematopoietic stem cells. 
Although the common lymphoid progenitor compartment seemed to be involved, our 
further exploration of this cellular complexity in immunological development suggested 
that EXTL3 plays an important role at the thymic stage of T cell development. It has 
been described that HSPGs influence hematopoietic progenitor cell development,13;14 in 
keeping with our finding that EXTL3 was most abundant in hematopoietic stem cells and 
early progenitor cells.
Hematopoietic stem cell transplantation (HSCT) in one of the EXTL3-deficient SCID 
individuals resulted in complete recovery of normal T cell development without affecting 
either the non-hematopoietic defects or the abnormal GAG findings in blood and urine 
samples.
In summary, we have presented nine individuals affected by a neuro-skeletal dysplasia 
phenotype in five independent families. The immunological features are variable—three 
of five families presented with a severe T cell immunodeficiency caused by a lack of 
CD4+ and CD8+ T cells. WES analysis revealed that all affected individuals harbored 
mutations in EXTL3. A remedy for this disorder is not available, but the T-cell-negative 
(S)CID phenotype seen in five of the nine affected individuals presented here indicates 
that preventive measures should be taken against infections and that a HSCT procedure 
could cure the severe T cell defect in these individuals. 
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Supplemental Data
Supplemental Note: Case Reports
Case report family A
Individual II-1 from family A was born at 37 weeks with an APGAR score of 9/9. Shortly 
after birth, she developed tachypnea with an increasing need for oxygen. At 20 weeks 
gestation a fetal ultrasound showed skeletal abnormalities, kidney and liver cysts. After 
birth, the skeletal abnormalities included short limbs, platyspondyly and brachydactyly 
(Figure 1). The girl had horseshoe-shaped kidneys with hyperechoic small-sized cysts 
and progressive renal insufficiency. Her liver also contained some moderately sized 
cysts, but liver function was normal. Brain abnormalities were detected by MRI including 
a hypoplastic anterior part of the corpus callosum, ventriculomegaly, and several small 
parenchymal hemorrhages. Erythrocytes, white blood cell counts and platelet number 
were normal. Because of cytomegalovirus (CMV) pneumonitis, her white blood cells 
were subtyped. Upon immunophenotyping, the child was found to have no circulating 
T cells, whereas B and NK cell numbers were normal (Figure 4A). The girl died at age 7 
weeks due to renal insufficiency.
Case report family B
The first child of family B (B:II-1, Figure 1, Table S1) was born at term after an uncomplicated 
pregnancy with low birth weight and birth length but normal occipitofrontal head 
circumference (OFC) and with contractures in both elbows. He developed seizures in 
the neonatal period and West syndrome at age of six months which both responded 
well to anticonvulsive therapy. Severe global developmental delay and microcephaly 
became evident at age of 6 months. The further course of disease was characterized 
by very slow development, severe muscular hypertonia and progressive microcephaly. 
Extensive clinical and metabolic work up gave normal results except a mildly elevated 
heparan sulfate concentration in plasma. The X-ray at age of 23 months displayed a 
delayed ossification and features of spondyloepiphyseal dysplasia (detailed description 
in Table S1). At the last examination the 8 years and 3 months old boy was affected by 
profound global developmental delay, stereotypic movements, severe muscular truncal 
hypotonia, and hypertonia in limbs. He was not able to walk, sit, crawl, speak or to get 
in social interaction. He was overweight (+2.1SD) with a disproportionate short stature 
(-2.0SD) but surprisingly normal OFC (+1.0SD). Facial dysmorphism included coarse facial 
features, long face, deep set eyes, long nose, bulbous nasal tip, long un-modulated 
philtrum, full cheeks, open mouth appearance and salivation. His neck was short, his 
chest broad. He had short upper and lower limbs, dimples and contractures of both 
elbows. His hands and feet were short and puffy, he had brachydactyly and clinodactyly 
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of digit V. MRI of the brain, ECG, EEG, ophthalmological examination as well as extensive 
laboratory and metabolic analyses gave normal results, ultrasound of the abdomen 
revealed increased echogenicity of liver. X-ray revealed deceleration of bone age and 
the previously described features of spondyloepiphyseal dysplasia (Figure 1). SNP-array 
was done with unrevealing results. The boy has experienced frequent viral upper airway 
infections and two pneumonias that required admission. He displayed moderate T cell 
lymphopenia affecting both CD4+ and CD8+ T cells, while B and NK cell count were 
normal. Immunoglobulins were moderately decreased, with proportionate reduction 
of IgG subclasses. Response to the vaccines was generally adequate, however no 
response to a pertussis vaccine could be detected. He did not display any features of 
autoimmunity.
The second child of family B (B:II-2), a girl, was born at term after an uncomplicated 
pregnancy with normal measure. Microstomia, preaxial polydactyly of the left hand and 
postaxial polydactyly on right foot were noticed directly after birth. Polydactyly was 
interpreted to be familial as the mother and several other maternal family members 
were similarly affected. At the age of three weeks microcephaly, massive eosinophila 
in the blood cell differentiation and erythrodermia with scaling of skin was observed. At 
three months of age, an analysis of lymphocyte subsets revealed absent CD8+ T-cells 
with abundant CD4+ T-cells, normal B cell count and elevated NK cell count. Whether 
the CD4+ T cells were maternal was not tested. Eosinophils and IgE were elevated. 
The diagnosis of SCID with skin involvement was established. ZAP-70 gene analysis 
gave inconspicuous results. IgG and IgM were above the normal range before IVIG 
administration. An allogeneic stem cell transplantation from a matched unrelated donor 
following conditioning with treosulfan, fludarabine and alemtuzumab was performed at 
the age of 20 weeks. Engraftment was prompt and donor chimerism remains >80% with 
>90% in T cells two years after HSCT. A transient GvHD I° of the skin occurred, without 
any further severe transplant related complications. In addition to the immunological 
features severe developmental delay, truncal muscular hypotonia and hypertonia in 
limbs with contractures in elbows were evident at age of 12 weeks. At the age of 20 
weeks seizures and nystagmus occurred. At 1 year and 5 months the girl was affected 
by severe developmental delay and generalized muscular hypotonia. She was unable 
to walk, sit, crawl, speak or to get in social interaction. Facial dysmorphism consisted in 
microcephaly (OFC -3,3SD), round face, up-slanting palpebral fissures, prominent nose 
with broad nasal tip, full cheeks, and small mouth. In addition, she had a short neck, dimples 
and contractures of both elbows, small and puffy hands, brachydactyly, hexadactyly on 
the left hand, hexadactyly on the right foot and generalized hypertrichiosis. MRI of the 
brain at four months of life revealed multiple kinking of the ACI, but the MRI at 1 year and 
11 months was normal. Echocardiography at five months showed hypsarrhythmia. ECG 
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at five months discovered a small ASD with left/right shunt, aneurysm of atrial septum 
and discrete dilatation of left atrium, which have been resolved at 1 year and 11 months. 
X-Ray displayed dissociated skeletal age and features of spondyloepiphyseal dysplasia 
(Figure 1A). Ultrasound of abdomen showed a prominent uterus but normal liver. Most 
recently measured immunological parameters were normal.
Case report family C
The affected individual in family C was born after uncomplicated pregnancy at 40 
weeks gestation. She developed hyperbilirubinemia and transient hypoglycemia which 
resolved. She was evaluated in the neonatal period because of facial dysmorphism like 
full lips, large tongue, bifid uvula and coarse facial features and significant lumbar gibbus 
deformity. She was tested for storage disorder but repeated measurements of urine 
mucopolysaccharides and oligosaccharides were negative. Additional testing included 
a g-banded Karyotype, transferrin isoelectric focusing to rule out carbohydrate deficient 
glycoprotein syndrome and full metabolic work-up including plasma amino acids, urine 
organic acids and acylcarnitine profile and targeted sequencing of the FGFR3 gene, 
all of which were normal. She had an echocardiogram at 2 years of age that showed a 
patent foramen ovale (PFO) and a cleft of the anterior leaflet of the mitral valve. Renal 
ultrasound was normal. Because of ongoing concern for a storage disorder lysosomal 
enzyme activity testing was done in fibroblasts and in white blood cells and were normal. 
She has a history of repeated upper airway infections particularly in the first 5 years of 
life. Complete blood counts have shown fluctuating numbers of white blood cells with 
normal neutrophil numbers but multiple instances of mild lymphopenia (lowest value 
0.45x109 lymphocytes/L, normal values between 1.5 and 7x109 lymphocytes/L). At 1 year 
of age she underwent decompression at the level of the foramen magnum due to 
craniocervical stenosis. She required bracing form age 4 years until last evaluation at 12 
when she underwent posterior spinal fusion with decompression, followed by anterior 
spinal fusion with tibial strut graft.
Case report family D
Individual IV-1 from family D presented prenatally with omphalocele detected at the 
12 weeks gestation ultrasound and with hepatic cysts and right lung sequestration 
suspicion at 26 weeks. She was born at 37 weeks (elective cesarian section) with an 
APGAR score of 9/10 and birth weight of 3210g. Postnatal period was complicated by 
neonatal hyperbilirubinemia and surgery of omphalocele at the second day of life. She 
had muscular hypotonia and mild motor development delay, and normal cognition with 
presently mild learning difficulties. Her stature was short and due to failure to thrive she was 
fed by nasogastric tube for several months. She developed a spondyloepimetaphyseal 
dysplasia characterized by cervical instability associated with C1 malformation and 
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spinal cord compression which required surgical intervention at 2 years of age; severe 
platyspondyly and vertebral body anomalies leading to progressive kyphoscoliosis and 
spinal surgery was required: T3-L4 arthrodesis at 11 years of age; pectus excavatum and 
rib deformity; coxa valga; smal upper femoral epiphyses; and radial deformity with head 
subluxation; and progressive deformity of the pelvis. At last examination at 12 years of age 
she had coarse facial features, strabismus and excess skin in palmar and plantar regions. 
The hepatic follow up revealed 7 non progressive liver cysts, normal liver function, and 
the hypothesis of biliary hamartomas was raised. She required cardiac follow-up due to 
interauricular communication with interauricular septum aneurysm (surgically corrected) 
and moderate mitral insufficiency. Enzymatic studies excluded gangliosidoses GM1 
and GM2 and mucopolysaccharidoses IVA, VI and VII. Urinary oligosaccharides and 
mucopolysaccharides electrophoresis was normal and total urine glycosaminoglycan 
measurements at 6 months of age was 15 mg/mmol creatinine (reference value is 11-35).
Individual III-1 from family D, a cousin of individual D:IV-1, was born at term after an uneventful 
pregnancy. Skeletal and craniofacial anomalies were detected from the neonatal period 
on. They evolved to a spondyloepimetaphyseal dysplasia, characterized by cervical 
spine malformation with instability and odontoide peg malformation; severe platyspondyly 
and severe kyphoscoliosis; pectus excavatum; radial deformity; progressive deformity of 
the pelvis, coxa valga and flat epiphyses at the upper femora and to a lesser extent 
the knees; brachydactyly bilateral second metacarpals; pseudoepiphyses. Kyphosis 
required repeated surgical interventions at the age of 10 years. The boy had borderline 
level of cognition. Several metabolic studies were performed and gave normal results: 
enzymatic studies excluded gangliosidoses GM1 and GM2 and mucopolysaccharidoses 
IVA, VI and VII; urinary oligosaccharides and mucopolysaccharides electrophoresis; total 
urine glycosaminoglycan measurements at 10 years of age was 12 mg/mmol creatinine 
(reference value is 4-11). He was lost for follow-up after 22 years of age and died at the 
age of 30 years of unknown reason. 
For individual III-2 from family D, a cousin of individual D:III-1 and D:IV-1 were only limited 
information available. She is a 38 year-old female with similar skeletal features than the 
other two cousins but apparently less severe. She had a normal neurodevelopment. 
Several metabolic studies were performed and gave normal results: very long chain 
fatty acids, urine glycosaminoglycan measurements: 2 mg/mmol creatinine (reference 
value if 1-5).
Case report family E
Individual E:II-1 was the first child of non consanguineous parents of Indian origin. Born 
at 38 weeks gestation, he was noted to be dysmorphic with truncal hypotonia but a 
Mutations in EXTL3 cause neuro-immuno-skeletal dysplasia syndrome
123
5
specific diagnosis was not made. He suffered from omphalitis caused by Staphylococcus 
aureus at eight days of age. Following this he developed a widespread eczematoid rash 
which improved with topical corticosteroids. He suffered some self limiting episodes of 
cyanosis. At two months of age he had a respiratory arrest associated with septicemia 
caused by S. aureus requiring ventilation and inotropic support on the intensive care 
unit. He was found to have small dysplastic kidneys with impaired renal function and an 
immunodeficiency was suspected. Immunological testing showed low T cell count with 
an oligoclonal pattern of V beta families and an absence of naïve T cells and TRECs. 
Natural killer and B cell numbers were normal. His skin rash was considered to be Omenn 
syndrome. By this stage he had multiple joint contractures in limbs, he demonstrated 
abnormal limb movements and myoclonic jerks interpreted as seizures. He was also 
found to have hypothyroidism with an elevated TSH. In the further course of disease he 
suffered from frequent episodes of apnoea probably associated with poor clearance 
of secretions. He required several admissions to intensive care for ventilator support 
became oxygen dependent. He showed very poor development and head growth. In 
conjunction with the family it was considered inappropriate to perform a haemopoietic 
stem cell transplant (HSCT) given the severity of the non-immunological problems. He 
died at 6 months of age from respiratory failure.
Individual E:II-2, the brother of individual E:II-1. Born was born at 37 weeks gestation 
with a birthweight of 2.520 kg and an Apgar score of 6/10. He was noted to have very 
similar dysmorphic features to his brother at birth as well as truncal hypotonia. The 
size of his kidneys was within the normal range and though echo bright they were not 
considered to be significantly dysplastic on ultrasound examination. Early immunology 
testing confirmed an absence of T cells with normal B and NK counts resulting in an 
immunoglobulin treatment and antibiotic prophylaxis. He suffered from recurrent 
apnoeas and poor secretion clearance and developed an oxygen dependence. He 
showed very poor development, he suffered from seizures and had an evidence of a 
bulbar palsy. At 6 months he developed an Omenn type skin rash associated with the 
appearance of circulating T cells with a memory phenotype and a restricted oligoclonal 
repertoire. As in his brother’s case, HSCT was considered inappropriate. He died at 10 
months of age of respiratory failure.
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Figure S1. Mild dysmorphic facial features in EXTL3 affected individuals. The nine affected individuals 
displayed mild dysmorphic facial features, including a coarse face, full cheeks, depressed nasal bridge, and a 
broad nasal tip. For affected individuals A:II-1 and D:III-2 there is no permission to publish photographs, and for 
affected individuals D:III-1, E:II-1 and E:II-2 no photographs were available.
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Figure S2. Normal B and T cell phenotype in affected individual C:II-1. Data are shown for affected individual 
C:II-1 and a healthy parent as the control. Same gating strategy used as described for Figure 4. (A) T and B 
cell subsets. (B) CFSE-labeled PBMCs were cultured with medium or CpG/IL-2. (C) CFSE-labeled PBMCs were 
cultured with either medium or anti-CD3/anti-CD28. (D, E, F) Levels of IgG and IgM in the supernatants after 6 
days of culture with either medium, CpG/IL-2 or anti-IgM/anti-CD40/IL-21, ND not determined.
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Table S2. Clinical features related to immunity in the EXTL3-mutated individuals.
 In B2, E1, E2, erythroderma at the age of 1, 4 and 6 months was diagnosed with a concomitant oligoclonal 
expansion (maternal cells have been excluded in all three). The erythroderma and clinical deterioration was 
most of immunological origin with a concomitant eosinophilia of 20-30% (>1500/µl). 
 Prophylactic antibiotics and IgG suppletion was shortly after birth initiated when the diagnosis of a SCID-
related PID syndrome was confirmed in E2.
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Cranioectodermal dysplasia syndrome-associated mutations 
disrupt formation of the IFT-A complex by loss of the 
peripheral subunit
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Abstract
The intraflagellar transport (IFT) is a bidirectional process that is essential for cilium 
assembly, maintenance, and disassembly, as well as, for signaling pathways that occur 
within the cilium. Retrograde IFT is carried out by the dynein-motor driven IFT-A complex, 
which consists of two subunits; the core and the peripheral subunit. Four out of the 
six IFT-A components are known to cause cranioectodermal dysplasia (CED), a rare 
ciliopathy involving craniofacial, skeletal, and ectodermal abnormalities. In this study, 
we developed a quantitative proteomics method to study the effect of CED-associated 
mutations on the stoichiometry of the IFT-A complex in patient-derived fibroblasts. In 
addition, we performed a CRISPR/Cas9 knock down of IFT43 and WDR19 in HEK293 
Flp-In cells. The affinity purification of the IFT-A complex in all cells was carried out using 
FLAG-tagged-TULP3. Results from both IFT43-, and WDR35-patient-derived fibroblasts, 
and IFT43_p.T181Nfs*2-Flp-In cells showed a loss of the IFT-A peripheral subunit along 
with an overrepresented IFT-A core subunit. This data confirms that retrograde IFT is 
affected as a result of mutations in IFT-A components, and suggests a possible remaining 
role for the components of the IFT-A core subunit. Furthermore, CED-associated IFT-A 
mutations may lead to defects in signaling pathways which could at least partially explain 
the phenotype of these patients. In conclusion, the herein described method can be 
used to evaluate the molecular consequences of genetic mutations in ciliopathies. 
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Introduction
 
Primary cilia are microtubule-based organelles that protrude from the plasma membrane 
of virtually every vertebrate cell during the quiescent phase of the cell cycle. A microtubule 
structure of nine doublets protrudes from the basal body enabling the transport of 
proteins via the intraflagellar transport (IFT) complexes. This transport is essential for cilium 
assembly, maintenance, and disassembly, and for signaling pathways that occur within 
the cilium. The bidirectional movement is carried out by two distinct protein complexes; 
IFT-B and IFT-A. The IFT-B complex is responsible for the anterograde transport of cargo 
from the base of the cilium towards the tip and requires a kinesin-2 motor for movement. 
The reverse movement is carried out by the IFT-A complex and is powered by a dynein 
motor enabling retrograde IFT. The IFT-B complex consists of 13 proteins; IFT20/22/
25/27/46/52/57/70/74/80/81/88, and IFT172. The IFT-A complex consists of 6 proteins; 
IFT43/122/140, WDR19/35, and TTC21B. Previous interaction studies have revealed the 
interactions between individual IFT-A components, and showed that the IFT-A complex, 
in fact, consists of two subunits, (1) the IFT-A core subunit, including IFT122, IFT140, and 
WDR19 and (2) the IFT-A peripheral subunit, consisting of WDR35, IFT43, and TTC21B.1; 
2 However, no studies have been published addressing the stoichiometry of the IFT-A 
complex. In this study, we reveal the absolute and relative proportions of each of the 
IFT-A components within the complex, and do this by performing a single purification 
step followed by absolute protein measurements on a mass spectrometer. In order to 
purify the IFT-A complex, we make use of an IFT-A complex interacting protein called 
Tubby-like protein 3 (TULP3). TULP3 belongs to the family of Tubby-like proteins that can 
coordinate multiple signaling pathways through their unique amino-terminal functional 
domains and their abilities to form bridges between distinct protein modules through 
phosphoinositide-binding properties. The amino terminus of TULP3 binds to the core of 
the IFT-A complex serving as an anchor to link this complex to the ciliary membrane.2; 3 
The stoichiometry of the IFT-A complex is intriguing to study as the IFT-A components 
are associated with skeletal ciliopathies, including cranioectodermal dysplasia 
(CED), and short-rib thoracic dysplasia (SRTD). Cardinal features of CED are sagittal 
craniosynostosis, narrow thorax with pectus excavatum, rhizomelia, brachydactyly, and 
ectodermal dysplasia.4 Four genes encoding for IFT122, WDR35, IFT43, and WDR19 
are associated with CED1 [MIM 218330], CED2 [MIM 218330], CED3 [MIM 614099], and 
CED4 [MIM 614376], respectively.5-8 The other two IFT-A genes, TTC21B and IFT140 are 
associated with SRTD4 [MIM 613819], and nephronophthisis [MIM 613820], and SRTD9 
[MIM 266920], respectively.9; 10 The main clinical features of the SRTD family are small 
rib cages and short limbs. In addition, patients can present with polydactyly, cleft 
lip/palate, and anomalies of a variety of organs, including the brain, heart, eyes, kidneys, 
liver, pancreas, intestines, and genitalia.11 In this study, we focus on two CED patients, 
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previously published by Gilissen et al. and Arts et al., in which they showed that mutated 
IFT43 and WDR35 result in defective retrograde IFT.6; 7 We made use of patient-derived 
fibroblasts to better understand the molecular consequence of these mutations on 
complex stoichiometry. This lead to the development of a method to unravel the absolute 
and relative proportions of the IFT-A complex in health and disease, bringing us closer to 
elucidating the mechanism of IFT43 and WDR35-associated ciliopathies.
Methods and materials
Generation of isogenic stable HEK293T Flp-In cells
Human embryonic kidney (HEK) Flp-In 293 host cells were transfected in 10cm culture 
dishes using 0.8μg of either pcDNA5/FRT/(N)-SF-IFT122, pcDNA5/FRT/(N)-SF-TULP3 
or pcDNA5/FRT/(N)-SF-LCA5 and 7.2μg of pOG44 (FLP recombinase) by means of 
lipofection (Lipofectamin2000, ThermoFisher Scientific) according to manufacturing 
recommendation. Control transfections were done with 0.8μg of expression vector 
but without pOG44. Medium was changed after 24h post transfection. After two days, 
cells were split in a ratio of 1:4 on 10cm dishes using growth medium supplemented 
with 100μg/ml hygromycin for selecting only cells carrying the plasmid which contains 
the hygromycin resistance gene. Two weeks later, single clones were picked. Each 
clone was transferred to one well of a 24-well plate containing 1ml growth medium 
supplemented with 100μg/ml hygromycin. Cells were expanded stepwise to 6-wells and 
10cm culture dishes. Stable expression level of the transgene was tested by western 
blot analysis (data not shown).
CRISPR/Cas9 knock down of IFT-A in HEK293T Flp-In TULP3 cells
Flp-In cells expressing (N)-SF-TAP-tagged TULP3 were transfected with a bicistronic 
vector expressing a specifically designed short guide RNA (sgRNA) sequence, as well 
as, Cas9 alone or together with an additional homology-directed repair (HDR) construct 
(see supplemental table 1 for oligonucleotide sequences). As a control, an additional 
transfection was done with the ‘empty’ vector (Cas9 gene only). For transfection, 
500ng DNA was mixed with 66μl polyethylenimine (PEI) and added dropwise to the 
cells. After 48h, selection was initiated adding Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 8μg/ml Puromycin and cells were cultivated for additional 
48h. Subsequently, cells were grown for several days in DMEM and transferred to 10cm 
culture dishes as well as seeded at very-low density (1:400) into a 14cm culture dish for 
single-clone selection. For single-clone selection, cells were washed and trypsinized 
using 20ml trypsin-solution (1:20 in PBS). After some minutes, cells started to detach 
and could be soaked and transferred to 24-well plates. Some weeks later, single clones 
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were characterized by PCR.
Generation of NTAP-TULP3 stable fibroblast cells
Fibroblasts derived from two cranioectodermal dysplasia patients, and two controls 
were cultured in DMEM containing 20% FCS. In order to obtain stable expressing NTAP-
TULP3 cells, the fibroblasts were transduced with a lentiviral NTAP-TULP3 construct using 
JetPrime (cat# 114, PolyPlus, Illkirch, France) according to the manufacturers protocol. Two 
weeks post-transduction, the fibroblasts were cultured in “heavy” stable isotope labeling 
of amino acids in cell culture (SILAC) DMEM (cat# 89985, ThermoFisher Scientific) 
supplemented with 13C, 15N L-lysine HCl, 13C, 15N L-arginine HCl (cat# 211604102 and 
cat# 201604102, Silantes, Munich, Germany), and L-proline (cat#) and containing 20% 
FCS. After five passages, all proteins were build with “heavy”-isotope labeled amino 
acids, and could be detected by mass spectrometry. 
Purification of IFT-A complex and mass spectrometry
The IFT-A complex was purified from (N)-SF-TAP-TULP3-Flp-In cells, as well as, NTAP-
TULP3-patient-derived fibroblasts using affinity purification in order to study the IFT-A 
complex stoichiometry. Cells were cultured in 14cm dishes, washed once with phosphate-
buffer saline (PBS), and placed on ice prior to cell lysis in 1ml lysis buffer, consisting of 
0.5% Nonidet-P40, phosphatase inhibitors, and protease inhibitors in 1x tris-buffered 
saline (TBS). Cells were detached using a cell scraper and the total protein lysate was 
incubated for 20min at 4°C under constant agitation. To separate cell debris from clear 
protein extract, lysates were centrifuged at 10,000xg for 10min at 4°C. The supernatant, 
containing the clear protein extracts, was transferred to fresh tubes. Absolute protein 
concentrations were determined using a Bradford assay12 to ensure equal protein to 
bead ratios during the affinity purification. The one-step affinity purification protocol 
using anti-FLAG-M2-agarose beads was previously published by Gloeckner et al.13 In 
brief, the protein cell lysate was incubated with anti-FLAG-M2 agarose beads for 2h 
at 4ºC under constant agitation. Beads were transferred to a micro spin column and 
washed three times with washing buffer (0.12% Nonidet-P40, phosphatase inhibitors, and 
protease inhibitors in 1x TBS). To elute bound proteins, beads were incubated with FLAG 
peptide for 10min at 4°C, followed by protein precipitation using a methanol-chloroform 
precipitation technique developed by Wessel and Flugge in 198414. Subsequently, an in-
solution digestion was performed to generate small peptides, and a desalting step was 
added to clean up the sample for liquid chromatography-mass spectrometry (LC-MS/
MS) analysis.13 
Mass spectrometry analysis of IFT-A protein complex
To achieve an accurate quantification a combination of an internal standard mixture with 
Chapter 6
144
targeted mass spectrometry was used to ascertain absolute quantification of the IFT-A 
protein complex. The internal mixture consisted of two representative peptides per 
protein of interest, the six IFT-A complex components, and each peptide was labeled 
with a “light” isotopic label (see Supplemental Table 2 for peptide sequences).15 The 
biological sample containing the purified IFT-A complex was spiked with a known amount 
of the synthesized standard mixture, and subsequent targeted mass spectrometry was 
performed to quantify each of the chosen peptides (Figure 1). The absolute amount 
of each peptide in the biological sample was calculated from the ratio of peak-areas 
of isotopically “heavy”-coded and “light”-coded peptide. The obtained ratios were 
normalized by setting the least abundant protein to 1, resulting in the stoichiometry of the 
IFT-A complex. Raw data from the targeted mass spectrometry were processed using 
the open source software tool Skyline.16 
Figure 1. Workflow for absolute quantification. To calculate the absolute amount of a protein complex, 
mammalian cell lines were cultivated in SILAC media to introduce an isotopic label. After affinity purification of 
the protein complex of interest and further tryptic digestion, a known amount of non-coded synthetic peptides 
was spiked into the biological sample. After targeted mass spectrometry analysis, the ratio of ‘light’ to ‘heavy’ 
peptide was calculated and then used to determine the absolute amounts of the selected proteins and the 
stoichiometry of the protein complex of interest.
Results
Stoichiometric analysis of IFT-A components
The IFT-A complex consists of 6 components; IFT122, IFT140, IFT43, TTC21B, WDR19, 
and WDR35.1 In order to study the relative proportions of each IFT-A component in the 
complex we performed stoichiometric analyses in Flp-In cells expressing three different 
(N)-SF-TAP-tagged fusion proteins, i.e. IFT122, TULP3, and LCA5 (Figure 2). Importantly, 
IFT122 is part of the IFT-A complex, whereas, TULP3 nor LCA5 are an integral part of 
the IFT-A complex, but bind strongly or transiently to the complex, respectively. The 
(N)-SF-TAP-IFT122-Flp-In cells showed an aberrant stoichiometry in comparison to the 
IFT-A-interacting protein expressing Flp-In cells. In fact, the relative proportion of IFT122 
was nearly three times higher in (N)-SF-TAP-IFT122-Flp-In cells than in TULP3 or LCA5 
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expressing Flp-In cells, and the relative proportions of both IFT-A core proteins WDR19 
and IFT140 were diminished. The stoichiometry of (N)-SF-TAP-TULP3-Flp-In cells and 
(N)-SF-TAP-LCA5-Flp-In cells, showed a slightly higher representation of the IFT-A core 
subunits compared to the IFT-A peripheral subunits. From this data we concluded that 
the (N)-SF-TAP-TULP3-Flp-In cells (from now on referred to as Flp-In cells) were best to 
use for further experiments.
Figure 2. IFT-A protein complex stoichiometry in Flp-In cells. The Flp-In cells were transfected with (N)-SF-
TAP-IFT122,  (N)-SF-TAP-TULP3, or (N)-SF-TAP-LCA5 to generate stable expressing cell lines for IFT-A complex 
stoichiometry analysis. Number of replicates for each cell line is four. 
CRISPR/Cas9 knock-down of IFT43 or WDR19 disrupts IFT-A complex
The effect of reduced expression of an IFT-A component was analyzed in Flp-
In cells in which either IFT43 or WDR19 was knocked down using the CRISPR/Cas9 
gene-editing technique. Two single clones for IFT43 (c.541_542insA, p.T181Nfs*2 and 
c. 582_583insG, p.Q195Afs*22) and two single clones for WDR19 (c.3107_3108delAT, 
p.Y1036Ffs*5 and c.3063_3074delinsAGATC, p.R1022Dfs*21) were generated by means 
of non-homologous end joining (NHEJ). Mass spectrometric analysis showed that the 
introduction of p.Q195Afs*22 in IFT43 did not decrease the absolute amount of IFT43 in 
cells, whereas, the p.T181Nfs*2 mutant almost completely diminished IFT43 levels (Figure 
3A). In addition, IFT43_p.T181Nfs*2-Flp-In cells showed diminished TTC21B and WDR35 
levels, and markedly reduced IFT122, IFT140, and WDR19 levels. These changes were 
also visible in the stoichiometric analysis, in which only 5% of the complex contained 
WDR35, TTC21B, and IFT43 and the remaining 95% was IFT122, WDR19, and IFT140 
(Figure 3B). A ~50% knock down of WDR19 was accomplished in WDR19_p.R1022Dfs*21 
Flp-In cells (Figure 3A). Flp-In cells carrying the second WDR19 mutant, p.Y1036Ffs*5, did 
not show a reduced level of WDR19 (data not shown). Interestingly, the absolute levels of 
all IFT-A complex components were halved in WDR19_p.R1022Dfs*21 Flp-In cells, while 
the stoichiometry of the complex remained unaltered (Figure 3). This data suggests that 
not all IFT-A mutants affect the stoichiometry of the IFT-A complex. 
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CED-associated IFT-A mutations cause loss of peripheral IFT-A subunit
Fibroblasts of two CED patients carrying mutations in (1) IFT43 (p.M1_K21del) or (2) 
WDR35 (p.I9Tfs*7 and p.E626G) were investigated for changes in the IFT-A complex. 
The absolute levels and relative proportions of the IFT-A complex components were 
measured in NTAP-TULP3 expressing patient-derived fibroblasts and compared to 
two NTAP-TULP3 expressing healthy control fibroblasts. Both controls showed highly 
Figure 3. IFT-A component CRISPR/Cas9 knock-out clones. IFT-A protein complex stoichiometry. (A) Absolute 
measurements. (B) Stoichiometry results IFT43 and WDR19.
CED-associated mutations disrupt formation of IFT-A complex by loss of the peripheral subunit
147
6
similar IFT-A complex measurements, and were also comparable to those of the Flp-In 
cells (Figure 4). The data showed that IFT122, IFT140, and WDR19 molecules together 
accounted for nearly two-thirds of the complex, and one-third consisted of the TTC21B, 
WDR35, and IFT43 molecules. Interestingly, the stoichiometry of the IFT-A complex was 
completely disrupted in the patient-derived fibroblasts. The IFT-A complex in fibroblasts 
carrying the homozygous mutant IFT43_p.M1_K21del showed diminished proportions of 
WDR35, TTC21B, and IFT43, in addition to an overrepresentation of IFT122, IFT140, and 
WDR19 (Figure 5).  IFT-A stoichiometric measurements for the patient-derived fibroblasts 
carrying two heterozygous WDR35 mutations, p.I9Tfs*7 and p.E626G, resembled those 
of IFT43_p.M1_K21del, however, the proportions of WDR35, TTC21B, IFT140, and WDR19 
were slightly higher (Figure 5). Interestingly, the relative proportion of IFT122 remained 
unchanged in cells from the WDR35 patient compared to those of the controls. In 
summary, CED-associated mutations in IFT43 and WDR35 give a similar disruptive effect 
of the IFT-A complex stoichiometry, where the IFT-A peripheral subunits were markedly 
diminished and the IFT-A core subunits overrepresented.
Figure 4. Absolute measurements of IFT-A components in Sensenbrenner patient-derived fibroblasts and 
controls.
Chapter 6
148
Discussion
TULP3 pull down of IFT-A components conserves complex stoichiometry 
In this study, we show the absolute and relative proportions of the IFT-A complex in 
health and disease. In a healthy state, the IFT-A core components account for about 60% 
of the complex, equally distributed over IFT140, IFT122, and WDR19, and the peripheral 
IFT-A proteins; TTC21B, WDR35, and IFT43 complete the IFT-A complex in a decreasing 
proportion, respectively. Our results show that when an IFT-A component is over 
expressed, for purifying the complex from the total protein lysate, the stoichiometry of 
the complex is disrupted. This means that to study any mutational effects on a complex, 
an independent protein that interacts with the complex, but is not an integral part of the 
complex should be used to pull down the complex of interest. NTAP-tagged TULP3 
protein proved to be an efficient protein for the pull down of the IFT-A complex without 
disturbing the stoichiometry of the complex. 
Figure 5. IFT-A complex stoichiometry in control and CED patient-derived fibroblasts.
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IFT-A stoichiometry is preserved between cell lines
The herein described method enabled us to study the effect of CED-associated 
mutations upon the absolute and relative proportions of the IFT-A complex components. 
Similar to the knock down of IFT43 in Flp-In cells, the CED-associated IFT43 mutation 
leads to an almost complete loss of the IFT-A peripheral subunit, and as a result, an 
overrepresentation of the IFT-A core components. Indicating that the stoichiometry and 
the internal IFT-A complex interactions remain preserved between different cell line 
models, such as HEK293T Flp-In cells. An important finding, since cell lines are often 
used as model systems to investigate human disease genes, including IFT-A related 
genes. 
CED-associated IFT-A mutations disrupt retrograde transport but not formation 
of the IFT-A core subunit
The absolute levels of the IFT-A peripheral subunit components, WDR35, IFT43, and 
TTC21B, are diminished in the herein studied fibroblasts derived from CED patients 
harboring mutations in IFT43 and WDR35. Moreover, these same patient cells presented 
with bulbous ciliary tips enriched for IFT-B proteins.6 The accumulation of IFT-B proteins 
at the ciliary tip as a direct consequence of losing either one of the IFT-A subunits was 
also seen in human telomerase reverse transcriptase-immortalized retinal pigmented 
epithelial (hTERT-RPE1) cells.17 In addition, the same study showed that for the IFT-A 
complex to be functional in retrograde transport, it requires both IFT-A subunits to interact 
and form a complex.17;18 Thus, the CED-associated mutations in IFT43 or WDR35 result 
in defective retrograde IFT, but interestingly, do not effect formation of the IFT-A core 
subunit. The presence of the IFT-A core subunit in these patient-derived fibroblasts, 
could indicate a possible secondary role for the subunit besides their role in retrograde 
transport. The exact mechanism how proteins enter the cilium remains largely unknown, 
however, several hypotheses have suggested a role for the IFT complexes as transport 
factors.17;19 For example, WDR19 is required for the ciliary entry of certain G-protein 
coupled receptors (GPCRs), and IFT140 is involved in mobilizing ciliary proteins from 
the cytoplasm during flagellar regeneration in Chlamydomonas.17;18 However, besides 
the involvement of IFT-A core components in mobilization and ciliary entry of certain 
proteins, there is also a role for the IFT-A peripheral components. It is believed that 
WDR35 is required for the ciliary entry of; WDR19, INPP5E, ARL13B and certain GPCRs.20 
Importantly, TULP3, the protein used to pull down the IFT-A complex in our experiments, 
binds to the IFT-A core subunit, and does not require the peripheral subunit for its 
binding to the IFT-A complex.2 Furthermore, WDR35 is described to be the organizer of 
the peripheral IFT-A subunit since WDR35 interacts with IFT43 and TTC21B, and loss of 
WDR35 causes diminished levels of both IFT43 and TTC21B.1;18 This data complements 
our findings in CED patient-derived fibroblasts.
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Loss of peripheral IFT-A subunit in CED patients may lead to defective GPCR trafficking
CED patients are characterized by sagittal craniosynostosis, narrow thorax with pectus 
excavatum, rhizomelia, brachydactyly, and ectodermal dysplasia.4 The four genes 
associated with this disease all belong to the IFT-A complex; IFT122, WDR35, WDR19, 
and IFT43. In this study, we show that mutations in IFT43 and WDR35 that are causative 
for CED, result in the almost complete loss of the peripheral IFT-A subunit. Knocking out 
WDR35 from hTERT cells resulted in defective retrograde transport, as well as, ciliary 
trafficking defects of three GPCRs; serotonin receptor (5HT6), Melanin-concentrating 
hormone receptor 1 (MCHR1), and somatostatin receptor subtype 3 (SSTR3).20 In addition, 
the ciliary targeting of Smoothened (Smo) upon activation of the Hedgehog pathway 
was hampered in WDR35 KO cells.20 The authors of this data argue that serotonin can 
act upon cell adhesiveness and ectoderm extension pathways, and thereby may give 
insight into the disease mechanism of the ectodermal features associated with CED.20 
The skeletal abnormalities presented in CED could be caused by abnormal Hedgehog 
signaling.20-22 The underlying mechanism of disease in IFT-A associated CED remains to 
be further elucidated. In conclusion, the herein described patient mutations, resulting in 
an almost complete loss of the peripheral IFT-A subunit, could result in a similar effect as 
the total knock out of WDR35 in hTERT cells.
A method to study mutational effects on protein complexes
In this study, we describe a new method to investigate the effects of pathogenic 
mutations on protein complex formation in patient-derived cells. To predict the effect of 
mutations on the protein itself is challenging, moreover, the resulting effect on a protein 
complex is even more so. The type of mutation can make predicting the outcome less 
or more challenging, but even nonsense mutations, likely to result in a loss of protein, 
are challenging as the effect of losing one protein from the complex remains unclear. 
The effect of missense mutations on protein function, complex formation and complex 
stoichiometry are likely one of the most difficult to predict and investigate. Since missense 
mutations rarely lead to the absence of the protein, but often to a single amino acid 
change. Knowledge about the structure of the protein and the function of each domain 
will help predicting the effect of the changed amino acid. However, not all protein 
domains are annotated, or known, and the exact function of certain domains remains 
elusive. An alternative strategy is to focus on a protein’s complex, instead of the protein 
itself. The method we applied here does this by studying protein complex formation 
and stoichiometry in a physiologically relevant manner by using patient-derived cells 
as a source. The use of patient-derived fibroblasts enabled us to investigate the effect 
of CED-associated missense mutations in the true physiological conditions. In earlier 
studies we transfected a cell-line with the mutated protein of interest, however, this lead 
to a major disruption of the complex (data not shown). This problem was overcome by 
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using NTAP-TULP3 expressing patient-derived fibroblasts. The data we obtained lead 
to a better understanding of the changes in the stoichiometry of the IFT-A complex 
upon CED-associated missense mutations and tells us that retrograde IFT is negatively 
affected, but that part of the IFT-A complex was still formed. To conclude, this method 
can be used to study a protein complex in health and disease, and eventually lead to an 
understanding of the mechanism of disease.
Conclusion
In this study, we unveil the stoichiometry of the IFT-A complex in health and disease 
and show that patient-derived cells provide an excellent model for ciliary protein 
complex analysis. The herein described method can be used to evaluate the molecular 
consequences of genetic mutations in ciliopathies. Moreover, a future perspective could 
be the implementation of this, or a similar, method in a diagnostic setting to investigate 
the impact of mutations on the formation and stoichiometry of protein complexes. 
Acknowledgements
We thank all participants for their contribution to this study. This study was funded 
by the Dutch Kidney Foundation (KOUNCIL consortium project CP11.18 to RR) and the 
Netherlands Organization for Scientific research (NWO Vici-865.12.005 to RR).
Chapter 6
152
Supplemental data
Oligo name Sequence 5’-3’
IFT43 sgRNA1_for caccgctgggaccatctgttcactg
IFT43 sgRNA1_rev gaccctggtagacaagtgaccaaa
IFT43 sgRNA2_for caccgcctccttctccgtctgcagt
IFT43 sgRNA2_rev cggaggaagaggcagacgtcacaaa
IFT43 HDR1 gctgggactgggaccacctgttcaccgaggtgtcctcagaggtcctcactgagtgggacccactgtagactgagaaagaggaccctgcggggcaggccaggcacacctgag
WDR19 sgRNA1_for caccgaaatactaactcgtgaatat
WDR19 sgRNA1_rev ctttatgattgagcacttatacaaa
WDR19 sgRNA2_for caccggaaaagagatatcttcaggc
WDR19 sgRNA2_rev ccttttctctatagaagtccgcaaa
WDR19 HDR1 gaaggagaaaagagatatcttcaggctggaaaattcttcttgctgtgtggccaatactaagaattctcacgcgttagtatttgccaagaaaatatacactgactccgcaggaataattg
WDR19 HDR2 cttgaaggagaaaagagatatcttcaggctggaaaattcttcttgctgtgtggccaatacttacgccttagcatttgccaagaaaatatacactgactccgcaggaataattgtagg
Table S1. Oligonucleotides for gene editing using CRISPR/Cas9 system. Oligonucleotides were purchased 
from Eurofins Genomics.
Table S2. Selected synthetic peptides for IFT-A components. At least three synthetic peptides (red) were 
selected per complex component. Peptides are proteotypic for IFT-A components that cover different regions 
of the proteins (amino acid positions highlighted in blue). Peptides were selected within a length of 6-12 amino 
acids.
IFT122
N-292GEYILLGGSDK302-xxx-674YLELISSIEER684-xxx-847WDEAFALGEK856-xxx-988
DTPSGISK995-xxx-998ILFTLAK1004-xxx-1142DSIGDEDPFTAK1153-C
IFT140 N-302FWDIER307-xxx-635SHLFVDEGLK644-xxx-1303AHGALTEAYK1312-C
IFT43 N-13YSLATSR19-xxx-77ASEEIEDFR85-xxx-166VLAPEHEVR174-C
TTC21B N-33YGSDPVFR40-xxx-90EAILESDAR98-xxx-1002LEDVPR1007-C
WDR19
N-4IFSLLEK10-xxx-65DGDVLAVIAEK75-xxx-108VGSFLAVGTVK118-xxx-529LVFIDEK
535-xxx-872AASVYIR878-xxx-885VGDLLPHVSSPK896-C
WDR35 N-439THVIAASK446-xxx-912EIGSLLAR919-xxx-920YASHLLEK927-C
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Abstract 
Background: Mainzer-Saldino syndrome (MZSDS) is a skeletal ciliopathy and part of the 
short-rib thoracic dysplasia group of ciliary disorders. The main characteristics of MZSDS 
are short limbs, mild narrow thorax, blindness, and renal failure. Thus far, mutations in two 
genes are associated with MZSDS, IFT140 and IFT172. In this study, we describe a one-
year old girl presenting with mild skeletal abnormalities, Leber congenital amaurosis, 
and bilateral hearing difficulties. In order to make an accurate diagnosis, we combined 
clinical, molecular, and functional analyses.
Methods: We performed diagnostic whole-exome sequencing (WES) analysis to 
determine the genetic cause of the disease and analyzed two gene panels, containing 
all currently known genes in blindness, and in hearing impairment. Upon detection of 
the likely causative variants, ciliary phenotyping was performed in patient urine-derived 
renal epithelial cells (URECs) to determine the pathogenicity of the detected variants in 
vitro. Cilium morphology, cilium length, and intraflagellar transport (IFT) were evaluated 
by immunocytochemistry.
Results: Diagnostic WES revealed two novel compound heterozygous mutations in 
IFT140, encoding IFT140. Thorough investigation of WES data did not reveal any variants 
in candidate genes associated with hearing impairment. Patient-derived URECs revealed 
an accumulation of IFT-B protein IFT88 at the ciliary tip in 41% of the cells indicative of 
impaired retrograde IFT, while this was absent in cilia from control URECs. 
Conclusions: By combining the clinical, genetic, and functional data from this study, 
we could conclude that the patient has SRTD9, also called Mainzer-Saldino syndrome, 
caused by mutations in IFT140. We suggest that mutations in IFT140 may underlie hearing 
impairment. Moreover, we show that urine provides an excellent source to obtain patient-
derived cells in a non-invasive manner to study the pathogenicity of variants detected 
by genetic testing. 
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Background
Short-rib thoracic dysplasia (SRTD) refers to a group of ciliopathies characterized by 
skeletal abnormalities, that are classified into 18 molecular subclasses; SRTD1-16, EVC, and 
EVC2. The characteristic skeletal findings comprise short ribs and a narrow thorax and 
are often combined with short stature, pelvic deformities, polydactyly, and brachydactyly. 
In addition to the skeletal abnormalities, other organ systems can be involved including 
the kidneys, the liver, and the central nervous system [1]. Since the phenotypic overlap 
between different SRTD subclasses is substantial, the classification is based on the 
underlying genetic defect and not on the clinical phenotype. Establishing an accurate 
diagnosis as early as possible is essential in order to provide the best personalized care 
for the patient. For example, monitoring renal function is likely to be more important for 
patients carrying a pathogenic mutation in IFT140, TTC21B, or WDR19 than for patients 
who carry DYNC2H1 or IFT80 mutations, as the latter two are primarily associated with 
a skeletal phenotype and IFT140, TTC21B, and WDR19 are associated with a skeletal 
phenotype accompanied by renal insufficiency [2, 3].
The majority of genes mutated in SRTDs encode intraflagellar transport (IFT) proteins, 
while a small subset encode proteins involved in hedgehog signaling, ciliogenesis, 
or DNA damage response signaling [1, 4, 3, 5-10]. IFT is required for cilium assembly, 
maintenance, and disassembly. Two axonemal transport modules can be distinguished: 
the IFT-B complex, powered by the kinesin-2 motor, for transport in anterograde direction 
(from ciliary base to tip), and the IFT-A complex, powered by the dynein-2 motor, for 
retrograde transport (from ciliary tip to base). Mutations in genes encoding subunits of 
the IFT-A particle are associated with SRTD types 3-5,7-9,11,and 15 [1, 3, 5, 6, 9].  
The effect of variants in ciliary genes can be studied at the protein level by analyzing 
the ciliary phenotype in patient-derived cells. Skin biopsies are commonly used to 
obtain patient-derived fibroblasts, however, this is an invasive and painful procedure. 
In 2015, Ajzenberg et al. reported on a non-invasive method to obtain patient-derived 
cells from urine [11]. Urine-derived renal epithelial cells (URECs) can be used to study the 
ciliary phenotype and are an excellent alternative for fibroblasts. In addition, since the 
development of cystic kidneys is one of the hallmarks of ciliopathies, it is beneficial to 
study the ciliary phenotype in cells that originate from this affected organ. 
In this study, we describe the use of URECs to determine the pathogenicity of two 
novel missense variants in IFT140 in a one-year old girl clinically diagnosed with a SRTD 
phenotype. By showing defective retrograde transport in patient-derived URECs we 
confirm the clinical and molecular diagnosis of SRTD9 / Mainzer-Saldino syndrome in 
this patient.
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Methods 
Collection of samples
Genomic DNA of patient II-3 was isolated from whole-blood and used for WES. Urine 
was collected from the patient, her unaffected parents and three healthy controls to 
study the ciliary phenotype. 
Diagnostic whole-exome sequencing 
Diagnostic WES was performed as described previously [12]. In brief, we analyzed the 
blindness gene panel (version DG 2.3.2) and the hearing impairment gene panel (version 
DG 2.3.2) [13, 14]. Exonic and intronic position -20 till +8 variants with a frequency <5% 
in dbSNP, <1% in in-house database, and <5% in the Exome Aggregation Consortium 
(ExAC) were evaluated and classified based on the guidelines for variant classification 
determined by the Association for Clinical Genetic Science (ACGS) [15]. The same filtering 
strategy was used for the analysis of the complete WES dataset.
Urine-derived renal epithelial cell isolation and culture 
The collection of urine, isolation of cells, and culturing of URECs was performed as 
described previously [11]. In brief, midstream urine was collected and refrigerated for 
up to 4 hours. Cells were retrieved from the urine, washed once, and cultured in 1 ml 
primary UREC culture medium consisting of a 1:1 ratio Dulbecco’s Modified Eagle’s 
medium (DMEM): Ham’s F12 Nutrient Mix containing 10% FCS, 0.1mg/ml Primocin (ant-
pm-2, Invivogen, Toulouse, France), and 1x REGM SingleQuots and growth factors (CC-
4127, Lonza; Basel, Switzerland) in a 24-well plate. Cells were incubated at 37°C with 5% 
CO2 and 0.5 ml primary UREC culture medium was added 24, 48, and 72 hours after 
cell isolation. At 96 hours after cell isolation, half of the culture medium was replaced by 
UREC proliferation medium consisting of REBM Basal Medium (CC-3191, Lonza; Basel, 
Switzerland) containing 1x REGM SingleQuots and growth factors, and 0.1mg/ml Primocin. 
Every day for up to 14 days half of the culture medium was replaced with fresh UREC 
proliferation medium until the URECs were visible and at approximately 80% confluence. 
Ciliary phenotyping in URECs 
In order to determine the ciliary phenotype of the patient, healthy family members, 
and controls, URECs were analyzed for cilium morphology, length, and IFT. 
Immunocytochemistry was used to visualize the cilia as described previously [16]. In 
short, URECs were cultured on glass coverslips until they reached ~80% confluence. 
After fixation, permeabilization, and blocking the coverslips were incubated with 
primary antibodies targeting IFT88 at 1:100 dilution (rabbit, 13967-1-AP, Proteintech 
Group, Manchester, UK), IFT140 at 1:100 dilution (rabbit, 17460-1-AP, Proteintech Group), 
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acetylated-α-tubulin at 1:1000 (mouse, T6793, Sigma-Aldrich, Zwijndrecht, Netherlands), 
and RPGRIP1L at 1:500 dilution (guinea pig, SNC039, homemade [17]). Upon washing the 
coverslips were incubated with fluor-labeled secondary antibodies; including goat-anti-
mouse IgG Alexa Fluor 568 (1:400), goat-anti-rabbit IgG Alexa Fluor 488 (1:400), and goat-
anti-guinea pig IgG Alexa Fluor 647 (1:400), obtained from Life Technologies (Bleiswijk, 
The Netherlands). Finally, the coverslips were embedded in Fluoromount-G (Southern 
Biotech, Birmingham, AL, USA) containing DAPI. Coverslips were microscopically 
analyzed with a Zeiss Axio Imager Z2 fluorescence microscope (Zeiss, Sliedrecht, 
Netherlands) equipped with an ApoTome slider. Images were obtained with ZEN 2012 
software (Zeiss) and processed with Photoshop CS4 (Adobe Systems, San Jose, CA, 
USA) and freely available FIJI software. 
Results 
Clinical examination 
The patient was born at term as the second child of a non-consanguineous couple 
from Bangladeshi descent (Figure 1A). The first child was unaffected. The mother had 
previously had a miscarriage at 10 weeks gestation due to an unknown etiology. During 
the neonatal period the patient presented with bilateral vision and hearing difficulties 
and was seen by a pediatrician. A behavioral observation audiometry (BOA) test, at 9 
months of age, showed a bilateral moderate-severe hearing loss of a sensorineural 
kind [18]. Hearing aids helped to make up for the progressive hearing loss that she 
was experiencing. Close examination of the eyes at the age of 7 months lead to the 
diagnosis of Leber congenital amaurosis (LCA). DNA of the patient was sent in for WES, 
and the patient was referred to a clinical geneticist upon retrieval of the WES results. 
The clinical geneticist performed a follow-up examination at one year of age, which 
showed mild skeletal abnormalities; short stature (-1.9 SD), mild narrowing of the thorax, 
and brachydactyly of both hands and feet. In addition, psychomotor development was 
delayed, however, stimulation from the parents together with the use of prescription 
glasses and hearing aids contributed to marked improvement in the course of her 
development. There were no signs of renal insufficiency at 6 months of age. 
Whole-exome sequencing 
To determine the underlying molecular cause of the disease a diagnostic WES analysis 
was performed. The blindness gene panel included 337 genes known to cause syndromic 
or non-syndromic blindness [13]. After filtering, 41 candidate variants were evaluated 
and only two variants were classified class 3 or higher. Both variants were found in 
IFT140 (NM_014714.3) c.992_993dup (class 5, clearly pathogenic) and c.2767T>G (class 
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3, unknown significance) corresponding to p.Tyr332Valfs*18 and p.Tyr923Asp in IFT140 
(NP_055529), respectively (Figure 1). Segregation analysis in the parents showed bi-
allelic inheritance that is in line with the expected recessive inheritance pattern of IFT140 
associated ciliopathies. Neither of the IFT140 variants have previously been described 
in literature nor are present in the ExAC database (February 2017) [19]. 
To investigate the possibility of a separate genetic cause for the progressive hearing 
impairment present in this patient, we screened the hearing impairment gene panel, 
consisting of 132 known deafness genes, but did not detect any likely pathogenic 
mutations. Subsequently, all detected WES variants were analyzed, but no candidate 
pathogenic variants for hearing impairment were found. This strengthens the hypothesis 
that pathogenic variants in IFT140 could underlie the hearing impairment present in this 
patient.
Ciliary phenotyping in URECs 
In order to determine the disruptive effect of the p.Tyr332Valfs*18 and p.Tyr923Asp 
variants on IFT140 protein function, we studied the ciliary phenotype in URECs of 
the patient and her unaffected parents, and compared them to three unrelated and 
unaffected controls (Figure 2A). The ciliary length of all four individuals was on average 
Figure 1. Clinical and molecular description (a) Pedigree of the patient (II-3), including WES results for 
mutations found in IFT140 (NM_014714.3). (b) Schematic view of IFT140 protein structure (NP_055529). IFT140 
consists of 1462 amino acids and has five WD repeats and nine tetratricopeptide repeats (TPR). The published 
IFT140 variants known to cause a syndromic disease are annotated in grey. The two novel IFT140 variants are 
positioned in the fifth WD repeat, p.Tyr332Valfs*18, and in the third TRP repeat, p.Tyr923Asp (black).
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3.57 µm and not significantly different in URECs from the patient (3.22 µm) (Figure 2B). 
We were able to detect IFT140 in primary cilia of the majority (90% or more) of cells from 
the patient, her parents, and three unrelated controls (Figure 2C). Abnormalities were 
observed when studying the localization of the IFT-B protein IFT88. We detected an 
Figure 2. Ciliary phenotype in URECs. URECs derived from the patient (II-3) were compared to URECs from 
three control individuals (C1-3). (a) Representative image of URECs stained for ciliary markers, i.e. acetylated-α-
tubulin (red) and RPGRIP1L (green). (b) Ciliary length measurements based on the acetylated-α-tubulin staining 
of the cilium. The dots represent individual cells and the horizontal line indicates the mean (N≥100). (c) Presence 
of IFT140 in the cilium. Parents (I-1 and I-2) are included in the analysis. (d) Cilia were visualized with acetylated-
α-tubulin (red) and RPGRIP1L (pink). The cells were analyzed for the presence of IFT88 (green) accumulation at 
the ciliary tip. Patient II-3 showed an accumulation of IFT88 in 41% of the cells.
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accumulation of IFT88 at the ciliary tip in 41% of the cells from the patient, and in 5% of 
the cells from the father (Figure 2D). This accumulation was not seen in cells from the 
mother nor in any of the unrelated controls. These data suggest that even though the 
mutated IFT140 localizes to the primary cilium and does not cause ciliogenesis defects, 
it does lead to defective retrograde transport.
Discussion 
In this study, we used diagnostic WES to detect mutations in IFT140 as a likely cause of 
the phenotype found in the patient. The classical syndromic phenotype associated with 
mutations in IFT140 includes skeletal abnormalities, renal disease, and retinal dystrophy. 
Hearing impairment has been described only once before to be part of the IFT140-related 
ciliopathy spectrum [20], when a patient described with otherwise non-syndromic retinal 
dystrophy, carrying mutations in IFT140,  was found to have progressive hearing loss. 
Our patient presented with progressive hearing loss in the neonatal period, and since 
the majority of congenital hearing loss has a genetic cause, we thoroughly investigated 
the WES data but could not detect any likely pathogenic variants in genes associated 
with hearing impairment. Although, we cannot exclude non-genetic causes to underlie 
the hearing impairment of our patient, we believe that the detected pathogenic IFT140 
mutations are causative for this feature, not previously described in Mainzer-Saldino 
patients.   
Since pathogenic variants in other IFT-A proteins could give rise to a similar cellular 
phenotype we carefully checked the remaining IFT-A and dynein motor complex proteins 
and could not find any pathogenic variants or copy number variations (CNVs) [21, 22]. In 
addition, we carefully checked IFT172, as this gene is known to give rise to a similar 
clinical phenotype [4], but did not find any (likely) pathogenic changes in this gene either. 
We next evaluated the detected IFT140 variants (workflow presented in Figure S1). IFT140 
is part of the IFT-A core subcomplex together with IFT122 and WDR19, which combined 
with the peripheral subcomplex, that includes IFT43, WDR35, and TTC21B,  forms the 
functional IFT-A complex [23, 24]. Previous studies have shown that defective retrograde 
transport causes an accumulation of proteins at the ciliary tip, and may result in shorter 
cilia [21, 25, 22, 26]. We studied URECs from the patient to determine whether the novel 
IFT140 variants caused defective retrograde IFT (workflow presented in Figure S1). We 
detected defective retrograde IFT in 41% of the cilia of the patient’s cells, while this was 
not seen in controls and only in a small percentage of cilia from the unaffected parents. 
Significant effects on ciliary length were not observed. Recent publications have shown 
that the IFT-A complex is not only required for retrograde transport, but that it is also 
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essential for the ciliary entry of transmembrane proteins, including G protein-coupled 
receptors (GPCRs), important for the transduction of intercellular signals [27, 28]. Cells 
defective for TTC21B, part of the peripheral subcomplex, showed an accumulation of 
both IFT-A and B at the ciliary tip, and a ciliary enrichment of GPCRs. Interestingly, cells 
defective in IFT-A core component WDR19, showed an accumulation of IFT-B proteins 
at the ciliary tip, while, IFT-A components and GPCRs were absent from the cilium [28]. 
This means that disruption of the IFT-A core subcomplex abolishes IFT-A complex 
formation and its entry into the cilium, not only resulting in defective retrograde IFT, but 
also withholding ciliary entry of GPCRs. Our data provide evidence that the defective 
retrograde IFT seen in the patient is caused by the mutated IFT140, though the possible 
effects on the ciliary entry of GPCRs was not assessed in this study. 
Combining the results from this study, we conclude that the patient carries two pathogenic 
mutations in IFT140 that give rise to SRTD9 also called Mainzer-Saldino syndrome. We 
suggest that mutations in IFT140 may cause progressive hearing impairment as well, and 
that this could be part of the MZSDS phenotype. The classic MZSDS phenotype includes 
renal failure, which is not seen in the patient until 1,5 years of age. Therefore, monitoring 
of renal function of the patient needs to be continued in the future as this may decline 
over time.
Conclusion 
In this study, we detected two novel IFT140 mutations, suggestive for MZSDS, in a one-
year old girl with skeletal, retinal, and hearing abnormalities. We used a non-invasive 
technique to obtain patient-derived cells in order to study the pathogenicity of the 
IFT140 variants in vitro. URECs from the patient displayed defective retrograde IFT that 
is most likely caused by the detected IFT140 variants. URECs provide a great source 
to assess the pathogenicity of nonsense, missense, and splice site variants found with 
genetic testing. The combination of a thorough clinical examination, genetic testing, and 
functional studies provided a definitive diagnosis of SRTD9.
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Image: Ciliary localization of acetylated-α-tubulin in a patient-derived UREC.
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Abstract
Cilia appear on nearly every vertebrate cell of the human body and are associated 
with  a broad phenotypic spectrum of disorders that are referred to as ciliopathies. In 
addition to this clinical heterogeneity, ciliopathies are also genetically heterogeneous 
and can be caused by mutations in more than 120 different genes (chapter 1). The 
clinical and genetic heterogeneity together causes difficulties for clinicians when they 
attempt to diagnose patients with these disorders. In approximately 40% of patients with 
a suspected ciliopathy genetic testing results in a conclusive diagnosis1. This means that 
in the majority of the cases a molecular diagnosis cannot be provided, which leaves 
the clinician with limited opportunities for counseling. In this thesis, I show how the use 
of functional studies in patient-derived cells increases knowledge about the underlying 
mechanisms of disease, and how it facilitates the interpretation of the nature of candidate 
variants. In summary, careful phenotypic examination, detailed molecular analysis, and a 
thorough functional investigation are essential to accurately diagnose patients, allowing 
proper clinical management and genetic counseling. 
1 The numbers refer to unpublished results from the department of human genetics, 
Radboudumc, Nijmegen in the Netherlands.
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1. Classification of ciliopathies 
More than twenty different subclasses of ciliopathies are described in literature. These 
are classified based on the type of cilium that is disrupted (motile or immotile) and on 
the presence of certain clinical features (chapter 1).1 However, the large phenotypic 
overlap between specific subclasses of ciliopathies complicates this classification 
system. For example, there is significant phenotypic overlap between the milder Joubert 
syndrome (JBTS) and more severe, perinatal lethal Meckel-Gruber syndrome (MKS).2 
Similarly, Mainzer-Saldino syndrome (MZSDS) and Jeune asphyxiating thoracic dysplasia 
(JATD) are skeletal ciliopathies that are thought to represent disorders of the same 
clinical spectrum, and can only be distinguished by subtle clinical differences. MZSDS 
patients generally have a milder skeletal rib phenotype compared to JATD patients, 
and the involvement of retinal dystrophy in MZSDS compared to JATD is more frequent, 
however, blindness does not exclude a diagnosis of JATD.3 Moreover, the two genes 
associated with MZSDS, IFT140 and IFT172, have also been found mutated in patients 
with JATD.4;5 For example, comparing 12 patients that carry mutations in IFT140 and 
present with skeletal, renal, and retinal abnormalities, 6 patients were diagnosed with 
JATD and 6 patients with MZSDS.4;6 This indicates that MZSDS and JATD belong to the 
same variable phenotypic spectrum resulting from, amongst others, IFT140 mutations. 
More detailed molecular analysis of tissue-specific alterations of the IFT140 function 
caused by different mutations is required to explain why in some patients the retina 
is affected, while in others it is not. These examples illustrate the vulnerability of the 
classification system mainly based on phenotypes, as it may lead to incomplete disease 
prognosis. An alternative system could be based on the genetic defect underlying the 
phenotype. This approach is already used for the subclassification of short-rib thoracic 
dysplasias (SRTD), a group of skeletal ciliopathies characterized by a narrow thorax, 
short ribs, shortened tubular bones, and a ‘trident’ appearance of the acetabular roof.7 
To date the SRTD group contains 18 entries each associated with mutations in a different 
gene or genomic location [MIM 208500, 611263, 613091, 613819, 614376, 263520, 
614091, 615503, 266920, 615630, 615633, 269860, 616300, 616546, 617088, 617102, 
617405, 225500]. The benefits of this molecular-based system compared to a mainly 
phenotypic-based system can be illustrated with an example of the variable phenotype 
resulting from mutations in IFT140 [SRTD9; MIM 266920], even though the IFT140-
associated variable phenotype is also not fully compatible with this classification system. 
For instance, the patient discussed in chapter 7 had compound heterozygous mutations 
in IFT140, and presented with skeletal, retinal abnormalities and hearing impairment. The 
latter had not previously been described for SRTD9. Besides its involvement in MZSDS 
and JATD, IFT140 dysfunction has also been associated with isolated retinal dystrophy. 
Mutations in IFT140 can thus cause various phenotypes. That means that knowing the 
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disease-causing mutation may facilitate diagnosis, but does not necessarily lead to 
accurate prognosis. Furthermore, there might be a possible role for modifier genes in 
the variability in phenotypes associated with a disease causing gene. For instance, it is 
speculated that the p.Pro209Leu mutation in, the JATD and nephronophthisis (NPHP) 
associated, TTC21B contributes to the development of renal cysts in an individual with 
Bardet-Biedl syndrome (BBS).8 I believe that knowing the functional consequences of a 
variant may help in this respect, and fully agree with the following statement of Baker and 
Beales: “prudent classification and diagnosis on phenotypic, genotypic, and ultimately 
physiological grounds is challenging but nonetheless important at the clinical level 
for accurate prognosis, counseling, prenatal screening, and management”.9 The most 
accurate classification system for ciliopathies should thus be based on a combination of 
data on: (1) phenotype, (2) genotype, and (3) mutational effect on the protein.
2. Diagnosis requires a combination of clinical, molecular, 
and functional data 
As previously mentioned accurate diagnosis of a genetic defect requires a combination 
of information from detailed clinical examination, molecular analysis, and functional 
investigation. All three components are essential as the genetic and phenotypic overlap 
in ciliopathies is significant. Of course, the diagnostic odyssey of the patient starts with a 
definition of the patient’s symptoms after a careful physical examination, in combination 
with the patients’ anamnesis, family history, and the likely hereditary pattern of the disease. 
Insight into the clinical features and the inheritance pattern may lead to a preliminary 
diagnosis and will definitely help the molecular specialist in the search for the genetic 
defect. More importantly, in the case of a novel disease gene it is important to describe 
the phenotype in great detail to narrow down possible candidates, e.g. by comparing 
the patients’ clinical features with those found in model animals that carry defects in 
a certain gene, and enable identification of possible other patients. Following clinical 
examination, genetic testing can be requested in the form of specific gene panels, or 
whole-exome sequencing (WES). The importance of identifying the molecular cause of 
the disease can be exemplified with skeletal ciliopathy patients, e.g. generally patients 
with mutations in DYNC2H1 are more likely to have a severe skeletal phenotype and no 
renal involvement, whereas IFT140 patients often have early-onset renal insufficiency 
and mild skeletal abnormalities.3 Such findings enable clinicians to form appropriate 
interdisciplinary teams for optimal clinical management. The molecular analysis pipeline 
begins with a general quality filtering of the obtained variants, followed by the selection 
of one or more candidate variant(s) that likely underlie the disease based upon the 
inheritance pattern and literature knowledge of the gene-associated phenotype. 
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Pathogenic variants that have already been described in literature to cause a comparable 
phenotype will likely result in a conclusive diagnosis, however, novel variants or variants 
described to cause a different phenotype, will require further functional investigation. 
One can even argue that every candidate variant requires functional follow-up studies 
in order to determine the impact of the variant on protein function, as the variant could 
have a different functional effect as one may expect solely based on the variant type. 
For example, I expected that the homozygous nonsense mutation (c.1726C>T, p.Arg576*) 
in INVS would have caused nonsense-mediated RNA decay resulting in a complete 
absence of the protein. However, our localization studies in patient-derived fibroblasts 
showed that inversin was only absent from the ciliary inversin compartment, while it 
was still detectable at the basal body (Chapter 3). The presence of mutated inversin 
at the basal body suggests that the protein is at least in part functional, otherwise it 
would have likely been degraded by the cell. This relatively fast and straightforward 
functional analysis already provided important information about the functional ciliary 
defect of the protein, and proved the prediction of nonsense-mediated RNA decay 
incorrect. Thus, functional studies can be informative for all types of mutations, even, 
the ones that are seemingly straightforward. The ability to reveal the impact of a variant 
on protein function, protein complex formation, and signaling pathways will ultimately 
lead to a better understanding of the molecular mechanism of disease. That said, the 
complexity of the molecular mechanism underlying ciliopathies cannot be explained by 
a simple test, and requires multiple tests performed in numerous patients. Proteomic 
studies exploiting a “guilt by association” approach, which relies on interacting proteins 
having similar functions, have tremendously increased our knowledge on protein 
functions that were previously unknown, and helped to identify new disease-relevant 
ciliary proteins and modules.10;11 For example, the glucose-induced deficiency (GID) RING 
E3 ubiquitin ligase complex, which is involved in regulating gluconeogenesis12, was 
found to interact with known ciliary proteins and localized to the ciliary base in both brain 
and kidney tissue. This data suggests a ciliary role for the GID complex in the cellular 
energy homeostasis of cilia and possibly identifies new ciliopathy candidate genes.10 
The investigation of the stoichiometry of a protein complex can also be informative for 
determining the impact of variants on protein function. For example, the quantitative 
proteomics study of the IFT-A protein complex resulted in valuable information about 
the composition of the IFT-A complex in cells derived from patients with mutations in 
genes encoding for IFT-A proteins, but this test does not demonstrate how the speed 
and accuracy of intraflagellar transport is impacted, and thus could not explain the exact 
mechanism underlying cranioectodermal dysplasia (CED) (Chapter 6). Notably, in order 
to be able to perform functional studies to determine the impact of a given variant, a 
certain level of background knowledge about the function and localization of the protein 
encoded by the mutated gene of interest is necessary. 
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To conclude, the potential to significantly improve patient diagnosis lies within a 
combination of clinical, molecular, and functional data. The ongoing development of 
NGS-techniques, as well as, the development and refinement of functional studies will 
lead to better variant-specific information resulting in improved diagnostics. 
3. Functional studies
 
Genetic variants can influence the function of the encoded protein in different ways. 
They can cause absence, misfolding or mislocalization of the protein, but may also result 
in loss of interactions and inability to regulate other proteins or genes. The functional 
effect of variants, in particular of missense variants, is often unclear. Bioinformatic tools, 
such as SIFT13, PolyPhen-214, and CADD15 can predict whether a change in amino acid is 
more or less likely to affect protein function, e.g. by comparing the size and charge of 
the native amino acid to the mutated amino acid, and take into account the evolutionary 
conservation of the affected amino acid. Yet, these tools have limited power and their 
use may result in contradictive predictions. A functional investigation of the mutated 
protein provides much more certainty about the impact and potential pathogenicity of a 
variant. For example, prediction tools were contradictive for the missense IFT140 variant 
(c.2767T>G, p.Tyr923Asp) found in a patient with a ciliopathy phenotype (Chapter 7); SIFT 
predicted the variant to be tolerated, whereas PolyPhen-2 predicted it to be probably 
damaging. In this case ICC studies in patient-derived URECs clearly showed defective 
retrograde transport, which is almost certainly caused by the detected variants in IFT140. 
A rescue assay in these cells should be performed in order to further prove that mutated 
IFT140 is indeed causing this ciliary phenotype. If the rescue is successful the function of 
retrograde IFT would be restored and there would be no more accumulation of IFT88 at 
the ciliary tip. Alternatively, the IFT140 mutation could be introduced in model cell lines or 
organisms to investigate if the variant causes a concordant ciliary phenotype. Subsequent 
rescue assays could be performed to determine the specificity of the mutational effect. 
A third option would be to make use of organoid cultures of induced pluripotent stem 
(iPS) cells to investigate the impact of a specific mutation. The current developments 
are such that a complex multicellular kidney organoid, that is transcriptionally similar to a 
human fetal kidney, can be generated from iPS cells.16 Such kidney organoids could be 
used as a disease model system to assess the efficacy of therapeutic interventions or to 
investigate basic molecular mechanisms of disease. Even though, further improvements 
concerning the functional maturation of the nephrons are required in order to fulfill its 
potential, the use of kidney organoids in functional studies is probably part of future 
research.
 Each genetic variant is unique and requires specific studies in order to determine 
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the mutational impact on protein function. For example, the impact of IFT-A gene variants 
on protein function can be studied with protein localization studies that target retrograde 
IFT proteins; one can assess the presence or absence of IFT-B protein accumulation 
at the ciliary tip. The investigation of variants in CEP290 is more complex. Mutations 
in CEP290 are associated with multiple ciliopathies, including Joubert syndrome 
[JBTS; MIM 610188], Meckel-Gruber syndrome [MKS; 611134], Bardet-Biedl syndrome 
[BBS; MIM 209900], Senior-Løken syndrome [SLS; MIM 610189], and Leber congenital 
amaurosis [LCA; MIM 611755]. CEP290 localizes to the transition zone of the cilium17, 
to a centrosomal protein complex18, and to the nucleus where is plays a role in DNA 
damage response (DDR)19. Thus, to determine the impact of CEP290 variants on the 
functionality of the encoded protein one should study DDR, assess CEP290 localization, 
and conduct protein complex interaction studies. This is a complicated task implying that 
functional testing may not always be feasible for each and every variant in a diagnostic 
setting. Finally, as signaling pathways are often affected in ciliopathies it is sensible to 
study the effect that variants may have on signaling pathway activity and localization 
of signaling molecules. Despite the uniqueness of each variant there are a number of 
widely applicable functional studies that can provide meaningful insights into the nature 
of a given variant; (1) Localization of the protein in a model cell line (Chapter 2) or in 
patient-derived cells (Chapter 3, 5, 7) will provide a first indication whether the mutated 
protein can still perform its normal function; (2) Ciliary phenotyping in model cell lines 
(Chapter 2) or in patient-derived cells (Chapter 3, 4, 7) will indicate whether the cilium is 
functioning properly; (3) Protein complex formation and stoichiometry analysis in patient-
derived cells (Chapter 6) will show the mutational effect on the capacity of the protein 
to interact with other proteins; (4) Signaling assays, e.g. Hh and Wnt signaling pathways, 
will indicate any direct or indirect effects of the mutated protein on signaling cascades; 
(5) Transcriptomics in patient-derived cells will enable the analysis of specific protein 
isoforms and provide insight into the up- or down regulation of signaling molecules. 
Together, these functional studies will clarify and strengthen the molecular diagnosis, 
leading to a higher diagnostic yield.
3.1 Functional studies in patient-derived cells 
In this thesis, I would like to emphasize the great potential of using patient-derived cells 
for mutational modeling to improve diagnosis. Patient-derived cells can be obtained 
from different tissues (skin and muscle) or fluids (urine, blood, and saliva) of the human 
body. The optimal choice of a specimen depends on several aspects; (1) the age, health, 
and well-being of the patient; (2) the clinically affected tissues; (3) the nature of the 
cell type that can be cultured from the specimen, and (4) the type of functional study 
that is required. In the following two paragraphs, I will highlight some advantages and 
disadvantages of using patient-derived cells for molecular modeling in ciliopathies. 
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3.1.1 Advantages
A major benefit of using patient-derived cells to study the impact of variants on protein 
function is that the exact mutation(s) is already present in the cells. The cells do not require 
any genetic editing, such as the CRISPR/Cas9 technique, or transfection to introduce a 
patient mutation. Transfection of primary cells with a construct is challenging and often 
results in a heterogeneous cell population in which only a certain percentage of cells 
carry the mutated construct. Cellular heterogeneity could in turn impact the detection of 
subtle differences caused by the mutation, and may result in false interpretations. The 
transfection yield is often higher in model cell lines, however, patient-derived cells may 
be a more physiologically relevant model to study mutational consequences. That said, 
it depends on the clinical phenotype if patient’s cells from certain sources are useful 
to study the functional impact of a variant; if a gene is only expressed in tissue A, but 
not in tissue B then studying cells derived from tissue B is unlikely to be informative 
about the impact of a mutation in gene X. One should also keep in mind that, despite 
the conservation in structure and protein profiles of primary cilia in different tissues, 
the expression of signaling molecules might differ.20 The recent development to use 
URECs in functional studies for ciliopathy patients addresses the issue of physiological 
relevance and is beneficial for the study of renal-associated ciliopathies (chapter 6). 
The capacity of URECs to grow into 3D spheroids that resemble a renal tube with a 
lumen, highlights the physiological advantage of these cells compared to cells that 
can only form monolayers in culture as some cellular anomalies, such as defects in 
cell polarity, may only be detectable in 3D and not in 2D.21 Another major benefit of 
URECs is the non-invasive collection method, and the possibility of serial collection as 
opposed to fibroblasts that require an invasive skin-biopsy. Finally, patient-derived cells 
are also useful in proteome-based studies to determine the impact of a variant. Although 
proteomic studies can be performed in a variety of cell types as the structure and protein 
profile of primary cilia is conserved, patient-derived fibroblasts are well-suited for the 
evaluation of changes in the stoichiometry of ciliary protein complexes and outperform 
model cell lines because there is no interference with the protein of interest (chapter 6). 
3.1.2 Disadvantages
In addition to the unfavorable invasive collection method of skin-derived fibroblasts, 
the reproducibility of experiments in fibroblasts may be poor. For example, technical 
duplicates of an assay in an identical control fibroblast line resulted in fluctuating ciliary 
length measurements (Figure 1A), and it appeared that culture density of the fibroblasts 
had a direct influence on ciliogenesis and ciliary length (Figure 1B-C). These findings 
indicate that seemingly small culture variabilities can lead to incorrect comparisons 
between patients and controls, which may in turn result in false interpretation of variant 
impact. These findings highlight the importance of equal culture conditions between 
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control and patient cells, and emphasize the need for repeat experimentation, as well 
as, the inclusion of multiple controls per experiment. One faces different disadvantages 
when attempting to use URECs for variant modeling compared to fibroblasts. One 
disadvantage is that only one-third of the urine samples result in URECs that can be 
used for functional studies. This is not ideal for research or diagnostics purposes. One 
of the reasons that a UREC culture could fail is due to fungal and bacterial infections. 
Perhaps this problem can be partially solved by immediately adding antibiotic reagents 
to the collection cup prior to sample collection instead of waiting until the cells are in 
culture. Another possible disadvantage of setting up a renal cell culture from urine is 
the heterogeneity of the cell population that is obtained. Even though, the proliferation 
medium selects for renal cells there are multiple types of renal cells in the sample, e.g. 
Figure 1. Impact of cell density on cilium formation and ciliary length in fibroblasts. (A) Ciliary length 
measurements of a single fibroblast line in five independent experiments that were technically identical. (B) 
Ciliogenesis analysis of control and CED patient-derived fibroblasts showing the correlation between number 
of ciliated cells and the cell density. (C) Correlation between ciliary length and cell density in control and 
patient-derived fibroblasts. 
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podocytes, proximal tubular cells, collecting duct cells, and kidney progenitor cells.22 The 
ciliary phenotypes of these different renal cells may vary and compromise the analysis 
of the mutational impact on protein function. For example, a transcriptome analysis of a 
heterogeneous cell population could be complicated by variable expression profiles of 
each of the present cell types, which might conceal the effect of the patient’s mutation. 
The upcoming technology of single-cell transcriptomics may solve this problem.23 
A general complicating factor of using patient-derived cells to determine the impact 
of a variant on protein function, is the possibility that modifier genes contribute to the 
ciliary phenotype that is analyzed. This scenario should always be considered when 
undertaking such studies. A method by which the effect of a specific variant can be 
confirmed is by introducing the variant in a model cell line or organism, as long as the 
protein’s function is maintained in the cell line or conserved between species. Finally, 
animal models are more beneficial compared to the use of cell cultures to study systemic 
features because it is possible to study the functionality of multiple organs and organ 
development can easily be monitored through time. However, studies in non-human 
model systems could introduce interspecies differences that are not relevant to humans, 
or even result in false conclusions.
3.2 Patient-derived cells as a read-out for efficacy of therapy
A great effort is currently being made to develop therapies for ciliopathy patients. One of 
the first examples was gene therapy treatment for patients with retinitis pigmentosa.24;25 
Another example is the repair of ciliary beating in ex vivo cell cultures from primary ciliary 
dyskinesia (PCD) patients harboring mutations in DNAI1.26 Besides gene therapy, the 
potential of drug treatments are being explored, e.g. to reduce or delay the formation 
of renal cysts.27;28 The efficacy of candidate drugs is currently being tested on animal 
models with cystic kidneys, such as zebrafish and mice, however, positive results in 
these model organisms do not guarantee a similar outcome in humans.29 In addition to 
the tests in model organisms, assays in patient-derived cells could provide important 
information on the effect of the candidate drug for individual patients. Even though a 
patient’s cellular response to a given drug may not mimic an in vivo response in that 
patient, drug testing in patient-derived cells possibly provides important predictive value 
with respect to drug response and may be a significant step towards personalized 
medicine. Several functional studies used in this thesis, such as the microscopic analysis 
of cilium phenotypes and protein interaction studies, could act as read-out systems to 
study the effect of the therapeutic intervention in each unique person.
3.3 Future perspectives of functional studies
The use of functional studies to explore the nature of ciliary proteins is not new; however, 
we only recently started to explore the potential of these studies to investigate the 
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impact of sequence variants on protein function. Once the functional impact of variants 
becomes known it may be possible to further explore genotype-phenotype correlations. 
In combination with online databases collecting detailed phenotypic information in a 
standardized way, such as PhenoDB30 and PhenoTips31, variant-specific genotype-
phenotype correlations could facilitate genetic counseling of ciliopathies. Furthermore, 
induced pluripotent (iPS) cells and multi-omics approaches are exciting new areas to 
explore for the assessment of the functional impact of genetic variants. 
3.3.1 The potential of iPS cells in functional studies
The iPS cell could be ideal to study the effect of a specific mutation by generating an 
isogenic iPS cell line in which a specific mutation is introduced and compared to the 
original cell line, eliminating the noise of possible modifier genes. Moreover, the effect of 
the variant could be studied in multiple tissues relevant to the phenotype of the patient, 
since iPS cells can be differentiated towards multiple tissue-specific cell types, including 
but not limited to nephron progenitor cells, kidney podocytes, neurons, photoreceptors, 
cardiomyocytes, and hepatocytes.32-36 Human iPS cells can also be used to generate 
organoids, miniaturized and simplified versions of an organ, e.g. kidney, liver, brain, and 
retina, serving as a model to investigate disease.16;37 In addition, organoids can serve as 
a model system for testing the efficacy of drugs and other therapeutic interventions, and 
the efficacy can be determined for each individual patient facilitating the personalization 
of medicine. 
3.3.2 The future perspective of multi-omics in ciliopathies
Multi-omics refers to the biological analysis of the genome, transcriptome, epigenome, 
proteome, and metabolome. A combined analysis of these different biological systems 
could significantly improve our understanding of ciliopathies. The broad phenotypic 
spectrum and genetic heterogeneity of ciliopathies make this group especially eligible 
for a multi-omics approach as this will show all layers of the disease allowing for 
more accurate diagnosis and facilitating better genetic management and counseling. 
Furthermore, multi-omics data can provide insight into (novel) therapeutic targets, 
biomarkers and the potential of drugs.38 For example, a multi-omics based genome 
and transcriptome study investigated dysregulated pathways underlying renal cyst 
development in autosomal dominant polycystic kidney disease (ADPKD) caused by 
PKD1 mutations. They found several upregulated signaling pathways in renal cysts that 
could potentially be targeted by therapeutic drugs, for example VEGF receptor inhibition, 
reduction of Wnt/β-catenin signaling, and down-regulation of the MAPK/ERK pathway.39 
The next step in the multi-omics field is single-cell multi-omics enabling analysis of a 
specific cell type relevant to the disease.23;40-42 For patients with nephronophthisis- 
and related disorders specific analysis of the affected collecting duct cells could be 
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performed that will provide more exact knowledge of the affected biological systems. 
Although, the current challenge for multi-omic approaches is the acquirement of huge 
amounts of data and the computational capacity necessary to analyze these datasets, 
this approach holds great promises for future personalized medical care. 
4. Concluding remark 
The road to excellence in patient care is never ending, and thus, research and diagnostics 
will have to continue to work together to develop and implement novel techniques and 
studies in the diagnostic field to reach this goal. The establishment of specific disease 
expertise centers in the Netherlands, encourages hospitals to excel in certain areas of 
disease and is expected to lead to improved patient care. For rare genetic diseases, 
such as ciliopathies, the establishment of functional testing in a diagnostic setting will 
likely lead to a better understanding of the molecular mechanism underlying the disease, 
thereby facilitating variant interpretation. All together a combination of detailed clinical 
examination, molecular analysis, and functional studies will improve accurate diagnosis, 
prognosis, and disease management resulting in better and personalized patient care. 
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List of abbreviations
ADPKD  Autosomal dominant polycystic kidney disease
BBS  Bardet-Biedl syndrome
CADD  Combined annotation dependent depletion
CED  Cranioectodermal dysplasia
CRISPR/Cas9 Clustered regularly interspaced short palindromic repeats/CRISPR
  associated protein 9
DDR  DNA damage response
ERK  Extracellular signal-regulated kinases
GID  Glucose-induced deficiency
Hh  Hedgehog signaling
IFT  Intraflagellar transport
iPS cell  Induced pluripotent stem cell
JATD  Jeune asphyxiating thoracic dysplasia
JBTS  Joubert syndrome
LCA  Leber congenital amaurosis
MAPK  Mitogen-activated protein kinases
MKS  Meckel-Gruber syndrome
MZSDS  Mainzer-Saldino syndrome
NGS  Next-generation sequencing
NPHP  Nephronophthisis
PCD  Primary ciliary dyskinesia
SIFT  Sorting intolerant from tolerant
SLS  Senior-Løken syndrome
SRTD  Short-rib thoracic dysplasia
URECs  Urine-derived renal epithelial cells
VEGF  Vascular endothelial growth factor
WES  Whole-exome sequencing
Wnt  Wnt signaling
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Image: Ciliary localization of acetylated-α-tubulin in a patient-derived UREC.
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Summary
Cilia appear on nearly every cell of the human body and dysfunction of these organelles 
is associated with a broad phenotypic spectrum of disorders that are referred to as 
ciliopathies. Mutations in more than 120 genes are associated with different ciliary 
phenotypes (chapter 1). The extensive clinical and phenotypic heterogeneity of 
ciliopathies implies that a wide-spread investigation is needed to reach an accurate 
diagnosis of patients. The objectives of this thesis were to show the power of combining 
genetic and functional experiments to facilitate better diagnosis, disease prognosis, and 
counseling of patients with disorders that affect the kidney and other organs. 
The potential of patient-derived fibroblasts to study the ciliary phenotype was shown in 
chapters 2, 3, and 4. In chapter 2, I showed that fibroblasts from an endocrine-cerebro-
osteodysplasia (ECO) syndrome patient with a p.R272Q mutation in intestinal cell kinase 
(ICK) form a reduced number of cilia compared to fibroblasts from control individuals. 
Furthermore, protein localization studies in model cell lines expressing mutated ICK 
(p.R272Q and p.G120C), showed abnormal enrichment of mutant ICK at the ciliary tip 
compared to cells expressing wild type ICK. Together these data indicate that ciliary 
dysfunction is involved in the etiology of ECO syndrome. In chapter 3, protein localization 
experiments in nephronophthisis (NPHP) patient-derived fibroblasts revealed that 
nonsense mutations in inversin (INVS) do not necessarily result in nonsense-mediated 
RNA decay. Instead, I found that some inversin was still produced and was present 
in the base of the cilium, but absent from the ciliary inversin compartment in patient-
derived fibroblasts. This finding emphasizes the importance of functional analysis to 
determine the impact of sequence variants on protein function. In chapter 4, I report 
on a patient with a de novo 14q24.2q24.3 microdeletion containing 65 protein-coding 
genes, including IFT43. Localization experiments in patient-derived fibroblasts showed 
defective retrograde transport, suggesting that a ciliary defect contributed to the 
pathogenesis of this disorder. The potential of urine-derived patient cells to study the 
function of retrograde intraflagellar transport (IFT) is shown in chapter 7. In this chapter, 
the localization of IFT88 was assessed in urine-derived renal epithelial cells (UREC) 
from a ciliopathy patient who had compound heterozygous mutations in IFT140. The 
results showed defective retrograde-IFT, confirming the diagnosis of short-rib thoracic 
dysplasia 9 (SRTD9).
In chapter 5, a combination of genetic and functional studies revealed that mutations 
in exostosin-like glycosyltransferase 3 (EXTL3) cause a novel neuro-immuno-
skeletal dysplasia syndrome. Studies in patient-derived fibroblasts showed abnormal 
glycosaminoglycan (GAG) concentrations, which is consistent with the function of EXTL3 
in GAG metabolism. Immunophenotyping in blood samples of a subset of patients, with 
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p.Arg513Cys, p.Asn657Ser, and p.Tyr670Asp mutations in EXTL3 rendered abnormal 
profiles that were consistent with severe combined immunodeficiency (SCID). In 
conclusion, this study shows that mutations in EXTL3 cause neuro-immuno-skeletal 
dysplasia syndrome with a variable expressivity. 
Clinical heterogeneity is also seen in ciliopathies. There are various cases in this thesis 
that illustrate this phenomenon. First, endocrine abnormalities were not detected in the 
fetus with ECO syndrome with a p.G120C mutation in ICK, whereas  such anomalies were 
found in fetuses with a p.R272Q mutation (chapter 2). Another example is that the mild 
skeletal abnormalities seen in the fetus with a p.R576* mutation in inversin (chapter 3) 
were not reported in other patients with infantile NPHP. Third, the phenotype associated 
with the IFT43 containing de novo 14q24.2q24.3 microdeletion is the opposite of the 
recessive IFT43 associated cranioectodermal dysplasia (CED) phenotype indicating the 
complexity of ciliopathies (chapter 4). Finally, the in chapter 7 described patient with 
mutations in IFT140 presented with progressive hearing loss, a feature that has not been 
described as part of the SRTD9 phenotypic spectrum before.
The use of patient-derived fibroblasts in proteomic studies is presented in chapter 
6. A novel quantitative proteomics-based method was developed to evaluate the 
molecular consequences of genetic variants in ciliopathies. Stoichiometry analysis of 
the intraflagellar transport complex A (IFT-A) in patient-derived fibroblasts obtained from 
CED patients and unaffected controls revealed that mutations in IFT43 or WDR35 result 
in a loss of the peripheral IFT-A subunit from the IFT complex, while the core of this 
complex remained intact.  
In chapter 8 a general discussion about the content of this thesis is provided, which 
is focused on strategies that can be used to improve the diagnosis of ciliopathy 
patients. The classification system for ciliopathies is discussed, as well as, possible 
ways to improve this system by using molecular data instead of solely phenotypic data. 
Furthermore, I emphasize the importance of combining information about genotype, 
phenotype and functional data for accurate diagnosis. The use of functional studies 
will clarify and strengthen the molecular diagnosis, leading to a higher diagnostic yield. 
The potential of using patient-derived cells for diagnostics is highlighted throughout 
this thesis, and chapter 8 discussed the advantages and disadvantages of the use of 
certain cell types for molecular mutation modeling in ciliopathies. In addition, the use 
of induced pluripotent stem (iPS) cells and multi-omics approaches to investigate the 
impact of variants on protein function is explored. In summary, there is ample evidence 
that a combination of detailed clinical examination, molecular analysis, and functional 
studies will improve accurate diagnosis, prognosis, and disease management resulting 
in optimized personalized patient care.
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Samenvatting
Cilia zijn te vinden op bijna elke cel van het menselijk lichaam en een verstoorde werking 
van deze organellen wordt geassocieerd met een breed spectrum van aandoeningen. 
Samen worden deze stoornissen ook wel ciliopathieën genoemd. Mutaties in meer dan 
120 genen zijn geassocieerd met de ciliopathieën (hoofdstuk 1). De enorme klinische 
en fenotypische heterogeniteit die deze stoornissen kenmerkt vereist een uitgebreid 
onderzoek om tot een nauwkeurige diagnose van patiënten te kunnen komen. Het doel 
van dit proefschrift was om aan te tonen dat men door middel van het combineren van 
genetische en functionele experimenten tot een betere diagnose, ziekteprognose en 
counseling van patiënten met ciliopathieën.
Studies in fibroblasten afkomstig van patiënten werden gedaan om te bepalen welke 
effecten mutaties hebben op de morfologie en functie van het cilium, het ciliaire fenotype 
(hoofdstukken 2, 3 en 4). In hoofdstuk 2 liet ik zien dat fibroblasten van een patiënt 
met endocriene-cerebro-osteodysplasie (ECO) syndroom, met een p.R272Q mutatie in 
het intestinal cell kinase (ICK) gen, een verminderd aantal cilia vormde in vergelijking 
met fibroblasten van controle individuen. Bovendien bleek uit eiwit lokalisatiestudies 
in modelcellijnen waarin gemuteerd ICK (p.R272Q en p.G120C) tot expressie werd 
gebracht, dat er een abnormale verrijking van mutant ICK in de ciliaire tip aanwezig 
was in vergelijking met cellen waarin wildtype ICK tot expressie werd gebracht. Deze 
bevindingen wijzen erop dat een ciliaire stoornis betrokken is bij de etiologie van ECO 
syndroom. In hoofdstuk 3 toonde ik aan met behulp van eiwit lokalisatie experimenten 
in fibroblasten van een nefronoftise (NPHP) patiënt dat een stopmutatie in inversin (INVS) 
niet noodzakelijkerwijs resulteert in ‘nonsense-mediated RNA decay’. In plaats daarvan 
vond ik dat kleine hoeveelheden inversin nog steeds aanwezig waren aan de basis 
van het cilium, maar afwezig uit het ciliaire inversin compartiment in fibroblasten van de 
patiënt. Deze bevinding benadrukt het belang van functionele studies om de invloed 
van DNA varianten op eiwitfunctie te bepalen. In hoofdstuk 4 rapporteer ik over een 
patiënt met een de novo 14q24.2q24.3 microdeletie die 65 eiwitcoderende genen 
omvat, waaronder IFT43. Lokalisatie experimenten in patiënt fibroblasten toonden 
een verstoord ‘retrograde’ intraflagellair transport (IFT) richting de tip (‘retrograde’ IFT) 
aan, wat suggereert dat een ciliaire stoornis bijdraagt aan de pathogenese van deze 
aandoening. Tot slot, beschrijf ik in hoofdstuk 7 hoe urine-afgeleide patiëntcellen 
gebruikt kunnen worden om het functioneren van ‘retrograde’ IFT te onderzoeken. In 
dit hoofdstuk werd de lokalisatie van IFT88 onderzocht in urine-afgeleide nierepitheel 
cellen (URECs) van een ciliopathie patiënt met samengestelde heterozygote mutaties in 
IFT140. De resultaten toonden een verstoord ‘retrograde’-IFT aan, wat de diagnose van 
korte-rib thoracale dysplasie type 9 (SRTD9) in deze patiënt bevestigde.
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In hoofdstuk 5, werd door middel van een combinatie van genetische en functionele 
studies aangetoond dat mutaties in exostosin-like glycosyltransferase 3 (EXTL3) een 
nieuw neuro-immuno-skeletal dysplasia syndroom veroorzaken. Studies in patiënt 
fibroblasten lieten afwijkende concentraties van glycosaminoglycanen (GAG) zien. 
Deze bevindingen zijn niet verrassend gezien de bekende functie van EXTL3 in 
GAG metabolisme. Immuno-fenotypering in bloedmonsters van een subset van deze 
patiënten, met p.Arg513Cys, p.Asn657Ser en p.Tyr670Asp mutaties in EXTL3, lieten 
afwijkende profielen zien wat past bij een ‘severe combined immunodeficiency’ (SCID). 
Ten slotte toonde deze studie aan dat mutaties in EXTL3 het neuro-immuno-skeletal 
dysplasie syndroom veroorzaken met een variabele expressie van het fenotype.
Zoals ik eerder al noemde, is klinische heterogeniteit ook één van de kenmerken van 
ciliopathieën. Dit proefschrift bevat verschillende voorbeelden die dit illustreren. Ten 
eerste, werden er geen endocriene afwijkingen gedetecteerd in de foetus met ECO 
syndroom met een p.G120C mutatie in ICK, terwijl dergelijke afwijkingen wel gevonden 
werden bij foetussen met een p.R272Q mutatie (hoofdstuk 2). Een ander voorbeeld is dat 
de milde skeletafwijkingen in de foetus met een p.R576* mutatie in inversin (hoofdstuk 
3) niet bij andere patiënten met infantiele NPHP zijn gemeld. Ten derde, het fenotype 
dat geassocieerd wordt met de IFT43 bevattende de novo 14q24.2q24.3 microdeletie 
is het tegenovergestelde van het recessieve IFT43-geassocieerde cranioectodermal 
dysplasia (CED) fenotype, hetgeen de complexiteit van ciliopathieën benadrukt 
(hoofdstuk 4). Tenslotte, beschreef ik, in hoofdstuk 7, een patiënt met mutaties in IFT140 
met progressief gehoorverlies, een fenotype dat nog niet eerder is beschreven als 
onderdeel van het SRTD9 fenotypische spectrum.
Het gebruik van patiëntfibroblasten in ‘proteomics’ studies wordt gepresenteerd in 
hoofdstuk 6. Een nieuwe kwantitatieve ‘proteomics’-methode werd ontwikkeld om 
de moleculaire gevolgen van genetische varianten bij ciliopathieën te evalueren. 
Stoichiometrie analyses van het intraflagellaire transportcomplex A (IFT-A) in patiënt 
fibroblasten van CED patiënten en gezonde controles lieten zien dat mutaties in IFT43 
of WDR35 resulteerden in een verlies van de perifere IFT-A subeenheid van het IFT 
complex, terwijl de kern van dit complex intact bleef.
In hoofdstuk 8 wordt een algemene discussie gegeven over de inhoud van dit proefschrift, 
dat gericht is op de strategieën die kunnen worden toegepast om de diagnose van 
ciliopathie patiënten te verbeteren. Het classificatiesysteem voor ciliopathieën wordt 
besproken, evenals mogelijke manieren om dit systeem te verbeteren door gebruik te 
maken van moleculaire data in plaats van enkel fenotypische data. Het combineren van 
data over het genotype, fenotype en functionele data resulteren in optimale diagnostiek 
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voor de patiënt en zijn/haar familie. Zoals ik al noemde wordt het potentieel van het 
gebruik van patiëntcellen in de diagnostiek wordt benadrukt in dit proefschrift, en in 
hoofdstuk 8 worden de voor- en nadelen van het gebruik van specifieke celtypen voor 
het moleculair modelleren van mutaties in ciliopathieën besproken. Daarnaast wordt het 
gebruik van geïnduceerde pluripotente stam (iPS) cellen en ‘multi-omics’ benaderingen 
om de impact van varianten op eiwitfunctie te onderzoeken verkend. 
Kortom, er is voldoende bewijs dat een combinatie van gedetailleerd klinisch onderzoek, 
moleculaire analyse en functionele studies de nauwkeurigheid van een diagnose, 
prognose en ziekte management zal verbeteren, wat resulteert in optimale persoonlijke 
patiëntenzorg.
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Eenvoudiger gezegd
Cilia zijn een soort “haartjes” die op bijna elke cel van het menselijk lichaam voorkomen. 
Ze functioneren als kleine antennes en geven signalen van buitenaf door aan de cel en 
andersom. Bij een verstoorde werking van deze “haartjes” ontstaan er problemen in de 
ontwikkeling van het menselijk lichaam. We noemen het ziektebeeld dat dan ontstaat 
een ciliopathie ofwel “ciliumziekte”. Welke organen en in welke mate de organen zijn 
aangedaan verschilt per ciliopathie. Vaak is de functie van de nieren, ogen, botgroei en/
of longen verstoord. Alle klinische kenmerken samen noemen we het ‘fenotype’ van 
de patiënt. Het ‘genotype’ is de aanduiding voor de opbouw van het erfelijk materiaal, 
het ‘DNA’. Het DNA bestaat uit vier verschillende blokken waarmee kleine of grote 
torens gemaakt kunnen worden. Deze torens verbeelden onze genen. De volgorde 
van de blokken in een toren bepaalt vervolgens de exacte code voor een eiwit, de 
bouwstenen van het menselijk lichaam. Wanneer één van de DNA blokken uit de toren 
verandert (bijv. blok A wordt blok C, of blok A valt weg) spreken we van een mutatie. De 
toren (het gen) heeft dan ineens een andere samenstelling en zal niet meer de juiste 
code voor het eiwit bevatten. In het geval van een verstorende mutatie in een gen dat 
het functioneren van cilia reguleert, zal dit leiden tot een ciliopathie.
Hoofdstuk 1 geeft een overzicht van alle ciliopathieën. Er zijn meer dan 120 genen 
betrokken bij deze groep aandoeningen en er zijn veel verschillende fenotypes. 
Ondanks deze diversiteit is er ook veel klinische overlap wat het stellen van de juiste 
diagnose bij deze patiënten lastig maakt. Er is dan ook uitgebreid onderzoek nodig om 
tot een nauwkeurige diagnose te komen.
Intestinal cell kinase ofwel ICK: een specifiek stuk DNA (een gen) dat codeert voor een 
eiwit dat betrokken is bij de groei en ontwikkeling van de cel.
Endocriene-cerebro-osteodysplasie syndroom ofwel ECO syndroom: een zeldzame 
erfelijke aandoening met aangeboren afwijking aan de hersenen, het hormoonstelsel 
en de botgroei.
Inversin ofwel INVS: een specifief stuk DNA (een gen) dat codeert voor een eiwit dat 
betrokken is bij de ontwikkeling van de nier en de links-rechts-asymmetrie van het 
menselijk lichaam.
In hoofdstukken 2, 3 en 4 zijn experimenten beschreven die ik gedaan heb in huidcellen 
van ciliopathie-patiënten om het functioneren van de cilia te kunnen beoordelen en 
vergelijken met die van cilia van gezonde personen. Hoofdstuk 2 laat zien dat mutaties 
in het gen genaamd ICK een verstoorde functie van het cilium veroorzaken, en dat het 
bijbehorende ziektebeeld genaamd ECO syndroom hierdoor tot de groep ciliopathieën 
Eenvoudiger gezegd
199
E
behoord. In hoofdstuk 3 wordt duidelijk gemaakt dat het soort mutatie niet altijd een 
voorspellende waarde heeft of het eiwit wel of niet gemaakt kan worden. Om dit goed 
te kunnen beoordelen moeten er experimenten gedaan worden die iets over de 
functie van het eiwit kunnen zeggen, zoals gedaan voor een mutatie in het gen INVS. In 
hoofdstuk 4 bestudeerde ik de cilium functie van cellen afkomstig van een patiënt met 
een deletie van 65 genen.
Exostosin-like glycosyltransferase 3 ofwel EXTL3: een specifiek stuk DNA (een gen) 
dat codeert voor een eiwit dat betrokken is bij de vorming van heparansulfaat, een 
suikerketen die aan eiwitten kan binden.
Neuro-immuno-skelet dysplasie syndroom: een zeldzame erfelijke aandoening met 
afwijkingen aan het zenuwstelsel, het immuunsysteem en de botgroei.  
In hoofdstuk 5 worden verschillende experimenten beschreven om aan te tonen dat 
mutaties in het gen genaamd EXTL3 een nieuw ziektebeeld veroorzaakt, genaamd 
‘neuro-immuno-skelet dysplasie syndroom’. Ondanks dat dit ziektebeeld overeenkomsten 
had met sommige ciliopathieën, bleek er geen verstoorde ciliumwerking aan ten 
grondslag te liggen.   
Cranio ectodermale dysplasie syndroom ofwel CED syndroom: een zeldzame erfelijke 
aangeboren aandoening met onder andere afwijkingen aan de schedel, huid, botgroei 
en nieren.
In hoofdstuk 6 wordt beschreven hoe huidcellen van patiënten gebruikt worden om 
het effect te bestuderen van ciliopathie-gerelateerde mutaties op de verbindingen 
tussen verschillende eiwitten. Experimenten met huidcellen van patiënten met het 
CED syndroom lieten zien dat sommige verbindingen tussen eiwitten verloren gaan als 
gevolg van mutaties in ciliopathie-gerelateerde genen.
Intraflagellaire transport eiwit 140 ofwel IFT140: een specifiek stuk DNA (een gen) dat 
codeert voor een eiwit dat betrokken is bij het transport van eiwitten in het cilium.
Korte-rib thoracale dysplasie type 9 ofwel SRTD9: een zeldzame erfelijke aangeboren 
aandoening met kenmerken als een vernauwde borstkas, korte ribben, en afwijkende 
botgroei.
In hoofdstuk 7 wordt het gebruik van niercellen afkomstig uit urine van een patiënt met 
een ciliopathie fenotype beschreven, om het effect van mutaties in het IFT140 gen op 
de functie van cilia te bepalen. In deze cellen kon worden aangetoond dat de transport 
functie in het cilium verstoord is. Dit inzicht hielp bij het stellen van de diagnose SRTD9 
200
in deze patiënt.  
In hoofdstuk 8 wordt een algemene discussie gehouden over de inhoud van dit 
proefschrift, die gericht is op verschillende manieren om de diagnostiek voor ciliopathie-
patiënten te verbeteren. De nadruk hiervoor wordt gelegd op het gebruik van specifieke 
experimenten in cellen van patiënten en modellen, en verschillende voor- en nadelen 
van technologieën en celtypes worden besproken.
Samengevat luidt de boodschap van dit proefschrift: de combinatie van klinisch 
onderzoek (het fenotype), mutatie analyse (de genetische defecten) en functionele 
studies (effecten op de functie van het eiwit) zal het stellen van een juiste diagnose, 
prognose en ziektemanagement verbeteren, wat leidt tot optimale persoonlijke 
patiëntenzorg.
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hoop van je geleerd. Ik kijk uit naar onze samenwerking om functionele diagnostische 
testen in te zetten om de diagnostiek voor ciliopathie-patiënten te verbeteren. 
My paranymphs Brooke and Arlette thank you so much for everything you have done 
throughout the years. Brooke, even though we met only a few years ago we already 
share many great memories. Whether it concerns skydiving boyfriends, hilarious 
moments with Coen or our latest adventures in the bouldering hall, there is never a dull 
moment with you. Thank you so much and let's create many more of these memories in 
the years to come!
Arlette, we kennen elkaar al zo lang en we hebben al zoveel meegemaakt dat ik niet 
eens weet waar ik moet beginnen. Vanaf het moment dat we elkaar in de tweede leerden 
kennen is onze vriendschap gebleven. Dank je wel voor al je steun de afgelopen jaren. 
Ik vind het super tof dat je mijn paranymf wilt zijn! 
The protein lab, the place to be! Sylvia, dank je wel voor al je hulp bij de SILAC 
experimenten (ik weet hoe blij je hiervan werd :P ). Ka Man, hartelijk dank voor alle keren 
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dat je de URECs hebt verzorgd. Stef, Jeroen, Minh, Zeineb, Mariam, Simone, Julio, Edgar, 
and Cenna thanks for all your help and the many fun moments inside and outside the 
lab.  Miriam, thanks for your useful input during our shared meetings and your willingness 
to help out whenever you can. Ladies, I treasure all the coffee moments we have had 
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this habit. Ideke, I feel like we did our PhD together. People even got us confused from 
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bedanken voor het toekennen van het Kouncil project. Ook wil ik alle leden van AGORA 
bedanken.
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ik Linda, Suzan, en Ellen bedanken, want naast het floorball genieten we ook regelmatig 
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Rob, Chris, Frank en Rianne ik had geen gezelligere schoonfamilie kunnen treffen. 
Bedankt voor jullie interesse in mijn onderzoek, alle momenten dat jullie op Coen 
hebben gepast en de gezellige vakanties samen, we hebben al heel wat werelddelen 
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van zodra Jelte en Coen samen de wereld gaan ontdekken. Welmoed and Salvatore, 
although we do not see each other in real life that often I always enjoy our time together. 
Welmoed, ik vind het super tof dat we samen de kaft van dit proefschrift hebben 
gemaakt, dank je wel! Tot skypes!
  
Paps en mams, mijn eeuwige dank gaat uit naar jullie voor de vele leerzame en leuke 
avonturen die jullie mogelijk gemaakt hebben. Ik denk nog steeds met veel genoegen 
terug aan mijn jaar in Canada. Jullie staan altijd voor me klaar en met de komst van Coen 
voor ons gezin. Paps, ik vind het heel speciaal om 36 jaar later net als jij te promoveren 
in de genetica. 
Mijn allerliefste Coen, zo jong als je nog bent zo belangrijk ben je al in mijn leven. Met 
jouw slimme en grappige uitspraken en je vrolijke karakter weet je altijd een lach op mijn 
gezicht te krijgen, dank je wel hiervoor!
Lieve Martijn, ook wij kennen elkaar via het ijshockey, je viel voor mij op het ijs (letterlijk 
en figuurlijk) en daar ben ik nog altijd blij om. Dank je wel voor alles … je geduld, 
interesse, luisterend oor, adviezen, grappen, heerlijke eten en aandacht voor mij. Ik ben 
trots op alles dat we samen voor elkaar hebben gekregen en dankbaar voor alle leuke 
avonturen die we tot nu toe samen hebben beleefd. Ik kijk nu al uit naar ons volgende 
avontuur! 
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RIMLS New Frontiers#
RIMLS PhD Retreat#
Genetics Retreat*
Cilia#
2012
2013
2014
2014
2014
2014
2014
2014
2015
2015
2015
2015
2015
2015
2015
2016
2016
2016
1
1
1
1
1.25
0.5
1
1.25
0.75
1
1
0.5
0.5
0.75
1
1
0.75
1.25
Other
Human Genetics journal club
Co-organisation RIMLS New Frontiers 
2013-2016
2016
3
2
* Oral presentation    # Poster presentation
Name PhD candidate: MM Oud
Department: Human Genetics
Graduate School: Radboud Institute for 
Molecular Life Sciences
PhD period: 01-01-2013 – 02-05-2017
Promotors: Prof. Dr. R. Roepman, 
Prof. Dr. H.G. Brunner
Co-promotor: Dr. H.H. Arts
RIMLS portfolio
RIMLS portfolio
213
P
Year(s) ECTS
TEACHING ACTIVITIES
Lecturing
Workgroup (bio)medical students
Workgroup (bio) medical students
Lecture “Ciliopathies” (bio) medical students
Workgroup (bio) medical students
2013
2015
2016
2016
0.2
0.8
0.1
0.5
Supervision of internships
Supervision master student
Supervision bachelor student
2014
2016
2
2
TOTAL 38.15


